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MESENCHYMAL STROMAL CELLS 
 
Introduction 
In addition to hematopoietic stem cells (HSCs), the bone marrow (BM) also 
contains mesenchymal stem cells (MSCs). These cellswere first recognized 
more then 40 years ago by Friedenstein et al. who described a population of 
adherent cells from the BM which were non-phagocytic, exhibited a fibroblast-
like appearance and could differentiate in vitro into bone, cartilage, adipose 
tissue, tendon and muscle.1 Moreover, after transplantation under the kidney 
capsule, these cells gave rise to the different connective tissue lineages.2  
MSCs have been demonstrated to display chemotactic abil ty, to migrate to sites 
of inflammation and injury,3 as well as to secrete paracrine mediators able to 
reverse acute organ failure.4 Indeed, MSC infusions have been successfully used 
in repairing tissue injury secondary to allogeneic hematopoietic stem cell 
transplantation (HSCT).5 In view of their immunosuppressive properties, as 
well as of their role in tissue repair and trophism, MSCs represent a promising 
tool in approaches of immunoregulatory and regenerativ  cell therapy.6,7 
Recently, a standardized nomenclature for MSCs has been proposed and the 
term “multipotent mesenchymal stromal cells” (with the acronym MSCs) has 
been introduced to refer to this population of fibroblast-like plastic-adherent 
cells.8 
In this study, we will refer to multipotent mesenchymal stromal cells with the 
acronym MSCs. 
 
Sources of MSCs 
Human MSCs were first identified in postnatal BM1 and later in a variety of 
other human tissues, including periosteum, muscle connective tissue, 
perichondrium, adipose tissue and fetal tissues, such as lung, BM, liver and 
spleen.9-13 Amniotic fluid and placenta have been found to be rich sources of 
MSCs;14,15 both fetal and maternal MSCs can be isolated from human 
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placenta.15 MSCs have been also identified in umbical cord blood (UCB); 
however, probably as a consequence of their low frequency in UCB, conflicting 
results in terms of success rate of MSC isolation have been initially 
reported.16,17 It is now clear that selection of UCB units to be processed by 
specific quality criteria, such as volume and storage time, can be considered 
critical parameters for the successful isolation of MSCs from this source.17  
In general, MSCs represent a minor fraction in BM and other tissues; the exact 
frequency is difficult to calculate because of the different methods of harvest 
and separation. However, the frequency in human BM has been estimated to be 
in the order of 0.001-0.01% of the total nucleated c lls, and therefore about 10 
fold less abundant than HSCs.18 Furthermore, the frequency of MSCs declines 
with age, from 1/104 nucleated marrow cells in a newborn to about 1/2x106 
nucleated marrow cells in a 80-year old person.18  
 
Multilineage potential of MSCs 
One of the hallmark of MSCs is their multipotency, defined as the ability to 
differentiate into several mesenchymal lineages, including bone, cartilage, 
tendon, muscle, marrow stroma and adipose tissue (AT).18-20 Usually trilineage 
differentiation into bone, adipose tissue and cartilage is taken as a criterium for 
multipotentiality.  
To induce osteogenic differentiation, cells are cultured in the presence of 
dexametasone, ascorbic acid and β-glycerophosphate. To detect osteogenic 
differentiation cells are stained for alkaline phosphatase activity by substrate 
solution and for calcium depositions with Alzarin Red.13 Adipogenic 
differentiation can be induced with dexametasone, isul n, indomethacin and 1-
methyl-3-isobutylxantine. Cells containing lipid vacuoles can be stained after 3 
weeks with Oil red O.13 Chondrogenic differentiation is obtained after culturing 
MSCs in pellets, in the absence of serum and in the presence of Transforming 
growth Factor-β3 (TGF-β3) and Bone Morphogenetic Protein-6 (BMP-6).21,22 
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Chondrocytes can be stained for extracellular matrix components with 
Toluidine Blue and/or by PCR for collagen type II, IX and X. 
Recently, it has been reported the existance of pluripotent cells that have the 
ability to differentiate into cells of the mesodermal lineage, but also into 
endodermal and neuroectodermal cell types, including neurons,23 hepatocyte24,25 
and endothelium.26 Such pluripotent stem cells have been identified in BM and 
referred to as multipotent adult progenitor cells (MAPCs),27 human BM-derived 
multipotent stem cells (hBMSCs),28 marrow-isolated adult multilineage 
inducible (MIAMI) cells,29 or very small embryonic-like stem (VSEL) cells.30 
Similar pluripotent cells have been reported by Kogler et al. in UCB, and have 
been referred to as “Unrestricted Somatic Stem Cells” (USSCs).31 
 
Immunomodulatory properties of MSCs in vitro 
MSCs display unique immunological properties that have been demonstrated by 
several independent groups both in vitro and in vivo, in animal models and in 
humans. In the beginning, most studies focused the attention on the effects of 
MSCs on T-lymphocytes; however, it is now become evident that these cells 
display their effects on other cells involved in immune responses, including B 




Figure 1. Immunomodulatory effects of MSCs. 
CTL indicates cytotoxic T cell; iDCs, immature dendritic cells; mDCs, mature dendritic 
cells; HGF, hepatocyte growth factor; IDO, indolamine 2,3-dioxygenase; PGE2, 
prostaglandin E2; IL, interleukin; IFN, interferon and TGF-beta, transforming growth 
factor beta. Illustration by Paulette Dennis; modified from Naut AJ, Fibbe WE, Blood 
2007. Copyright: permission.  
 
MSCs were first demonstrated to suppress in vitro T lymphocyte proliferation 
induced by alloantigens,35 mitogens,36 CD3 and CD28 agonist antibodies.37,38 
MSCs have been reported to inhibit the cytotoxic effects of cytotoxic T cells 
(CTLs), probably due to suppression of CTL proliferation.39 This inhibition of 
T-cell proliferation is not HLA-restricted; MSCs are able to induce a similar 
degree of inhibition in the presence of both autolog us and allogeneic 
responder cells, this supporting the concept that MSCs can be considered 
universal suppressors.35,38 Since the separation of MSCs and PBMCs by 
transwell experiments does not completely abrogate the suppressive effect, 
most human MSC-mediated immune suppression on activated T-lymphocyte 
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has been attributed to the secretion of anti-proliferative soluble factors, such as 
TGF-β, hepatocyte growth factor (HGF), prostaglandin E2 (PGE2), 
indoleamine 2,3-dioxygenase (IDO), nitric oxide and i terleukin (IL)-10.35-44  
However, published data do not exclude that a part of the immunosuppressive 
effect exerted by human MSCs on alloantigen-induced T-cell activation be 
dependent on cell-to-cell contact mechanisms. Of interest, the calcineurin 
inhibitors, cyclosporine-A and tacrolimus, currently employed to prevent or 
treat graft-versus-host disease (GvHD), enhance the immune suppressive 
effect of human MSCs, in particular for what concers the in vitro activation 
of alloantigen-specific, T-cell mediated cytotoxic a tivity.45 Some authors 
have shown that the unresponsiveness of T cells in the presence of MSCs is 
transient and that T cell proliferation can be reinitiated after MSC 
removal.32,36,38 
Inhibition of lymphocyte proliferation by MSCs has not been associated with 
the induction of apoptosis, but it is rather interpr ted as due to inhibition of cell 
division, thus preventing T-lymphocyte capacity to respond to antigenic 
triggers, while maintaining these cells in a quiescent state.36,38,46 MSCs have 
been also reported to induce regulatory T cells (Treg), as demonstrated by the 
increase in the population of CD4+CD25+FoxP3+ cells in mixed lympocyte 
cultures in the presence of MSCs.47  
MSCs have been reported to interfere with dendritic cell (DC) differentiation, 
maturation and function. Differentiation of both monocytes and CD34+ 
progenitors into CD1a+-DCs is inhibited in the presence of MSCs and DCs 
generated in this latter condition are impaired in their function, in particular in 
their ability to induce activation of T cells.48,49 Transwell experiments have 
demonstrated that the suppressive effect of MSCs on DC differentiation is at 
least partly mediated by soluble factors, namely IL-6 and M-CSF, PGE2, IL-
10.49 Alternatively, MSCs might favor the induction of regulatory APCs, 
through which they could indirectly suppress T cellproliferation. 
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The ability of MSCs to inhibit B cell proliferation was first reported in murine 
studies.46 Thereafter, human MSCs have been demonstrated to suppress the 
proliferation of B cells activated with anti-Ig antibodies, soluble CD40 ligand 
and cytokines, as well as to interfere with differentiation, antibody production 
and chemotactic behaviour of B lymphocytes.50 Krampera et al. have reported 
that MSCs are able only to reduce the proliferation of B cells in the presence of 
IFN-gamma, thanks to its ability to induce IDO activity by MSCs.51 In contrast 
with these observations, Traggiai et al. have recently reported that BM-derived 
MSCs are able to promote proliferation and differentiation into immunoglobulin 
secreting cells of transitional and naive B cells isolated from both healthy 
donors and pediatric patients with systemic lupus eryth matosus.52  
It has been reported that MSCs are able to suppress NK cell proliferation after 
stimulation with IL-2 or IL-15.39,47,53 Indeed, while MSCs do not inhibit the 
lysis of freshly isolated NK cells,39 these latter cells cultured for 4 to 5 days with 
IL-2 in the presence of MSCs display a reduced cytotoxic potential against 
K562 target cells.51 Transwell experiments have suggested that the suppression 
of IL-15 driven NK cell proliferation as well as oftheir cytokine production by 
MSCs, is mediated by soluble factors.51,53 On the contrary, the inihibitory effect 
displayed by MSCs on NK cell cytotoxicity required cell-cell contact.53  
Altough MSCs were initially considered immunoprivileged and therefore 
capable of escaping lysis by freshly isolated NK cells,39 recent experiments 
have demonstrated that IL-2-activated both autologous and allogeneic NK cells 
are capable of effectively lysing MSCs.53,54 Although MSCs express normal 
levels of MHC class I that should protect against NK-mediated killing, they 
display ligands that are recognized by activating NK receptors that, in turn, 
trigger NK alloreactivity.54 Moreover, it has been recently demonstrated that 
MSCs can be lysed also by cytotoxic T-lymphocytes, when infused into MHC-
mismatched mice, resulting in their rejection.55 
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In conclusion, several studies have demonstrated tha MSCs are capable of 
modulating in vitro the function of different cells active in the immune 
response. Whether this effect is displayed through real suppression of immune 
responses or to a nonspecific antiproliferative effect is still unclear. The 
mechanisms by which MSCs display their immunosuppressiv  effect are largely 
restricted to in vitro studies. The in vivo biological relevance of the in vitro 
observations, therefore, represents an important issue that is currently addressed 
by several research groups.  
 
Ex vivo isolation/expansion and characterization of MSCs 
MSCs can be relatively easily isolated from BM and other tissues and display a 
remarkable capacity for extensive in vitro expansion to numbers that allow in 
vivo testing in humans.20,56-61 
Most of the information available on MSC phenotypic and functional properties 
are derived from studies performed on cells cultured in vitro. To date, MSC 
isolation/identification has mainly relied on their adherent properties, 
immunephenotype by flow-cytometry and differentiation potential. In detail, ex 
vivo expanded MSCs have been phenotypically characterized on the basis of the 
expression of nonspecific markers, including CD105 (SH2 or endoglin), CD73 
(SH3 or SH4), CD90 (Thy-1), CD166, CD44, and CD2918,19 (see Table 1). In 
addition, culture-expanded cells lack the expression of some haematopoietic and 
endothelial markers, such as CD14, CD31, CD34 and CD45, at least in case of 
BM-derived cells, whereas a proportion of adipose ti sue-(AT) derived MSCs 
express CD34.11,62,63  
Little is known about the characteristics of the primary precursor cells in vivo, 
since it has not yet been possible to isolate the most primitive mesenchymal cell 
from bulk cultures. One of the hurdles has been the inability to prospectively 
isolate MSCs because of their low frequency and the lack of specific markers. 
Recently, the identification and prospective isolati n of mesenchymal 
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progenitors, both in murine and human adult BM, have been reported, based on 
the expression of specific markers. 64-70 
One group has reported the identification, isolation and characterization of a 
novel multipotent cell population in murine BM, based on the expression of the 
stage-specific embryonic antigen-1 (SSEA-1). This primitive subset, that is 
found both directly in the BM and in mesenchymal cell ultures, can give rise to 
SSEA-1+ MSCs and is proposed to be placed at the apex of the hierarchical 
organization of the mesenchymal compartment.64  
In human cells, surface markers such as SSEA-4, STRO-1 and the low affinity 
nerve growth factor receptor (CD271),65-68 which enrich for MSCs, have been 
employed with the aim to prospectively isolate MSCs. Moreover, Battula et al. 
have recently isolated by flow cytometry MSCs from human BM using 
antibodies directed against the surface antigens CD271, mesenchymal stem cell 
antigen-1 (MSCA-1) and CD56, and identified novel MSC subsets with distinct 
phenotypic and functional properties.69 Platelet derived growth factor receptor-
beta (PDGF-RB; CD140b) has been also identified as a selective marker for the 
isolation of clonogenic MSCs68 and other reports have demonstrated a 9.5-fold 
enrichment of MSCs in human BM cells with prominent aldehyde 
dehydrogenase activity70 (see Table 1). The relevance and usefulness of these 
markers for the prospective isolation and consequent expansion of MSCs from 
BM and/or other sources is being evaluated and will possibly allow a more 













CD105 (endoglin, SH2)18-20 Expanded Human, murine 
CD73 (ecto-5’ nucleotidase, 
SH3, SH4)18-20 
Expanded Human 
CD166 (ALCAM)13 Expanded Human 
CD29 (β1-integrin)13,18-20 Expanded Human, murine 
CD44 (H-CAM)18-20 Expanded Human, murine 
CD90 (Thy-1)13,18-20 Expanded Human 
TRA-1-81 Expanded Human (placenta) 
Sca-1 Expanded Murine  
STRO-166 Primary Human (BM) 
CD349 (frizzled-9)68 Primary Human (BM, 
placenta) 
SSEA-464,65 Primary Human +/- (BM, 
placenta) 
Oct-430 Primary Human +/- (BM, 
placenta, fetal 
tissues) 
Nanog-3 Primary Human +/- (BM, 
placenta) 
SSEA-130,64,65 Primary Murine (BM) 
CD271 (low-affinity nerve 
growth receptor)67,69 
Primary Human 
MSCA-169 Primary Human (BM) 
CD140b (PDGF-RB)68 Primary Human 
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MSCs can be expanded in vitro to hundreds of millions of cells from a 10 to 20 
ml BM aspirate.60,61 The cell yield after expansion varies with the age and 
condition of the donor and with the harvesting technique. Therefore, differences 
in isolation methods, culture conditions, media additives greatly affect cell yield 
and possibly also the phenotype of the expanded cell product.61,71,72 For these 
reasons, efforts have been made within the European Group for Blood and 
Marrow Transplantation (EBMT) MSC expansion consortium for the 
standardization of MSC isolation and expansion procedures. This organization, 
including European centers interested in the biology and clinical application of 
MSCs, has defined common protocols, in order to facilit te comparisons 
between cell products generated at different sites and to run large-scale clinical 
studies. 
In this regard, MSCs are currently expanded in vitro, either under experimental 
or clinical grade conditions, in the presence of 10% fetal calf serum (FCS)71,72 
and serum batches are routinely pre-screened to guarantee both the optimal 
growth of MSCs and the bio-safety of the cellular product. Despite this, the use 
of FCS has raised some concerns when utilized in clinica  grade preparations, 
because it might theoretically be responsible for the transmission of prions and 
still unidentified zoonoses. It may also cause immune reactions in the host, 
especially if repeated infusions are needed, with consequent rejection of the 
transplanted cells.73 In view of these considerations, serum-free media, 
appropriate for extensive expansion and devoid of the risks connected with the 
use of animal products, are under investigation. The possibility of using 
autologous or allogeneic human serum for in vitro expansion of MSCs has been 
tested and autologous serum has proved to be superior to both FCS and 
allogeneic serum in terms proliferative capacity of the expanded MSCs.74 The 
reduction of bovine antigens by a final 48-hour incubation with medium 
supplemented with 20% human serum, to prepare hypoimmunogenic MSCs, has 
also been proposed.75 Human platelet-lysate (PL), which consists of human 
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platelet growth factors (GFs) in a small volume of plasma, has been recently 
demonstrated to be a powerful substitute for FCS in MSC expansion.76,77 Indeed, 
the high concentration of natural GFs contained in platelets may offer a 
significative advantage in terms of proliferative capacity of MSCs, providing 
high numbers of cells in a short culture-period.76,77 However, further studies are 
needed to better understand the behaviour of PL-expanded MSCs (MSCs-PL), 
as compared to those cultured in FCS-based medium. In particular, a 
comprehensive characterization of the biological and functional properties of 
MSCs-PL, in comparison with FCS-expanded MSCs, needs to be performed 
before introducing this culture supplement in the routine preparation of cellular 
products for clinical application. Moreover, clinical data on the safety and 
efficacy of MSCs have been mainly obtained with cells expanded in the 
presence of FCS, whereas relatively little in vivo experience is available with 
MSCs cultured in PL.  
Another issue related to the ex vivo expansion of MSCs is that the manipulation 
may alter the functional and biological properties of the cells, leading to the 
accumulation of genetic alterations, as already shown by few groups.62,78,79 The 
use of MSCs in clinical applications requires that t e bio-safety of these cells be 
carefully investigated through appropriate and sensitive tests. In particular, the 
absence of transformation potential in cultured cells has to be documented 
before infusion into patients, particularly into immune-compromised subjects 
where failure of immune surveillance mechanisms might further favor the 
development of tumors in vivo. The possibility that karyotyping on expanded 
cells be included in the release criteria for MSC administration into patients is 
currently being discussed. A precise characterization of the genetic profile of 
MSCs could allow to identify phenomena of senescence, developing in cells at 
the end of their life-span, versus transformation of cells, due to the occurrence 
of genetic alterations.  
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In vivo animal models to test the properties of MSCs 
The immunomodulatory and reparative/anti-inflammatory properties of MSCs 
have been tested in a variety of animal models (see Table 2). 
Both in a sheep model and in non-human primates, it has been shown that 
MSCs can engraft and distribute to a number of tissue  after systemic 
infusion.80,81 A number of studies have documented that marrow stroma remains 
of host origin after allogeneic HSCT in the majority of the patients,82-86 although 
others have shown the contrary.87-89 Therefore, the transplantability of MSCs in 
humans remains controversial. 
Systemic infusion of allogeneic BM-derived MSCs from baboons has been 
demonstrated to prolong the survival of allogeneic skin grafts, as compared to 
animals not receiving MSCs.90 Moreover, human MSCs have been shown to 
promote engraftment of UCB-derived HSCs in NOD-SCID mice and in fetal 
sheep80,91,92 and this enhancing effect was particularly prominent when 
relatively low doses of HSCs were transplanted.91 
For years, MSCs have been considered cells which could be potentially ignored 
by the immune system. However, it has been recently demonstrated that 
allogeneic MSCs are not intrinsically immunoprivileged, as, under appropriate 
conditions, they can induce an immune response, resulting in their rejection 
when infused into MHC-mismatched mice.55 On the contrary, the infusion of 
syngeneic host-derived MSCs resulted, in the same model, in enhanced 
engraftment of allogeneic stem cells.55 These observations are interpreted to 
indicate that MSCs may promote engraftment, provided that they survive in 
vivo and are not rejected as the result of an allo-immune response.  
Several animal studies have addressed the issue of the suppressive effect of 
MSCs in the context of GvHD prevention/treatment, wi h the aim of elucidating 
whether it can be ascribed to a true ‘immune’ effect, rather than a nonspecific 
antiproliferative function of the cells. However, conflicting results have been 
published, in particular on the role of MSCs in GvHD prevention. In one study, 
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AT-derived MSCs have been infused systemically in mice early after 
transplantation of haploidentical hematopoietic stem cells and were able to 
rescue the animals from lethal GvHD.93 Sudres et al. have reported that a single 
dose of BM-derived MSCs at time of allogeneic BM transplantation did not 
affect the incidence and severity of GvHD in mice,94 whereas UCB-derived 
MSCs administered at weekly intervals were able to prevent GvHD 
development after allogeneic transplantation of human peripheral blood 
mononuclear cells in NOD/SCID mice.95  
Thanks to their capacity to modulate immunoresponses and/or to promote tissue 
repair, MSCs are considered a potential novel treatm n  modality for 
autoimmune diseases.5,7,33,34 In this context, studies on the effects of MSCs in 
animal models of autoimmunity have been recently repo ted. Murine MSCs 
have been demonstrated to ameliorate experimental autoimmune 
encephalomyelitis (EAE), a model of human multiple sclerosis, through the 
induction of peripheral T-cell tolerance against the pathogenic antigen.96,97 In 
contrast, infusion of MSCs had no beneficial effects on collagen-induced 
arthritis (CIA) when tested in a murine model of rheumatoid arthritis.98 In 
mouse models, MSCs have been used also for the treatment of diabetes and 
their infusion led to an increase in the number of pancreatic islets and insulin-
producing β cells.99 In a murine model of systemic lupus erythematosus, MSCs 
were able to inhibit autoreactive T and B cells ameliorating the signs and 
sympthoms of the disease.100 Moreover, the infusion of rat MSCs in a rat 
experimental model of glomerulonephritis was able to s imulate glomerular 
healing, probably due to the secretion of soluble factors.101 Besides EAE, 
infusion of MSCs has been thought to play a role in the protection of neurons 
from damage occurring in other conditions, such as spinal cord injury, stroke 
and amyotrophic lateral sclerosis.102-104 Very recently, the topical implantation 
of BM-derived MSCs has been demonstrated to be beneficial also in the healing 
process of experimental colitis in rats, confirming the ability of these cells to 
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modulate immune-responses and to promote tissue repair through their trophic 
activity.105 Other studies in animal models of organ injury (heart, lung, kidney 
and liver) have suggested similar results in terms of MSCs ability to promote an 
anti-inflammatory effect and, thus, to protect against tissue injury.4,106-109 
In most of the reported studies, the therapeutic effect of MSCs does not seem to 
be associated with their differentiation into the resident cell-types, but appears 
to be mostly related to their anti-proliferative and anti-inflammatory effect, as 
well as to their capacity to stimulate survival and functional recovery in injured 
organs, likely through paracrine mechanisms. 
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Table 2. MSC therapy in experimental disease models  
 
Tx, transplantation; HSCT, hematopoietic stem cell transplantation; GvHD, graft-
versus-host-disease; EAE, experimental autoimmune enc phalomyelitis; CIA, collagen-




Animal, model Outcome Reference 
no. 
 
Baboon, skin graft  Tx 
NOD-SCID mouse, HSCT 
Fetal sheep, HSCT 














Rat, experimental colitis  
 
Rat, heart transplantation 
 
Rat, myocardial infarction 
 
Mouse, lung injury 
 
Mouse, ischemia 
/riperfusion kidney injury 




Prolonged skin graft survival 
Promoted engraftment 
Promoted engraftment 
Decresed graft rejection (syngeneic 
MSCs) 
Prevention of GvHD  
No effect on development of 
GVHD 
Prevention of GvHD, unefficacious 
for GvHD treatment 
Prevention of EAE development 
No effect 
Ameliorated diabetes and kidney 
disease 
Ameliorated signs and sympthoms 
of SLE 
Stimulated glomerular healing 
Stimulated intestinal mucosa 
healing 
Migrated to the heart during chronic 
rejection  
Promoted an anti-inflammatory 
effect 



































Clinical applications of MSCs  
The immunesuppressive capacity and the regenerative/reparative potential of 
MSCs have generated clinical interest in the field of HSCT, in order to prevent 
graft rejection and to prevent/control GvHD, as well as in the context of 
Regenerative Medicine with the aim of facilitating tissue repair (see Table 3). 
The ability of MSCs to enhance the engraftment of HSCs after transplantation 
has been demonstrated both in animal models,80,91,92 as previously mentioned, 
and in clinical trials. The experimental data in vivo, together with the known 
physiological role played by MSCs in sustaining haem topoiesis, have provided 
the rationale for testing the capacity of these cells to facilitate haematological 
recovery after HSCT in humans. The first clinical trial on the use of MSCs for 
accelerating haematological recovery was performed in 28 breast cancer 
patients given autologous transplantation and co-infused with 1–2×106 
MSCs/kg body weight. No MSC-related toxicity was registered, whereas a 
rapid haematopoietic recovery was noted.110 After this study, a multicenter trial 
aimed at evaluating the safety of MSC infusion was conducted in 46 patients 
receiving allogeneic HSCT from an HLA-identical siblings.111 MSC co-infusion 
was not associated with adverse events; haematopoieic recovery was prompt 
for most patients and moderate to severe acute GvHD was observed in 28% of 
the patients. 
The most impressive clinical effect of MSCs in vivo has been observed in the 
treatment of acute GvHD developing after allogeneic HSCT. The first striking 
report of this effect was reported by Le Blanc et al. who described a pediatric 
patient experiencing grade IV acute GvHD of the livr and gut after allogeneic 
HSCT from an unrelated volunteer and resistant to multiple lines of immune 
suppressive therapy. The child was rescued by the infusion of BM-derived 
MSCs isolated from the mother.112 
In view of the promising experimental results on the use of MSCs for the 
treatment of autoimmune diseases,96-101 their role in the clinical setting is now 
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beginning to be explored. MSCs isolated from patients with systemic sclerosis 
have been reported to be functionally impaired in vitro;113 while, other reports 
have documented that these latter cells, as well as MSCs from patients with 
variuos autoimmune diseases, exhibit the same phenotypical and functional 
properties as their healthy counterparts.114,115  
Both in animal models and in patients, it has been shown that BM-derived cells 
play a role in the healing process following intestinal injury and in the 
regeneration of various cellular components of the mucosa.105,116-118 Recently, in 
a phase-I clinical trial, autologous, AT-derived MSCs have been successfully 
employed for the treatment of 4 patients with fistul zing Crohn’s Disease 
(CD).119 Based on these encouraging results, a phase-II trial on autologous AT-
derived MSCs120 and a phase-III trial on third-party, BM-derived MSCs121,122 in 
CD patients refractory to conventional therapies, are underway.  
Therapeutic infusion of MSCs has been employed in the context of 
Osteogenesis Imperfecta (O.I.), a genetic disease characterized by production of 
defective type I collagen which is responsible for the occurrence of fractures, 
retarded bone growth with progressive bone deformation and premature death. 
Horwitz et al. first reported that transplantation of BM cells from an HLA-
identical sibling could, at least transiently, ameliorate the clinical conditions of 
patients with O.I., as donor-derived, mesenchymal progenitors contained  
transplanted BM could migrate to the bones and give r s  to osteoblasts. 
However, so far no clear demonstration that MSCs were r sponsible for the 
claimed improvement of bone structure and clinical ondition has been 
provided. 123,124 The same group has subsequently reported that the infusion of 
purified allogeneic MSCs might have been capable of nhancing the therapeutic 
benefits of allogeneic BM transplantation in O.I. patients.73  
Since MSCs express high levels of arylsulfatase A and alfa-L-iduronidase, MSC 
treatment has been proposed also for patients affected by metachromatic 
leukodystrophy (MLD) and Hurler disease, 2 inherited diseases caused by the 
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deficiency of the above mentioned enzymes. In a report from Koc et al., donor-
derived MSCs were infused in 11 patients with MLD and Hurler disease after 
allogeneic HSCT. Although there was no major improvement in the overall 
health of the patients, in 4 of 5 children with MLD an improvement in nerve-
conduction velocity was observed.125 
Although, little is known on the engraftment and i  vivo survival of MSCs, the 
few clinical studies performed so far suggest that eir clinical use is feasible 
and safe. To date, no severe adverse reactions have been recorded in humans 
after MSC administration, both in terms of immediate, infusional toxicity and of 
late effects. These observations might also be due to the limited survival of 
MSCs in vivo or to short follow-up time of the patients treated. Another 
important clinical safety concern is the possibility of ectopic tissue formation 
after MSC treatment. Recently calcifications were observed in the infarcted 
hearts of mice that received local MSC treatment.126  
The mechanisms by which MSCs exert their immunomodulatory and reparative 
effects in vivo are still poorly understood and require extensive in vitro and in 
vivo testing. The possibility that allogeneic MSC may be rejected due to 
recognition by the immune cells of non immune-ablated hosts, as already 
suggested in an animal model,55 or due to sensitization to bovine proteins 
remaining in the cell product after ex vivo expansion, deserves further 
investigation.  
Moreover, concerns remain over the potential systemic i munosuppression 
mediated by MSCs after in vivo administration. In immunocompetent mice, 
Djouad et al. demonstrated that local as well as systemic infusion of MSCs 
suppressed the host antitumor immune response, thus favoring allogeneic tumor 
formation.127 In humans, recent data suggest that the co-transplantation of MSCs 
and HSCs may result in increased risk of relapse in hematologic malignancy 
patients, as compared to patients receiving standard HSCT.128  
 28
Finally, ex vivo expanded MSCs should be properly studied to demonstrate their 
genetic stability before administration into patiens, to avoid any possible risk 
related to the infusion of transformed cells, bearing genetic alterations 
developed during in vitro culture. 
In conclusion, while MSC treatment represents a promising and novel modality 
for the treatment of many disorders, concerns remain over the potential of 
systemic immune suppression, ectopic tissue formation and malignant 
transformation of MSCs. These concerns apply, in particular, to the use of 
autologous and expanded MSCs. Long term follow-up st dies are required to 
address these issues. 
To completely exploit the potentiality of this new treatment modality more in 
vivo work is required to increase our knowledge on how MSCs mediate their 
suppressive effect and reduce inflammatory responses. Moreover, in vivo 
tracking studies to examine the survival, distribution and homing of MSCs after 
infusion in humans are necessary. The identification of a universal MSC marker 
is warranted both to dissect the hierarchy of the diff rent MSC subsets and to 
facilitate the generation of homogenous cell products at different sights. Once 
more largely defined, these in vivo biological activities of MSCs could be 
properly employed as a novel therapeutic strategy to stimulate tissue repair and 
modulate immune responses in a variety of immune-mediat d and inflammatory 
diseases. 
 
AIMS OF THE PRESENT STUDY     
In this thesis we will focus on the biological and functional characterization of 
human MSCs and on the role of these cells in the context of hematopoietic stem 
cell transplantation. The ability to differentiate into cell-types of mesodermal 
origin, in partcular into the chondrogenic lineage, the immune regulatory effect 
of BM- and UCB-derived MSCs expanded in medium supplemented with either 
FCS or PL and the potential susceptibility to undergo malignant transformation 
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after long-term in vitro culture are evaluated. Moreover, preliminary results on 
the use of BM-derived MSCs in different clinical context of HSCT, such as 
haploidentical T-cell depleted HSCT from a partially matched family donor, 
UCB transplantation and steroid-resistant, severe acute GvHD are reported.  
A lot of interest has recently emerged in techniques for cartilage tissue 
engineering where mesenchymal progenitor cells can be delivered within an 
appropriate carrier system to repair and regenerate p thologically altered 
cartilage.26,56 In chapter 2 the ability to diffentiate into the chondrogenic 
lineage of MSCs isolated from different fetal and adult tissue sources is studied 
and compared. For this purpose, MSCs are isolated and expanded from fetal 
lung and BM, as well as from maternal placenta and dult BM, with the aim of 
investigating which is the preferred MSC source to be employed for cartilage 
repair. The influence of the cell passage on the ability of MSCs to differentiate 
into chondrocytes is also evaluated. 
Table 3. Clinical experience with MSCs (published rports) 
 









Acute GvHD, allogeneic 
HSCT 
Fistulizing Crohn’s disease, 
local infusion 
O.I., allogeneic HSCT 
 










































Accelerated hematological recovery 
 
Prompt haematopoietic recovery, GvHD 
prevention 
Resolution of grade IV acute GVHD 
 
Repair of fistulas 
 
Improvement of bone structure and 
clinical condition (?) 
No major improvement in overall health. 
(MLD:improvement in nerve-conduction 
velocity) 
Increased risk of relapse 
 

























MSCs are mainly expanded in vitro, either under experimental conditions or in 
clinical grade preparations, in the presence of FCS.59,61 However, the use of 
FCS raises some concerns when utilized in the clinical setting.71 For this reason, 
the identification of a serum-free medium that allows extensive expansion of 
MSCs for clinical application, is warranted. In chapter 3, the use of PL as 
alternative culture supplement for MSC ex vivo isolation and expansion is 
tested. The aim of the study is to characterize MSCs expanded in the presence 
of PL for their phenotype, differentiation and proliferative capacity, 
immunoregulatory effect on alloantigen-specific immune responses, as well as 
genetic stability, as compared to MSC cultured in FCS-based medium.  
 
Concerns that adult human MSCs may be prone to malignant transformation 
have been recently raised.62,79 The absence of transformation potential in 
cultured MSCs has to be documented particularly when considering their 
infusion into immune-compromised subjects where failure of immune 
surveillance mechanisms might further favor the development of tumors in vivo. 
Chapter 4 describes the analysis of the potential susceptibility to malignant 
transformation of human BM-derived MSCs at different in vitro culture time 
points. The aim of this study was to ascertain whether he biological properties 
of MSCs after ex vivo expansion remain appropriate for their use in cell th rapy.  
 
For many children with life threatening hematological diseases stem cell 
transplantation is the only curative option. In those children lacking a matched 
related or unrelated donor, haplo-identical peripheral blood stem cell 
transplantation (PBSCT) from a healthy parent is a fe sible alternative. To 
reduce the risk of fatal GvHD, as a complication of transplantation across major 
histocompatibility antigens, intense T cell depletion is required. However, this 
significantly increases the risk of either graft failure or early rejection129,130 In 






transplantation of BM-derived, ex vivo expanded MSCs of donor origin in 
children undergoing transplantation of granulocyte colony stimulating factor 
(G-CSF)-mobilized, CD34+ selected progenitor cells from an HLA-disparate 
relative. The study is intended to sustain hematopoietic engraftment and reduce 
graft failure rate by means of the co-infusion of MSCs. Children with 
hematological malignancies or non-malignant disorders, lacking an HLA-
matched donor were enrolled in the study in two participating centers (Leiden 
University Medical Center and Fondazione IRCCS Policlinico S. Matteo).  
 
GVHD is a potentially life threatening complication f HSCT or the infusion of 
donor lymphocytes (DLI).131,132 The mainstay of treatment for established 
GvHD is cortico-steroids with a response rate in the order of 30-50%. In those 
patients resistant to steroid treatment, second line therapy remains 
unsatisfactory and overall survival is poor.131 Several studies indicate that MSCs 
have immunosuppressive and reparative properties; for these reasons these cells 
are proposed as new terapeutic tool in GVHD management.32-34,41 In chapter 6 
the results of a multicenter, phase II study on the use of BM-derived MSCs to 
treat steroid-resistant, severe acute GvHD after allogeneic HSCT in 55 pediatric 
and adult patients, affected by either malignant or non-malignant disorders, are 
reported. This study addresses the issue of safety nd efficacy of the infusion of 
HLA-identical or disparate, in vitro expanded, BM-derived MSCs for the 
treatment of severe, steroid-resistant acute GvHD.  
 
CD is a chronic inflammatory enteropathy in which a dysregulation of the 
immune response towards intestinal bacteria in genetically susceptible 
individuals plays a pathogenetic role.134,135 Despite the large number of 
therapeutic options available,136 there is a growing number of CD patients with 
refractory/recurrent disease and alternative strategies are needed both to 






quality of life. Thanks to their capacity to modulate immune response and 
promote tissue repair, MSCs represent a potential novel treatment for 
autoimmune/inflammatory diseases, including CD. Chapter 7 describes the 
phenotypical and functional characterization of in vitro expanded MSCs from 
CD patients, in view of their future clinical application. The aim of the study 
was to evaluate the feasibility of isolating and expanding ex vivo MSCs from 
BM of CD patients with active disease, and to carry out a phenotypical and 
functional characterization of these cells in comparison with BM-MSCs isolated 
from healthy donors.  
 
The frequency of MSCs in UCB is very low and the prsence of mesenchymal 
progenitors in full-term UCB has been questioned in recent years. The attempts 
of many groups to obtain MSC from this source, employing FCS-based media, 
have either failed137,138 or yielded low numbers.16,139 In chapter 8 we test the 
ability of a PL-supplemented medium to support the generation and ex vivo 
expansion of MSCs from full-term UCB (UCB-MSCs), as well as characterize 
these latter cells for their biological and functional properties, in comparison to 
PL-expanded BM-MSCs. In particular, we focus on the inv stigation of both the 
genetic stability and the immunoregulatory function, exerted on alloantigen-
specific immune response, of UCB-MSCs.  
 
In chapter 9 the results and conclusions of these studies are summarized and 
the future clinical applications of MSCs in the context of HSCT and 
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Mesenchymal stem cells are multipotent cells capable of differentiation into 
several mesenchymal lineages. These cells have been isolated from various 
tissues such as adult bone marrow, placenta and fetal tissues. Since a specific 
phenotypical marker for MSCs is lacking, MSCs are currently characterized on 
the basis of phenotype and capacity to differentiate into multiple mesenchymal 
lineages. However, how the potential of these cells to differentiate into the 
chondrogenic lineage is influenced by the tissue of origin has not been 
examined. The aim of this study was to investigate wh ther MSCs isolated from 
different sources exhibit differential multilineage differentiation potential. 
 Design: MSCs from fetal and adult tissues were phenotypically characterized 
and examined for their differentiation capacity, based on morphological criteria 
and expression of extracellular matrix components.  
Results: Our results show that both fetal and adult MSCs undergo 
chondrogenesis under appropriate conditions. Neverthel ss, MSCs of bone 
marrow origin, either fetal or adult, exhibit a higer chondrogenic potential than 
fetal lung and placenta derived MSCs, as demonstrated by the appearance of 
typical morphological features of cartilage, the intensity of Toluidine Blue 
staining and the expression of collagen type II, IX and X after culture under 
chondrogenic conditions. In addition, the capacity of MSCs to differentiate into 
chondrocytes was reduced upon passaging of cells. 
Conclusions: MSCs are an attractive source for cartilage tissue engineering 
strategies. Hence, exploring the chondrogenic potential of different sources is of 
great interest for such a purpose. Our study indicates that bone marrow is to be 










Articular cartilage has a limited capacity of healing after injury. Traumatic 
damage and degenerative diseases of the cartilage such as osteoarthritis or 
rheumatoid arthiritis are common health problems worldwide. Therefore a lot of 
interest has recently emerged in techniques for cartilage tissue engineering. The 
current strategies of cartilage repair, based on the use of autologous 
chondrocytes, have some limitations including the small number of cells 
available with restricted proliferative capacity and the further damage at donor 
site of harvest. For these reasons, new techniques are now focusing on the use 
of mesenchymal progenitor cells to be delivered within an appropriate carrier 
system to repair and regenerate pathologically altered cartilage 1,2. In fact, 
mesenchymal stem cells (MSCs) play a role in bone and cartilage homeostasis 
and it has been shown that the chondrogenic activity of hese cells is reduced in 
patients with advanced osteoarthritis (OA) 3. One of the mechanisms involved 
in the repair of damaged articular cartilage may be the de novo chondrogenesis 
from MSCs 4,5. Therefore, based on the in vitro observation of the 
differentiation into chondrocytes, on their expandability and availability, MSCs 
can be considered as an attractive candidate for purposes of cartilage 
engineering 6,7. 
MSCs are multipotent cells with the ability to differentiate into several 
mesenchymal lineages, including osteoblasts, adypocytes and chondrocytes 8-10. 
Although MSCs were originally isolated from bone marrow 11, they have also 
been isolated from other tissue sources. MSCs have been identified in fetal 
tissues such as lung, bone marrow, liver and spleen in first- and second-
trimester 12,13. Placenta has been shown to be another rich source f MSCs of 
both fetal and maternal origin 14; and MSCs have been also isolated from 
umbical cord blood, although in low frequency, and adipose tissue. At present 
no unique phenotype has been identified for MSCs; therefore the isolation and 






markers on culture expanded cells and on their ability to differentiate into the 
various mesenchymal differentiation lineages.  
In the present study, we investigate the multilineage differentiation potential of 
MSCs derived from 4 different sources and whether tis capacity is influenced 
by the tissue of origin. 
 
Materials and methods 
Isolation and culture of human MSCs 
Fetal tissues 
Fetal lung (fL) and fetal bone marrow (fBM) were obtained from the same fetus 
from women undergoing elective termination of pregnancy between 15 and 22 
weeks of gestation.  The study was approved by the hospital ethical committees 
and informed consent was obtained. Single cell suspensions of fetal lung were 
made by mincing and flushing the organ through a 100 µm nylon filter with 
IMDM medium (Cambrex, Verviers, Belgium) containing 1% 
penicillin/streptomycin (P/S; Cambrex, Verviers, Belgium) and 2% heat-
inactivated fetal calf serum (FCS; Cambrex, Verviers, Belgium), i.e. washing 
medium. Single cell suspensions of fetal bone marrow were obtained by 
penetrating the long bones with a needle (23 gauge) and flushing the bones with 
washing medium. After washing, the cell suspension was depleted of red cells 
by incubation for 10 minutes in NH4Cl (8,4 g/L)/KHCO3 (1/g) buffer at 4 °C. 
The cells were subsequently plated at 160.000/cm² in culture medium consisting 
of M199 (Gibco, Paisley, Scotland) supplemented with 10% FCS, P/S, 
Endothelial Cell Growth Factor (ECGF) 20 µg/ml (Roche Diagnostics GmbH, 
Mannheim, Germany) and heparin 8 U/ml in tissue culture flasks (Greiner Bio-
One GmbH, Mannheim, Germany) previously coated with 1% gelatin for 30 








Placenta    
Placentas (PL) were derived from second- and third-trimester pregnancies after 
informed consent and approval by the hospital ethical committees. Tissue 
specimens of placenta (maternal origin) were first washed with PBS; single cell 
suspensions were made by mincing and flushing the tissue through a 100 µm 
nylon filter with washing medium. The cells were sub equently cultured as 
described above. To confirm the maternal origin of these cells, molecular HLA-
typing was performed on the PL-MSCs cultures. 
 
Adult bone marrow 
Adult bone marrow (aBM) samples were obtained from healthy donors for 
allogeneic stem cell transplantation under a protocol approved by the Ethical 
Review Board. Mononuclear cells were isolated by density gradient (Ficoll, 
1.077 g/ml) and plated at 160.000/cm² in culture medium consisting of DMEM-
Low Glucose (Gibco, Paisley, Scotland) supplemented with 10% FCS and P/S. 
All cells were kept in a humidified atmosphere at 37 °C with 5% CO2. Three to 
five days after plating, non-adherent cells were removed and the medium was 
refreshed. When grown to confluency, adherent cells were detached with 
trypsin/EDTA (Cambrex, Verviers, Belgium) for 5 minutes at 37 °C and 
reseeded for expansion or differentiation. 
 
Flow cytometric analysis  
Culture expanded fL-, fBM-, aBM- and PL-MSCs were phenotypically 
characterized by flow cytometry (FACSScan, Becton Dickinson). Fluorescein 
isothiocyanate (FITC) or phycoerythrin (PE) conjugated antibodies against 
CD166 (CLB, Amsterdam The Netherlands), CD105 (Ancell Corporation, 
Bayport, MN, USA), CD90 (Pharmingen, San Diego, CA), CD34, CD45 and 






HLA-ABC (Instruchemie, Hilversum, The Netherlands), HLA-DR (Beckton 
Dickinson, San Jose, CA) were used, as well as isotype controls. 
 
Osteogenic and adipogenic differentiation    
The adipogenic and osteogenic differentiation capacity of MSCs from the 4 
different sources was determined as previously described 13. In short, to induce 
osteogenic differentiation, cells were cultured in α-MEM supplemented with 
10% FCS, P/S, dexametasone (10-7 M) and ascorbic acid (50 µg/ml). β-
glycerophosphate (5 mM) was added from day 7 onwards. For adipogenesis, 
insulin (10 mg/ml), indomethacin (0,25 M) and 1-methyl-3-isobutylxantine 
(IBMX, 50 mM) were added to this medium. Cells were incubated in 
differentiation medium for 3 weeks, with medium replacement twice a week, at 
37°C with 5% CO2. To detect the osteogenic differentiation cells were stained 
for alkaline phosphatase (AP) activity using Fast Blue and for calcium 
depositions with Alzarin Red. The adipogenic differentiation was evaluated 
through the morphological appearance of fat droplets. 
 
Chondrogenic differentiation 
For chondrocyte differentiation, 200,000 MSCs were placed per well in 96-well 
suspension culture plates, U-shape, (Greiner Bio-One GmbH, Mannheim, 
Germany) and centrifuged at 1200 rpm for 4 minutes to a pellet. Pellets were 
cultured at 37 °C with 5% CO2 in 200 µl of serum-free chondrogenic medium 
consisting of DMEM-High Glucose (Gibco, Paisley, Scotland), 40 µg/ml 
proline (Sigma, USA), 100 µg/ml sodium pyruvate (Sigma, USA), 50 mg/ml 
ITS+Premix (BD Biosciences, Bedford, MA), 1% Glutamx (Gibco, Paisley, 
Scotland), P/S, 50 µg/ml ascorbate-2-phosphate (Sigma, USA), 10-7 
dexametasone (Sigma, USA), 10 ng/ml Transforming growth Factor-β3 (TGF-






(BMP-6, kindly provided by dr. S. Vucikevic) The medium was refreshed every 
3 days for 21 days. We investigated at least three samples per source and 3 
different passages per sample. 
 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
Total RNA was extracted from 1 million undifferentiated MSCs and from 
pellets at day 21 of the differentiation period, from each source, using RNAeasy 
kit (Quiagen Gmbh, Hilden). RNA was reverse transcribed into cDNA using 
First Strand cDNA Synthesis kit for RT-PCR (Roche Diagnostics Gmbh, 
Mannheim, Germany) according to the manifacturer’s instructions. cDNA was 
amplified using a GeneAmp PCR System 2400 (Applied Biosystems, Foster 
City, CA). Expression of collagen type II, IX and X mRNA was quantified by 
real-time quantitative PCR using the Bio-Rad iCycler with SYBR Green. Data 
were corrected for β2-microglobulin expression. The following oligonucleotide 
primers were used:  
collagen type II: forward 5'-CCCTCTCCCACACCTTCCTC-3' and reverse 5'-
GGGTGAGGGATTCCAGGGAAA-3';  
collagen type IX: forward 5'-AGGACACAAGGGTGAAGAAGGT-3' and 
reverse 5'-TTTTCCCCTTTGTCCCCAACTATG-3';  
collagen type X: forward 5'-TTTTGCTGCTAGTATCCTTGAACTT-3' and 
reverse 5'-AGGAGTACCTTGCTCTCCTCTTACT-3';  
β2-microglobulin: forward 5'-TGCTGTCTCCATGTTTGATGTATCT-3' and 
reverse 5'-TCTCTGCTCCCCACCTCTAAGT-3'.  
All PCR reactions were performed with 5 ng cDNA and according to the 
manufacturer's protocol of the qPCR Core Kit (Eurogentec, Southampton, UK) 
in a final volume of 25 µl. 
The cDNA was amplified using the following thermal cycling conditions: one 
cycle at 50 °C for 2 min and 95 °C for 10 min, followed by 40 cycles of 15 s at 






used as a negative control. Fluorescence spectra wee recorded and the 
threshold cycle number (Ct) was read. For each source mean Ct was calculated 
and from this value the fold difference from expression in the human growth 
plate according to the equation 2-∆∆Ct. For visualization, this value was log-
transformed and expressed in figure 2C. 
 
Histological analysis 
After 21 days of culture in chondrogenic medium, pellets were fixed in 10% 
formalin, dehydrated by treatment with graded ethanols and incubated in 
butanol overnight. Thereafter pellets were embedded in paraffin and cut into 5 
µm sections using a Reichert Jung 2055 microtome (Leica, Rijswijk, The 
Netherlands). The sections were then mounted on glass slides and stained with 
Toluidine Blue.  
The immunohistochemical staining for collagen type X was performed on 
deparaffinized sections. To block non-specific activity, sections were pretreated 
with hydrogen peroxidase. Sections were stained with mouse monoclonal 
antibody against collagen type X (Quartett, Berlin, Germany). The binding of 
mouse IgG was detected by biotinylated rabbit-anti-mouse IgG (DAKO, 
Glostrup, Denmark), followed by incubation with horse adish-peroxidase-
conjugated-streptavidine (Amersham Biosciences, UK). The peroxidase activity 
was revealed using 3-amino-9-ethylcarbazole (AEC) substrate. After sections 
were washed, they were counterstained with hematoxylin.  
 
Results 
Morphology and immunophenotypic characterization of MSCs 
MSCs isolated from all four different sources displayed the characteristic MSC-
like spindle-shape, however subtle differences in morphology were present 
(Figure 1A). fL- and PL-MSCs showed a more elongated and thin shape 







Figure 1A. Morphology of culture-expanded MSCs. MSCs from the four different 
sources display the characteristic spindle-shaped morphology, however subtle 
differences are present. a, b: Morphology of fBM- and aBM-MSCs respectively, 
showing a splindle-round shape. Magnification x5. c, d: Morphology of fL- and PL-
MSCs respectively, displaying a spindle-thin shape. Magnification x10.  
 
MSCs from all samples were immunophenotypically analyzed at passage 2 or 3. 
The phenotypes of fL-, fBM-, aBM- and PL-MSCs were similar and in 
agreement with previous publication 9,13,14, i.e. CD90, CD105, CD166, HLA-
ABC positive and CD34, CD45, CD31, CD80, HLA-DR negative (Figure 1B).  
 
Figure 1B. Immunophenotype of culture-expanded MSCs. Immunophenotypic 
characterization of MSCs from a representative sample for each source of MSCs. MSCs 
of all origin were positive for CD90, CD105, and CD166 surface antigens and negative 






Osteogenic and adipogenic differentiation  
To examine the differentiation capacity of MSCs from the different sources, 
cells were induced into osteoblasts and adipocytes and examined by histological 
stainings. fL-, fBM-, aBM-MSCs and PL-MSCs were allble to differentiate 
into osteoblasts as demonstrated by the histologic detection of alkaline 
phosphatase activity and calcium depositions, and into adipocytes as revealed 
by the formation of lipid droplets (data not shown). However, PL-MSCs 
showed a lower ability to form both osteoblasts anddipocytes, while fL-MSCs 
were less capable to differentiate into the adipogenic lineage, as compared to 
bone marrow sources (Table 1).  
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+/- +/- - - 0/4 
 
 
The presence of adipocyte-like morphology, the intensity of Alzarin Red and Toluidine 
Blue staining and the chondrocyte-like morphology are scored as: -, +/-, +, ++. The 
adipocyte-like morphology is defined by the appearance of fat droplets. The 
chondrocyte-like morphology is defined by the following features: decrease in cell 
density with distance between cells, rounded morphology of cells and nuclei, deposition 
of extracellular matrix, presence of chondrocytic la unae. Only pellets that are scored + 
or ++ for both the Toluidine Blue staining and the chondrocyte-like morphology are 
considered positive for cartilage formation (last column on the right).  
 
The differentiation capacity into osteoblasts and adipocytes was maintained, 






The chondrogenic differentiation capacity of MSCs is influenced by the tissue 
of origin  
Next, the chondrogenic differentiation capacity of MSCs of different origin was 
examined and compared. FL- (n= 4 samples), fBM- (n= 3 samples, derived 
from the same fetus), aBM- (n= 4 samples) and PL-MSCs (n= 4 samples, 
maternal origin) were centrifuged into micromasses, cultured as pellets and 
differentiated in serum-free medium containing ascorbate-2-phosphate, 
dexamethasone, TGF-β3 and  BMP-6.  
MSCs from all sources formed a pellet after centrifugation, although pellets 
consisting of fL- and PL-MSCs were frequently less stable and showed a more 
irregular shape compared to the pellets from fBM- and BM-MSCs that were 
firm and spherical. Pellets derived from fBM- and aBM-MSCs were larger in 
size after 21 days of culture compared to those derived from fL- and PL-MSCs. 
In particular, fBM- and aBM-MSCs showed an increase in both the diameter 
and the area of the pellets after 3 weeks of culture in chondrogenic medium 
(data not shown). Furthermore, a 4.2- and a 2.9-fold increase in weight was 
observed in pellets formed by fBM and aBM-MSCs respectively at day 21 of 
culture, whereas fL- and PL-MSCs exhibited a decrease in weight of pellets 
over the culture period (Figure 2A). These observations suggest that cartilage 
extracellular matrix has been syntesized and deposited in pellets from bone 
marrow cells, leading to the increase in size and weight.  
To more specifically analyze the process of chondrogenesis, the expression of 
collagen type II, IX and X was measured by Q-PCR on undifferentiated cells 
and on pellets 3 weeks after induction (Figure 2B). Pellets formed by fBM- and 
aBM-MSCs showed a marked increase in the expression of collagen type II, IX 
and X after the induction period, compared to fL- and PL-MSCs pellets. These 
data were confirmed by the histological analysis: fBM- and aBM-MSCs 
produced more proteoglycans, hence more extracellular matrix, and expressed 






Blue staining (Figure 2C). Moreover, the immunohistochemical staining for 
collagen type X was positive only in sections derivd from fBM and aBM 
samples, suggesting that only these cells started to terminally differentiate into 
hypertrofic chondrocytes  (Figure 2D). A scoring system was used to compare 
the different degrees of chondrogenic differentiation between the 4 sources; 
evaluating the intensity of the Toluidine Blue staining and the appearance of the 
typical chondrocyte-like morphology, both scored from – to ++. The stained 
sections from both fBM- and aBM-MSCs obtained the highest score with 100% 
of the samples evaluated demonstrating differentiatia on into chondrocytes; in 
fact, fBM- and aBM- cells showed the most intense Toluidine Blue staining and 
the typical morphological features of differentiated cartilage such as the 
decrease in cell density with distance between cells, the rounded morphology of 
cells, the deposition of extracellular matrix stained in purple and the presence of 
chondrocytic lacunae, whereas samples from fL- and PL-MSCs didn’t (Tab. 1). 
The chondrogenic differentiation capacity of MSCs decreases with passage 
number. In order to examine whether the number of cell passage  has an 
influence on the chondrogenic differentiation capacity of MSCs, different 
passages of fL-, fBM-, aBM- and PL-MSCs were evaluated. When considering 
fBM- and aBM-MSCs, a passage-dependent decrease in cart lage formation was 
observed (Table 2). In particular, the early passage  (P2-3) displayed the most 
intense Toluidine Blue staining and all the typical features of differentiated 
cartilage, whereas the later passages (P4-5 and P6-7) showed only a moderate or 
mild staining with less evidence of cartilage differentiation (data not shown). 
Moreover, the capacity of BM-MSCs to differentiate into chondrocytes declined 
between passage 6 and 8. For fL- and PL-MSCs, the influence of cell passage 
was not evident since little or no differentiation towards the chondrogenic 







Figure 2. Chondrogenic differentiation of MSCs from different sources. (A) Wet 
weights of the pellets from the four different sources at day 1 and 21 of the induction 
period (n = 3). (B)  Real-time RT-PCR analysis of collagen type II, IX and X during 
chondrogenic differentiation corrected for the housekeeping gene β2 microglobulin. 
Values are fold difference compared to expression in human growth plate (GP) and 






after 3 weeks of differentiation. Representative pictures from each source at passage 3 
are shown: a) fL-MSCs; b) fBM-MSCs; c) aBM-MSCs; d) PL-MSCs; e) and f) are 
enlargements of figure 2C b) and c) respectively, for detailed morphology. (D) 
Immunohistochemical staining for collagen type X on deparaffinezed sections after the 
induction period. Representative pictures at passage 3 are depicted: a) fL-MSCs; b) 
fBM-MSCs; c) aBM-MSCs; d) PL-MSCs; e) and f) are enlargements of figure 2D b) 
and c) respectively, for detailed morphology. 
 
Table 2. Influence of cell passage on the chondrogenic capacity of MSCs from 
different tissue sources. 
  
 P2-3 P4-5 P6-7 
fL-MSC 0/4 0/4 0/4 
 
fBM-MSC 3/3 3/3 1/3 
 
aBM-MSC 4/4 4/4 2/4 
 
PL-MSC 0/3 0/3 0/4 
 
 
The differentiation capacity is expressed as number of positive samples on the total 
number of samples evaluated per passage-group. A sample is scored positive when 
satisfying the criteria described in Table 1. 
 
Discussion 
Skeletal defects resulting from disease, malformation or injury are an interesting 
area of application for stem cell therapy. The therap utic effect of the 
transplantation of MSCs in children with Osteogenesis Imperfecta,  genetic 
disorder resulting in the abnormal production of collagen type I 15-17, suggests 
the potential of MSCs to ameliorate bone disorders.  
MSCs are an ideal candidate for strategies of tissue engineering since they are 
easily isolated and can be rapidly expanded to numbers that are required for 
clinical application 10,18,19. 
In this study we compared the chondrogenic differentiation potential of culture 
expanded MSCs derived from fetal BM and lung, placenta and adult BM. In 
comparison with fetal lung and placenta, fetal BM derived MSCs exhibited a 






by the increase in weight, diameter and area of pellets formed by bone marrow 
cells over the differentiation period, the increased l vels in the expression of 
mRNA of extracellular matrix components, such as collagen type II, IX and X, 
the positivity of the immunohistochemical staining for collagen type X and the 
marked intensity of the Toluidine Blue staining. A similar prefered 
chondrogenic potential was observed for adult BM-derived MSCs, showing that 
BM as a source of MSCs was responsible for this differentiation potential, 
rather that the fetal developmental stage of the tissue. The chondrogenic 
differentiation was reduced and ultimately lost, afer prolonged passages of the 
cultures. Although in vivo experiments are required to further substantiate the 
biological significance of these findings, our result  suggests BM as the 
preferred source for cartilage tissue engineering. 
MSCs have been shown to require specific culture conditi ns to induce 
differentiation towards the chondrogenic lineage. These requirements include a 
high cell density facilitating cell-cell contact and the use of serum-free medium 
with the addition of bioactive factors 20. In particular BMP-6, a member of the 
TGF-β superfamily of growth factors, has been demonstrated to enhance the 
chondrogenic differentiation of human MSCs in a pellet culture system 21,22. Our 
results confirm these findings and add that not only aBM-MSCs but also MSCs 
isolated from fetal tissues, namely lung and bone marrow, can undergo 
chondrogenesis under the same conditions. 
In a study from in’t Anker and colleagues 13 it was shown that MSCs isolated 
from second-trimester fetal bone marrow, lung, liver and spleen exhibit a 
different potential to differentiate into osteoblast and adipocytes, despite a 
similar immunophenotype. Moreover, a recent study from Im et al 23 
demonstrated that adipose tissue-derived MSCs possess a lower osteogenic and 
chondrogenic potential than BM-derived MSCs. Also in our experiments, 
despite MSCs derived from the four different sources showed a comparable 






more expressed in fBM- and aBM-MSCs. Moreover, we found that PL-MSCs 
were less capable to form both osteoblasts and adipocytes, while fL-MSCs 
showed to have a lower ability to differentiate into the adipogenic lineage 
compared to bone marrow sources. These differences in the differentiation 
potential might reflect some intrinsic diversities of MSCs residing in the various 
tissues, suggesting that the relation between immunophenotype and function of 
MSCs needs to be further investigated. Alternatively, the frequency of cells 
with lineage-specific differentiation capacity may differ between tissue sources. 
Indeed, the identification of specific markers enabling to distinguish between 
different populations of MSCs would be an important tool in the understanding 
and employment of these cells in the clinical setting. 
We found that the chondrogenic potential of MSCs decreases with the increase 
of the cell passage, as shown by the inferior growth in size and the mild 
intensity of the Toluidine Blue staining in pellets from the later passages (P6-7). 
These findings are in agreement with the study from Sekiya et al 22 in which a 
decrease in the chondrogenic potential of adult bone marrow-derived MSCs was 
seen after each consecutive passage under very similar culture conditions. In 
Sekiya experience, only a selected population of MSCs, the so called small and 
rapidly self-renewing cells (RS cells), retained the ability to form cartilage at 
P5. This loss of chondrogenic potential may be due to the graduate elimination 
of MSCs with chondrogenic potential and overgrowth by MSCs that lack 
differentiation potential, or may be due to functional alterations in chondrogenic 
MSCs. 
In conclusion, our results show that: I) MSCs of both fetal and adult origin 
undergo chondrogenesis under appropriate culture conditi ns; II) fBM- and 
aBM-MSCs express a higher chondrogenic ability than fL- and PL-MSCs, 
based on morphological, molecular, histochemical and immunohistochemical 
criteria; III) an inverse correlation between passage number and chondrogenic 






considering the attractive role that MSCs could play in strategies of cartilage 
tissue engineering, our data suggest that bone marrow cells are to be considered 






























supported by grants from the European Community (FP6 Program, Allostem) 
and CNR (Consiglio Nazionale delle Ricerche) to F.L., research grant 03-3014 
from the Dutch Cancer Society, the Netherlands, EuroCo d Nederland 









References    
 1. Heng BC, Cao T, Lee EH. Directing stem cell differentiation into the 
chondrogenic lineage in vitro. Stem Cells 2004;22:1152-1167. 
 2. Jorgensen C, Gordeladze J, Noel D. Tissue enginering through 
autologous mesenchymal stem cells. Curr Opin Biotechnol 2004;15:406-
410. 
  3.  Murphy JM, Dixon K, Beck S, Fabian D, Feldman A, Barry F. Reduced 
chondrogenic and adipogenic activity of mesenchymal stem cells from 
patients with advanced osteiarthritis. Arthritis Rheum 2002;46:704-713. 
 4. Alsalameh S, Amin R, Gemba T, Lotz M. Identificat on of mesenchymal 
progenitor cells in normal and osteoarthritic human articular cartilage. 
Arthritis Rheum 2004;50:1522-1532. 
 5. Tallheden T, Dennis JE, Lennon DP, Sjogren-Jansson E, Caplan AI, 
Lindahl A. Phenotypic plasticity of human articular chondrocytes. J Bone 
Joint Surg Am 2003;85-A Suppl 2:93-100. 
 6. van der Kraan PM, Buma P, van Kuppevelt T, van de  Berg WB. 
Interaction of chondrocytes, extracellular matrix and growth factors: 
relevance for articular cartilage tissue engineering. Osteoarthritis 
Cartilage 2002;10:631-637. 
 7. Risbud MV, Sittinger M. Tissue engineering: advnces in in vitro 
cartilage generation. Trends Biotechnol 2002;20:351- 6. 
 8. Caplan AI. The mesengenic process. Clin Plast Surg 1994;21:429-435. 
 9. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD. 
Multilineage potential of adult human mesenchymal stem cells. Science 
1999;284:143-147. 
 10. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential 
clinical uses. Exp Hematol 2000;28:875-884. 
 11. Friedenstein A. Stromal mechanisms of bone marrow: cloning in vitro 
and retransplantation in vivo. In: Thienfelder S, Rodt H, Kolb HJ, eds. 
Immunology of Bone Marrow Transplantation. Berlin: Springer-Verlag; 
1980:19-20. 
 12. Campagnoli C, Roberts IA, Kumar S, Bennet PR, Bellantuono I, Fisk 
NM. Identification of mesenchymal stem/progenitor cells in human first-
trimester fetal blood, liver, and bone marrow. Blood 2001;98:2396-2402. 
 13. in 't Anker PS, Noort WA, Scherjon SA, Kleijburg-van der Keur C, 
Kruisselbrink AB, van Bezooijen RL. Mesenchymal stem cells in human 
second-trimester bone marrow, liver, lung, and spleen xhibit a similar 
immunophenotype but a heterogeneous multilineage differentiation 
potential. Haematologica 2003;88:845-852. 
 14. in 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings 
GM, Claas FH, Fibbe WE. Isolation of mesenchymal stem cells of fetal or 






15.  Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M. 
Transplantability and therapeutic effects of bone marrow-derived 
mesenchymal cells in children with osteogenesis imperfecta. Nat Med 
1999;5:309-313. 
16.  Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY. 
Isolated allogeneic bone marrow derived mesenchymal stem cells engraft 
and stimulate growth in children with osteogenesis imperfecta: 
implications for cell therapy of bone. PNAS 2002; 99: 8932-8937. 
17. Le Blanc K, Gotherstrom C, Ringden O, Hassan M, McMahon R, 
Horwitz E. Fetal mesenchymal stem-cell engraftment in bone after in 
utero transplantation in a patient with severe osteogenesis imperfecta. 
Transplantation 2005; 79:1607-1614. 
18.  Fibbe WE, Noort WA. Mesenchymal stem cells andhematopoietic stem 
cell transplantation. Ann N Y Acad Sci 2003;996:235-244. 
19.  Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and 
biological characterization. Int J Bioch & Cell Biol 2004; 36: 568-584. 
20.  Yoo JU, Barthel TS, Nishimura K, Solchaga L, Caplan AI, Goldberg VM. 
The chondrogenic potential of human bone-marrow-derived 
mesenchymal progenitor cells. J Bone Joint Surg Am 1998; 80: 1745-
1757. 
 21. Indrawattana N, Chen G, Tadokoro M, Shann LH, Ohgushi H, Tateishi T. 
Growth factor combination for chondrogenic induction from human 
mesenchymal stem cell. Biochem Biophys Res Commun 2004;320:914-
919. 
 22. Sekiya I, Colter DC, Prockop DJ. BMP-6 enhances hondrogenesis in a 
subpopulation of human marrow stromal cells. Biochem Biophys Res 
Commun 2001;284:411-418. 
 23. Im G-I, Shin Y-W, Lee K-B. Do adipose tissue-derived mesenchymal 
stem cells have the same osteogenic and chondrogenic potential as bone 

















Optimization of  in vitro expansion of human multipotent 
mesenchymal stromal cells for cell-therapy approaches: 





Bernardo ME, Avanzini MA, Perotti C, Cometa AM, Moretta A, Lenta E, Del 



























There is great interest in mesenchymal stromal cells (MSCs) for cell-therapy 
and tissue engineering approaches. MSCs are currently expanded in vitro in the 
presence of fetal calf serum (FCS); however, FCS raises concerns when used in 
clinical grade preparations. The aim of this study was to evaluate whether 
MSCs expanded in medium supplemented with platelet-lysate (PL), already 
shown to promote MSC growth, are endowed with biological properties 
appropriate for cell-therapy approaches. We confirm p eviously published data 
showing that MSCs expanded in FCS/PL display comparable morphology, 
phenotype and differentiation capacity, while PL-MSCs were superior in terms 
of clonogenic efficiency and proliferative capacity. We further extended these 
data by investigating the immune-regulatory effect of MSCs on the alloantigen-
specific immune response in mixed lymphocyte culture (MLC). We found that 
MSCs-PL are comparable to MSCs-FCS in their capacity to: i) decrease 
alloantigen-induced cytotoxic activity; ii) favor differentiation of CD4+ T-cell 
subsets expressing a Treg phenotype; iii) increase rly secretion of IL-10 in 
MLC supernatant, as well as induce a striking augmentation of IL-6 production. 
As compared with MSCs-PL, MSCs-FCS were more efficint in suppressing 
alloantigen-induced lymphocyte subset proliferation and reducing early IFNγ-
secretion. Resistance to spontaneous transformation into tumor cells of 
expanded MSCs was demonstrated by molecular karyotyping and maintenance 
of normal morphology/phenotype after prolonged in vitro culture. Our data 
support the proposed immunological functional plasticity of MSCs and suggest 
that MSCs-PL can be used as an alternative to MSCs-FCS, although these latter 










Mesenchymal stromal cells (MSCs) are multipotent progenitors with the ability 
to differentiate along multiple cell lineages, such as osteoblasts, adipocytes and 
chondrocytes.1-3 Bone marrow (BM) is the most common source of MSCs; 
however, MSCs have been isolated from various other sources, namely 
placenta, amniotic fluid, cord blood, adipose tissue and fetal lung.4-11 Today 
MSCs are considered a useful tool for cell therapy nd tissue engineering 
approaches;12-14 in fact, these cells can be relatively easily isolated, mainly from 
BM, and display a remarkable capacity for extensive in vitro expansion. Indeed, 
MSCs have been already employed in clinical trials n a number of contexts, 
such as the facilitation of hematopoietic and immune reconstitution after 
hematopoietic stem cell transplantation (HSCT),15,16 prevention and treatment of 
acute and chronic graft versus host disease (GvHD), 16,17 treatment of children 
with Osteogenesis Imperfecta (O.I.)18-20 and metabolic disorders,21 as well as for 
regeneration of bone and cartilage in degenerative disorders using tissue 
engineering techniques.14,22,23. 
MSCs are currently expanded in vitro, either under experimental or clinical 
grade conditions, in the presence of 10-20% fetal calf serum (FCS), which is 
considered crucial for the x-vivo expansion of MSCs.24,25 FCS characteristics 
are routinely pre-screened to guarantee both the optimal growth of MSCs and 
the bio-safety of the cellular product. Despite this, the use of FCS raises some 
concerns when utilized in clinical grade cellular peparations, since the 
administration of animal products to humans might theoretically cause the 
transmission of prions and still unidentified zoonoses. Moreover, bovine 
proteins or peptides might be incorporated by MSCs during culture 
procedures26,27 and cause immune reactions in the host, especially if repeated 
infusions are needed, with consequent rejection of the transplanted cells.19 As a 
results, several countries have legislated warnings and restrictions on the 






these considerations, the identification of a serum-free medium appropriate for 
both the extensive expansion necessary to reach the larg  numbers of MSCs 
required for clinical application, and the exclusion f risks connected with the 
use of animal products, is warranted. 
Recently, platelet-derived products have gained clinical interest due to their 
efficacy in enhancing bone regeneration and soft tissue healing.28-30 Platelet-
lysate (PL) is a concentration of human platelet growth factors in a small 
volume of plasma, obtained by lysing the platelet bodies through temperature-
shock; therefore, PL contains all the fundamental growth factors that are 
secreted by platelets to initiate wound healing, including platelet-derived growth 
factors (PDGFs), basic fibroblast growth factor (b-FGF), vascular endothelial 
growth factor (VEGF), insulin-like growth factor-1 (IGF-1) and transforming 
growth factor-β (TGF-β).30,31  
As Doucet et al.31 have recently demonstrated, PL is a powerful substit te for 
FCS in MSC expansion, thus we carried out a study aimed at evaluating 
whether human MSCs expanded in vitro in PL-supplemented medium are 
endowed with biological properties appropriate for their use in cell therapy 
approaches. In particular, we focused on the investigation of the immune 
regulatory effect of MSCs on alloantigen-specific immune response and the 
evaluation of MSC resistance to spontaneous transformation into tumor cells, a 
potential risk related to expansion procedures. 
 
Materials and methods 
Bone marrow donors 
Bone marrow aspirates were harvested from eight heal hy hematopoietic stem 
cell donors (median age 13.5 years), after obtaining written informed consent. 
Thirty ml of bone marrow (BM) from each donor were assigned to MSC 
generation; heparin was added as anticoagulant. The Institutional Review Board 






PL preparation  
Apheresis procedures were performed at the Transfusion Service of our 
Hospital, collecting platelets (PLTs) from ten healthy volunteers, using the 
Trima Cobe (Lakewood, Co, USA) cell separator devic. Written informed 
consent was always obtained. All apheresis products contained 5x1011 PLTs and 
were qualified according to Italian legislation. Immediately after collection, 
PLT apheresis products were frozen at -80°C and subsequently thawed at 37°C 
to obtain the release of PLT-derived growth factors. Heparin (5000 UI) was 
added to PLT bags to avoid gel formation. Apheresis were centrifuged at 900 g 
for 30 minutes, three times to eliminate platelet bodies. Finally, PL preparations 
obtained through this procedure were pooled in a single culture supplement to 
be used for the generation and expansion of MSCs from all BM donors enrolled 
in the study.  
 
Isolation and culture of BM-derived MSCs 
Mononuclear cells were isolated from BM aspirates (30 ml) by density gradient 
centrifugation (Ficoll 1.077 g/ml; Lymphoprep, Nycomed Pharma, Oslo, 
Norway) and plated in non-coated 75-175 cm2 polystyrene culture flasks 
(Corning Costar, Celbio, Milan, Italy) at a density of 160,000/cm². Four 
different culture conditions, based on the basal medium (Mesencult, StemCell 
Technologies, Vancouver, Canada) supplemented with 2mM L-glutamine and 
50 µg/ml gentamycin (Gibco-BRL, Life Technologies, Paisely, UK) were 
tested: I) 10 % FCS (Mesenchymal Stem Cell Stimulatory Supplements, 
StemCell Technologies); II) 5% PL; III) 2,5% PL; IV) 1% PL. Cultures were 
maintained at 37°C in a humidified atmosphere containing 5% CO2. After 48 
hour adhesion, non-adherent cells were discarded and culture medium was 
replaced twice a week. MSCs grown under the four different culture conditions, 
were harvested after reaching ≥ 80% confluence, using Trypsin (Sigma-Aldrich, 






5. MSCs from four donors were cultured until P10. The same approach was 
employed for eight different BM donors from whom MSCs were generated and 
cultured in parallel under the four conditions mentio ed.  
The colony-forming unit-fibroblast assay (CFU-F) was performed as described 
previously.32,33 CFU-F formation was examined under the four culture 
conditions after incubation for 12 days in a humidifie  atmosphere (37°C, 5% 
CO2); the clonogenic efficiency was calculated as the number of colonies per 
106 BM mononuclear cells seeded. According to the International Society for 
Cellular Therapy on the nomenclature of mesenchymal progenitors, the cells 
cultured for this study were defined as multipotent stromal cells.34 
 
MSC Multilineage differentiation potential  
The adipogenic and osteogenic differentiation capacity of MSCs was 
determined at P2-3 for all BM donors as previously described (in’t Anker et al, 
2003), utilizing the respective supplement (10% FCS, 5% PL, 2.5% PL, 1% PL) 
for each culture condition. To detect the osteogenic differentiation, cells were 
stained for alkaline phosphatase (AP) activity using Fast Blue (Sigma-Aldrich) 
and for calcium deposition with Alzarin Red (Sigma-Aldrich). Adipogenic 
differentiation was evaluated through the morphological appearance of fat 
droplets with Oil Red O (Sigma-Aldrich). 
 
Flow cytometry 
FITC, PE, PerCP, or PerCPCy5.5 monoclonal antibodies (MoAb) specific for 
the following antigens were employed: 1) CD45, CD14, CD34, CD13, CD80, 
CD31, HLA A-B-C, HLA-DR, CD90, CD73, CD62L, CD11a, CD11c, CD18, 
CD49d, anti-human integrin β7 (BD PharMingen, San Diego, CA, USA), 
CD105, CD166, CD44, CD29 (Serotec, Kidlington, Oxford, UK) for the 
assessment of MSC surface phenotype; 2) CD3, CD4, CD8, CD56, CD25, 






CA, USA), for evaluation of lymphocyte subsets. Appropriate isotype-matched 
controls (BD Bioscience, eBioscience) were included. Intracellular staining for 
CD152 (CTLA4) and Foxp3 was performed following the manufacturer’s 
instructions. In brief, cells were stained with MoAbs to surface antigens (CD4 
and CD25), washed, fixed, permeabilized and stained for intracellular antigens 
with specific anti-CD152 or anti-Foxp3 MoAb. Two-color or three-color direct 
immune fluorescence cytometry, with FACScalibur flow cytometer (BD 
Biosciences), was performed according to a previously described method.35  
Mixed lymphocyte cultures (MLCs) and cytotoxicity ass y 
Peripheral blood mononuclear cells (PBMCs) were obtained by Ficoll-Hypaque 
density gradient from healthy volunteer’s heparinized PB samples and 
employed on the same day of collection. Primary MLCs were performed 
according to previously described methods;35,36 the only difference with 
previously employed methodological approaches was the use of 10% FCS 
supplemented RPMI 1640, instead of RPMI 1640 supplemented with 5% 
pooled human serum in order to avoid any interference with human cytokines 
measurement. Briefly, non-irradiated “third-party” MSCs, allogeneic to both 
responder (R) and stimulator (S) PBMCs, were added at the R to MSC ratio of 
10:1. The immune regulatory effect of MSCs cultured with either 5% PL 
(MLC+MSC-PL) or 10% FCS (MLC+MSC-FCS) was compared, using MLC 
performed in the absence of MSC as a control (ctrl-MLC). T and NK-
lymphocyte subset expansion was evaluated by counting CD3+CD4+ or 
CD3+CD8+ T-cells and CD3negCD56+ NK-cells per ml of culture, recovered 
after 10-days MLC and comparing those with the initial number of cells (day 0). 
Differentiation of regulatory T cells (Treg) was evaluated by the detection of the 
percentage of CD4+CD25+ and CD4+CD25bright T lymphocytes, together with 






Alloantigen-induced cell-mediated cytotoxic activity was tested in a 5-hour 51Cr-
release assay as previously described.35,36 Results are expressed as % of specific 
lysis of target cells. 51Cr-labeled target cells included PHA-activated S-PBMCs 
(S-PHA) and the same lots of MSC-PL or MSC-FCS added to MLCs. The only 
difference with previously employed methodological approaches35 was that 
adherent MSCs 51Cr-labeled over-night were the target for the cytotoxicity assay.  
 
Measurement of growth factors and cytokines by ELISA  
The concentration of PDGF-AB, TGF-β1, b-FGF, IGF-1, VEGF in PL and FCS 
was evaluated using commercially available ELISA kits (R&D Systems, 
Minneapolis, MN, USA), following the manufacturer’s instructions. The 
concentration of IFN-γ, IL10, IL6, IL12, IL7, IL2, IL15 and TGFβ in supernatant 
of MLC after 12, 24, and 48 hours, was quantified by ELISA using monoclonal 
antibody pairs (Pierce Endogen, Rockford, IL, USA). Briefly, plates (Corning 
Costar) were coated with purified antibodies at the appropriate concentrations. 
Standard curves were prepared with recombinant human cytokine (Pierce 
Endogen). Biotin-labelled antibodies (Pierce Endogen) were added and HRP-
conjugated streptavidine (Pierce Endogen) was used to develop the reactions. 
Plates were read at 450 nm (Titertek Plus MS 212M). 
Molecular karyotyping 
Molecular karyotyping was performed through array comparative genomic 
hybridization (array-CGH) with the Agilent kit (Human Genome CGH 
Microarray, Agilent Technologies, Santa Clara, CA, USA) on MSCs cultured 
either in 10% FCS or 5% PL. Cultures from four BM donors at different 
passages (from P2 to P7) were analyzed. The array-CGH platform is a 60-mer 
oligonucleotide-based microarray that allows a genome-wide survey and 
molecular profiling of genomic aberrations with a resolution of ~35 kb (kit 






Aldrich) according to the manufacturer’s protocol. DNA (7µg) from MSCs and 
controls of the same sex (control DNA, Promega, Madison WI, USA) were 
double-digested with RSAI and AluI (Promega) for 3 hours at 37 °C. After 
column purification, 2 µg of each digested sample were labeled by random 
priming (Invitrogen, Carlsbad, CA, USA) for two hours using Cy5-dCTP 
(Amersham, GE Healthcare, UK) for the MSCs DNA and Cy3-dCTP 
(Amersham) for the control DNA. Labeled products were column purified 
(CyScribe GFX Purification Kit, Amersham). After probe denaturation and pre-
annealing with 50 µg of Cot-1 DNA (Invitrogen), hybridization was perfo med 
at 65 °C with shaking for 40 hours. After two washing steps, the array was 
analyzed through the Agilent scanner and the Featur Extraction software 




CFU-F numbers and cumulative cell counts obtained un er the four different 
culture conditions were compared through analysis of variance followed by post 
hoc comparisons between each possible pair condition (10% FCS, 5% PL, 2.5% 
PL, 1% PL) applying the Bonferroni correction for multiple tests. The non 
parametric Kruskall-Wallis test was performed for the comparison of the 
expansion time from P0 to P5; post hoc comparisons between each possible 




MSC CFU-F frequency and proliferative capacity  
In order to compare the effect of FCS with that of decreasing PL concentrations 
on the proliferative capacity of MSCs, BM-derived mononuclear cells from 






culture conditions (I, II, III, IV, see “Materials and Methods” section). BM 
samples were assayed for CFU-F frequency after 12-days culture and the results 
were as follows: condition I (10% FCS) showed a mean v lue of 15.75 ± 2.06 
CFU-Fs per 106 mononuclear cells plated, whereas the mean value of MSC 
cultured in medium II (5% PL), III (2.5% PL) and IV (1% PL) was 28.50 ± 3.61 
(P<0.00001), 17.33 ± 6.21 (P=0.5), 2.25 ± 1.22 (P<0.00 01) CFU-Fs, 
respectively. As compared to MSCs cultured in the presence of 10% FCS, the 
calculated cumulative cell counts (Figure 1) were significantly higher when 
MSCs were cultured in the presence of 5% PL (P<0.00001), comparable in the 
presence of 2.5% PL (P=0.13) and significantly lower hen MSCs were grown 
in the presence of 1% PL (P<0.00001). Indeed, a cler dose-dependent effect of 
PL on the proliferative capacity of MSC was present in all cultures; this effect 
was also noted in the capacity to form CFU-F in the presence of 5% PL, as this 
condition yielded the highest frequency of units that were also the largest in size 
(data not shown). Moreover, the median time to reach 80% confluence was 
shorter for all passages from 1 to 5 in the presence of 5% PL (5.5 days) than for 
all other culture conditions. In fact, the required median time to approach 80% 
confluence was 7.5, 8, and 10 days for condition III (2.5% PL), I (10% FCS), 
and IV (1% PL) respectively. In particular, when cultured in the presence of 5% 
PL, MSC reached P5 in 39.5 ± 1.2 days (P<0.00001), whereas it took 50 ± 2.5 
and 66.5 ± 2.3 days for conditions III (P=0.23) and IV (P<0.00001) 
respectively. The time needed for MSCs to reach P5 in the presence of FCS was 
51.7 ± 2.9 days. Therefore, condition II was associated with an advantage in 
terms of time, approximately 10 days for a complete cycle of expansion, 
yielding a number of cells that was more than 1 logarithm superior when 
compared to condition I. Condition II was the only one employed in the 
comparison with FCS in the analysis of immune regulatory effect and molecular 







Figure 1. Calculated cumulative cell counts of MSCs cultured from passage (P) 0 to 5, 
in the presence of 10 % FCS; 5 % PL; 2,5 % PL; 1% PL. Results are expressed as the 
mean calculated from data obtained from eight BM donors. 
 
MSC Morphology, surface phenotype and differentiation capacity  
MSCs isolated in the presence of either FCS or one f the three PL 
concentrations displayed the characteristic MSC-like spindle-shape; however, 
subtle differences in morphology were observed (Figure 2A). In fact, MSCs 
cultured in PL-containing media (condition II, III and IV) showed a thinner 
shape compared to the thicker MSCs expanded in the presence of FCS; 
moreover, PL-MSC frequently tended to grow in cluster  rather than a uniform 
distribution in the flask. MSCs cultured in the presence of each concentration of 
PL required only 2-3 minutes incubation with trypsin at room temperature to 
obtain their complete detachment from the plastic, whereas 5-8 minutes at 37°C 
were necessary to harvest MSCs supplemented with 10% FCS. In this regard, 
the expression of surface adhesion molecules and integr s (CD166, CD62L, 
CD44, CD49d, CD29, CD11a, CD18, CD11c, anti-human integrin β7) was 
comparable on MSCs expanded both in FCS and 5% PL (data not shown).  
The surface phenotype of MSCs cultured under the four different conditions 
was analyzed by flow cytometry at P1, P3 and P5; the p enotypes were similar 
and in agreement with previous reports;3,9,10 (data not shown). In particular, by 
the third passage, contamination with hematopoietic cells was no longer 






the MSC-typical surface marker pattern. In detail, MSCs were positive for 
CD90, CD73, CD105 and CD13 surface antigens and negativ  for CD34, 
CD45, CD14, CD80, CD31 molecules. The expression of HLA-DR was always 
below 2% under all culture conditions, whereas HLA-class I was uniformly 
present on MSCs (>98% of positive cells). 
MSCs expanded under the four culture conditions were induced into osteoblasts 
and adipocytes and examined for their differentiation capacity by histological 
staining. Results demonstrated that MSCs cultured in medium I, II, III and IV 
were all comparably able to differentiate into osteblasts (Figure 2B) and 
adipocytes (Figure 2C). In accordance with previously reported data31, no 
macroscopic differences were detected in the capacity to form both osteoblasts 
and adipocytes under the four culture conditions for the eight donors studied.  
MSC cultures expanded from four donors, in the presence of either FCS or 5% 
PL, were prolonged until P10 without observing any alteration in their 
morphology and surface phenotype.  
 
Figure 2. MSC morphology and differentiation capacity. A) Representative photographs 
of MSCs expanded in the presence of 10% FCS (MSCs-FCS) and 5% PL (MSCs-PL) 






2.5% and 1% PL was similar to cells cultured with 5% PL. MSCs-PL display the 
characteristic spindle-shaped morphology, however cells tend to be thinner compared to 
MSCs-FCS and to grow in clusters. Magnification x10. B) Osteogenic differention 
capacity of MSCs-FCS and MSCs-PL (+5% PL). The differentiation into osteoblasts is 
demonstrated by the histological detection of AP activity (purple reaction) and calcium 
deposition stained with Alzarin Red staining. Shown are representative photographs 
from donor 2. Magnification x 20. C) Adipogenic differentiaton capacity of MSCs-FCS 
and MSCs-PL. The differentiation into adipocytes is revealed by the formation of lipid 
droplets (stained with  Oil Red O staining). Shown are representative photos from donor 
2. Magnification x 20. For B) and C) results for MSCs expanded in 2.5% and 1% PL 
were comparable. 
 
Ex-vivo expanded MSC immune regulatory effect  
As mentioned above, for this set of experiments, MSCs cultured in the presence 
of FCS (MSCs-FCS) were compared with MSCs expanded in the presence of 
5% PL (MSCs-PL). 
The immune regulatory capacity of ex-vivo expanded MSCs was evaluated by 
assessing the in vitro interaction between MSCs and the alloantigen-specific 
immune response elicited in primary MLC in two independent experiments. In 
agreement with several previously reported studies, we observed that the 
addition of both MSCs-FCS and MSCs-PL were able to inhibit alloantigen-
induced lymphocyte proliferation, even though MSCs-FCS apparently 
displayed a stronger inhibitory effect than MSCs-PL (Figure 3A).  
The stronger inhibitory effect of MSCs-FCS, as compared to MSCs-PL, was 
evident on total CD3+ cells (Figure 3B), on CD4+ (Figure 3C) and CD8+ (Figure 
3D) T lymphocytes, as well as on CD3negCD56+ NK cells (Figure 3E). In 
particular, the inhibitory effect of MSCs-PL on CD4+ T lymphocyte 







Figure 3. Effect of MSCs on T and NK-lymphocyte subet expansion induced by 
allogeneic stimulus. Recovery of total number of lymphocytes (A), CD3+ (B), CD4+ 






initial number (white columns), was assessed after 10-days primary culture (gray 
columns). MLC was performed in the absence (Ctrl-MLC) or presence of third-party 
MSCs cultured in 10% FCS (MLC+MSCs-FCS) or 5% PL (MLC+MSCs-PL). The 
MSCs were added at a R-PBMC/MSC ratio of 10:1; results are expressed as number of 
cells/ml of culture. Two independent experiments (Exp 1, Exp 2) are presented. 
 
 
The percentage of CD4+CD25+ T cells considerably increased after 10-days 
primary ctrl-MLC in both experiments, as compared to day 0 (Figure 4A); a 
comparable increase was observed in MLC supplemented wi h either MSC-FCS 
or MSC-PL in experiment 1, while a higher percentage of this cell subset was 
observed after addition of MSC-PL, as compared to ctrl-MLC, in experiment 2. 
In an attempt to discriminate CD4+CD25+ Tregs from conventional early 
activated CD4+CD25+ T lymphocytes, expression of the level of CD25 
(CD4+CD25bright T cells, Figure 4B), as well as  CD27, CTLA4 and FoxP3 
molecules (Figure 4C) was evaluated within the CD4+CD25+ T cell subset. We 
found a higher percentage of CD4+CD25bright and an augmented percentage of 
FoxP3+ cells in the presence of either MSCs-FCS or MSCs-PL as compared to 








Figure 4. Effect of MSCs on differentiation of CD4+CD25+ T-lymphocyte subsets 
induced by allogeneic stimulus. Percentages of CD4+ 25+ cells (A) and CD25bright (on 
gated CD4+ cells) (B) were calculated on effectors recovered after 10 days (gray 
columns) and compared to the initial cell counts (white columns). Percentages of 
CTLA4+, CD27+ and Foxp3+ cells (C) were calculated on gated CD4+CD25+ cells. 
MLC was performed in the absence (Ctrl-MLC) or presence of third-party MSCs 
cultured in 10% FCS (MLC+MSCs-FCS) or 5% PL (MLC+MSCs-PL). The MSCs were 
added at a R-PBMC/MSC ratio of 10:1; results are expr ssed as percentage of positive 
cells. Two independent experiments (Exp 1, Exp 2) are presented. 
 
Evaluation of the cytokine production kinetics, documented that: i) MSCs-FCS 
are able to inhibit, while MSCs-PL increase early IFNγ secretion in primary 
MLC; ii) both types of MSCs increase early secretion of IL-10 in primary MLC; 
iii) a remarkably high production of IL-6 can be observed in MLC grown in the 






MSCs alone (see Table 1). IL-12, IL-7, IL-2 and IL-15 were undetectable in all 
culture conditions, while results of TGFβ secretion were considered unreliable, 
due to the high concentration of this cytokine in the FCS supplemented medium 
employed for MLC experiments.  
 
Table 1. Kinetics of cytokine secretion in culture supernatants 
 Exp1 Exp2 
 12h 24h 48h 12h 24h 48h 
ctrl-MLC 14 43 506 <0.21 <0.21 12 
MLC+MSCs-
FCS  
9 32 172 <0.21 <0.21 2 
 
IFNγ 
MLC+MSCs-PL 14 43 514 <0.21 18 78 
Ctrl-MLC 251 303 174 5 39 29 
MLC+MSCs-
FCS 
296 416 404 22 192 170 
 
IL-10 
MLC+MSCs-PL 338 391 417 13 237 222 
Ctrl-MLC 3174 2870 1475 <1.9 624 <1.9 
MLC+MSCs-
FCS 
53000 75000 64000 2093 15900 64400 
 
IL-6 
MLC+MSCs-PL 49000 55000 77415 1107 12600 27370 
 
Concentration of IFN-γ, IL-10, IL-6 and TGFβ was quantified in MLC-supernatants 
collected after 12, 24, 48 hours culture in the absence (ctrl-MLC) or the presence of 
MSCs-FCS or MSCs-PL. IFNγ, IL-10 and IL-6 were undetectable in the supernatat of 
MSCs simultaneously cultured in the absence of PBMCs. Results are reported as pg/ml. 
Two independent experiments (Exp 1, Exp 2) are present d.  
 
In order to assess the effect of MSCs on alloantige-specific cytotoxic 
lymphocytes, effector cells recovered from MLC were tested for their cytotoxic 
capacity towards allogeneic target cells (S-PHA blasts), that were stimulator 
cells in MLC. Results shown in Figure 5A demonstrate that both MSC-FCS and 
MSC-PL are endowed with the capacity to inhibit allo ntigen-induced cell-
mediated cytotoxicity. Alloantigen-induced cytotoxic capacity was also tested 
towards the same lot of “third-party” MSC-FCS or MSC-PL, added to MLC at 
day 0. This part of the experiments was planned to investigate the ability of 






party” MSCs, to mediate cell lysis of MSCs themselves. Results demonstrate a 
low level of MSCs lysis in both ctrl-MLC experiments; the presence of either 
MSC-FCS or MSC-PL only marginally affected this type of cytotoxic activity 
(Figures 5B and 5C). 
 
Figure 5. Effect of third-party MSCs on cell-mediated cytotoxic activity induced by 
allogeneic stimulus. 51Cr-labeled target cells included S-PHA (A) and the same lots of 
MSCs-FCS (B) or MSCs-PL (C) added to MLCs. Effector to target (E:T) ratios ranged 
between 20:1 to 0.15:1. Results are expressed as % specific lysis of target cells. Two 







Also for this set of experiments, MSCs-FCS and MSCs-PL were chosen and 
tested for their genomic situation; in particular four of the eight BM donors 
were studied at baseline (BM mononuclear cells) and t ifferent passages in 
culture by means of array-CGH. In order to avoid false positive results, we 
performed the array-CGH on BM mononuclear cells against control DNA and 
by mixing MSCs-PL with MSCs-FCS. In the latter case, duplications/deletions 
that could be found in MSC-FCS or MSC-PL against control DNA but not in 
MSC-FCS against MSC-PL could be safely considered polymorphisms, 
whereas duplications present in MSC-FCS against control DNA that 
corresponded to deletions in MSC-PL against MSC-FCS or viceversa were 
considered indicative of a true imbalance.  
The results of array-CGH demonstrated that MSCs expanded in vitro, both in 
the presence of PL and FCS, do not show imbalanced hromosomal 
rearrangements; indeed we could not detect any, deletion or duplication of 
material in the samples studied even at a submicroscopic level. However, array-
CGH is not able to unravel balanced chromosomal rearrangements; this has to 








Figure 6. Representative array-CGH profiles of  chromosome 1 of the same MSCs 
donor. A) MSCs cultured in the presence of 5% PL at P1; B) MSCs cultured in the 
presence of 10% FCS at P7; C) The two experiments are superimposed: blue and red 
lines apply to MSCs cultured in 5% PL and in 10% FCS respectively; D,E,F) 
Enlargements of the regions indicated by the blue panels in every experiment shown 
above. The array-CGH profiles of MSCs cultured in 5% PL and 10% FCS are linear and 
perfectly overlapped. This demonstrates that in vitro expanded MSCs do not show 








Many insights in the MSC biology, as well as of their immune regulatory 
properties and regenerative potential, have been obtained in the last few years 
and these have provided the support for considering MSCs today as an 
attractive and powerful tool for cell therapy-based approaches.12-23 FCS is 
currently utilized to supplement culture medium in protocols designed to 
generate and expand in vitro MSCs to be employed for clinical use.25 However, 
for cell therapy-based approaches, MSCs should be expanded according to 
Good Manufacturing Practice (GMP) procedures that require very stringent 
quality criteria for sterility and the utilization of specific reagents, preferably 
devoid of heterologous proteins (see European Commission-Health and 
Consumer Protection Directorate-General. Technical requirements for the 
coding, processing, preservation, storage, and distribution of human tissues and 
cells. Directive 2004/23/EC). Alternatives to the use of FCS might be 
autologous serum  
PL preparations have already been demonstrated to be a powerful source of 
growth factors, useful in the treatment of a variety of soft and hard-tissue 
surgical conditions and in the management of non-healing wounds.28-30 The 
utilization of PL as a culture supplement for MSC expansion in cell therapy-
based protocols has been recently suggested as a promising alternative to FCS.31 
In this study, we have tested three different concentrations of PL, and compared 
them with FCS, for in vitro expansion of human MSCs, in particular focusing 
on the immune regulatory activity of the different types of MSC and the 
maintenance of their karyotype stability at the endof the expansion procedure.  
Our data demonstrate that 5% PL is superior to 10% FCS in terms of clonogenic 
efficiency and proliferative capacity, therefore providing more efficient 
expansion, together with significant a time saving. When lower concentrations 
of PL were employed, the clonogenic efficiency was either comparable (2.5% 






Altogether these data suggest that PL preparations exert a dose-dependent effect 
on MSC expansion. The expansion promoting effect is likely due to the high 
concentration of natural growth factors contained in PL. Indeed, we have 
measured the concentrations of PDGF-AB, TGF-β1, b-FGF, IGF-1 and VEGF 
in the pooled PL and all values resulted remarkably superior to the 
concentrations of the same growth factors present in our lot of FCS (data not 
shown).  
Our findings are in keeping with those published byDoucet et al.31 
demonstrating that growth factors contained in PL are ble to promote MSC 
expansion in a dose-dependent manner. However, while Doucet and 
colleagues31 showed that 5% PL was able to increase the size of CFU-F but not 
their number; we found that the clonogenic efficieny of MSCs generated in the 
presence of 5% PL was significantly superior (P<0.00 01) as compared to 10% 
FCS. This discrepancy might be explained by differences in the MSC isolation 
procedure (spongious bone fragment supernatant vs BM aspirates as a starting 
material, plating concentrations) or in the assessmnt time of CFU-F (10 vs 12 
days).  
Moreover, in contrast with the observations of Doucet et al.31, we noted a subtly 
different morphology in our MSCs cultured in the presence of each 
concentration of PL, as compared to cells grown in 10% FCS. In fact, MSCs 
expanded in PL, although maintaining a spindle-shape, resulted finer/thinner in 
width and tended to grow in clusters in the flasks. Moreover, MSCs cultured in 
PL behaved differently from those grown in 10% FCS in the trypsinization 
phase, requiring a very short time for detachment from the plastic. In a recent 
study from Shahdadfar et al.37, in which autologous serum (AS) was compared 
to FCS for efficiency in supporting the expansion of MSCs, a similar 
phenomenon was described, the use of AS providing a very rapid detachment of 
MSCs from the flasks. In agreement with their results, also in our experiments, 






of MSCs expanded both in 10% FCS and 5% PL could not account for this 
different behavior.  
As compared to MSCs-FSC, the different concentrations f PL altered neither 
the purity nor the phenotype of the expanded MSCs and the expression of the 
typical MSC markers was maintained unmodified until P5 in all donors tested. 
In keeping with Doucet et al.31, MSCs expanded in the presence of PL retained 
their ability to differentiate into osteogenic and adipogenic lineages, 
demonstrating that PL do not affect the multipotency of these cells.  
Four MSC samples, expanded in the presence of either FCS or PL until P10 (in 
a time-frame of around 14 weeks) demonstrated a progressive decrease in the 
expansion capacity together with the maintenance of their original surface 
phenotype and spindle shape morphology. These data suggest that BM-derived 
MSCs do not display an aptitude for spontaneous transformation, in contrast to 
what has been recently described by Rubio et al.38 for MSCs derived from 
adipose tissue.  
The bio-safety of BM-derived MSCs was further confirmed by karyotype 
analysis performed by means of array-CGH; in fact, the results of these 
experiments demonstrated that MSCs expanded in vitro both in the presence of 
PL and FCS are devoid of genomic imbalances. Recently, array-CGH has been 
introduced as a rapid and high-resolution method for the detection of both 
benign and disease-causing genomic copy-number variations.39 This technique 
has been successfully used for analysis of tumor samples and cells lines40,41, and 
more recently also used to test cultured embryonic stem cells42. The relevant 
interest emerging regarding the utilization of MSCs in clinical approaches in 
several fields in medicine, requires that their karyotype be tested after prolonged 
in vitro culture in order to guarantee their bio-safety. In fact, detection of 
cytogenetic aberrations arising during the expansion period in cells would 
obviously represent a strong and clear contraindication for their clinical use. 






the method of choice to test the genetic situation of MSCs expanded in vitro, 
although balanced chromosome rearrangements should contemporarily be 
excluded by traditional cytogenetics.  
Our study demonstrates that the immune regulatory properties of MSC-PL are 
comparable to those of MSCs-FCS in terms of their capa ity to decrease 
alloantigen-induced cytotoxic activity, favor the differentiation of CD4+ T cell 
subsets expressing the Treg phenotype43, increase the early secretion of IL-10 in 
MLC supernatant, as well as induce a striking augmentation of IL-6 production. 
On the contrary, the suppressive effect on alloantige -induced lymphocyte 
subset proliferation and early IFNγ-secretion was more evident with MSCs-
FCS, as compared to MSCs-PL. Both MSCs-FCS and MSCs-PL are susceptible 
to partial lysis by cytotoxic cells emerging from MLC. Taking into account that 
both alloantigen-specific cytotoxic T lymphocytes and alloreactive NK or NK-
like cells are able to mediate alloantigen-induced cell-mediated cytotoxic 
activity36,44,45, these results are in keeping with two recently published studies 
documenting that in vitro activated NK cells are able to lyse either autologus 
or allogeneic human MSC46,47. 
The immune regulatory function of human MSC has been extensively 
investigated48. While there is general agreement on the fact that human MSCs 
are able to impair alloantigen-induced lymphocyte proliferation48,35, conflicting 
results on other immune properties of MSCs have been r ported and these 
discrepancies might perhaps be explained by the functional plasticity of these 
cells. For instance, several studies have demonstrated that the immune 
suppressive activity of MSCs is related to their capacity to alter dendritic cell 
function and to impair antigen-presenting cell (APC) maturation35,49,50,51, while 
even more recent reports documented antigen-presenting properties of these 
cells.52,53 Taking into account that IL-6 is a pro-inflammatory cytokine involved 
in the regulation of several immune functions including the enhancement of 






here on the production of large quantities of IL-6 in MLC supernatants, related 
to the presence of MSCs, should be in line with theantigen-presenting 
properties of these cells. On the other hand, in the same MLC we also observed 
MSC capacity to decrease alloantigen-specific cytotoxic activity. 
Altogether, our data support the hypothesis of a rema kable immunological 
functional plasticity of human MSCs and suggest that t e use of MSCs-PL, 
which seem to be endowed with a relatively low immune suppressive activity, 
could be more appropriate in reparative/regenerative cell-therapy approaches or 
in strategies aimed at improving hematopoietic/immune recovery after HSCT. 
On the contrary, as MSCs-FCS seem to display a more pronounced immune 
suppressive function, they might be more suitable for preventing or treating 
alloreactive-related immune complications, such as severe GvHD in HSCT and 
graft rejection in HSCT and solid organ transplantation. 
In view of our results, we propose that 5% PL may replace FCS in the 
generation and expansion of MSCs in some cell-therapy protocols. Indeed, in 
the clinical setting where at least 1x106 MSC/Kg are required, the use of 5% PL 
appears to provide very efficient expansion in a time-frame of 2-3 weeks, 
instead of 4-5 weeks necessary with current protocols. In this regard, further 
studies are necessary to precisely characterize the growth factor composition of 
PL, considering its variability from donor to donor, to optimize the preparation 
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Significant improvement in the understanding of mesenchymal stem cell (MSC) 
biology has opened the way to their clinical use. However, concerns regarding 
the possibility that MSCs undergo malignant transformation have been raised. 
We investigated the susceptibility to transformation f human bone marrow 
(BM)-derived MSCs at different in vitro culture time points. MSCs were 
isolated from BM of 10 healthy donors and propagated in vitro until reaching 
either senescence or passage (P) 25. MSCs in the senescence phase were closely 
monitored for 8-12 weeks before interrupting the cultures. The genetic 
characterization of MSCs was investigated through array-comparative genomic 
hybridization (array-CGH), conventional karyotyping and subtelomeric 
fluorescent in situ hybridization (FISH) analysis both before and after 
prolonged culture. MSCs were tested for the expression of telomerase activity, 
hTERT transcripts and alternative lengthening of telom re (ALT) mechanism at 
different passages. A huge variability in terms of proliferative capacity and 
MSCs life-span was noted between donors. In eight of ten donors, MSCs 
displayed a progressive decrease in proliferative capa ity until reaching 
senescence. In the remaining two MSC samples, the cultures were interrupted at 
P25 to pursue data analysis. Array-CGH and cytogenetic analyses demonstrated 
that MSCs expanded in vitro did not document chromosomal abnormalities. 
Telomerase activity and hTERT transcripts were not expressed in any of the 
examined cultures and telomeres shortened during the culture period. ALT was 
not evidenced in the MSCs tested. BM-derived MSCs can be safely expanded in 
vitro and are not susceptible to malignant transformation, thus rendering these 








In recent years, a significant improvement in the understanding of multipotent 
mesenchymal stromal cell (MSC) biology1 has opened the way to the clinical 
use of these adult stem cells. MSCs have been employed in several approaches 
for reparative/regenerative cell therapy, as well as in the perspective of 
modulating immune response against alloantigens.2-13 
MSCs have the ability to differentiate into multiple lineages, such as 
osteoblasts, tenocytes, adipocytes and chondrocytes14-16 and may be identified 
by both their capacity to adhere to plastic and their phenotypic characterization 
through a panel of cell surface molecules including CD90, CD105 and CD13. 
However, a unique and specific MSC marker, which would allow their 
exclusive identification, has not yet been found.  
The large interest in MSC applicability for clinical approaches relies on the ease 
of their isolation from several human tissues such as bone marrow (BM), 
adipose tissue, placenta and amniotic fluid17-19, on their extensive capacity for in 
vitro expansion and on their functional plasticity.  
Concerns that adult human MSCs may be prone to malignant transformation 
have been recently raised. In fact, human adipose tis ue-derived MSCs have 
been shown to undergo spontaneous transformation after long-term in vitro 
culture.20 The same phenomenon was also noted in murine BM-derive  MSCs21, 
which, after numerous passages in culture, increased telomerase activity and 
proceeded to malignant transformation. A previously published study22 has also 
documented that murine gastric epithelial cancer originates from BM-derived 
cells, presumably MSCs, after recruitment of these cells to the chronically 
injured mucosal site.  
The use of MSCs for clinical approaches in many fields of medicine first 
requires that the bio-safety of these cells be carefully investigated through 
appropriate and sensitive tests. Indeed, the absence of transformation potential 






cells into patients, particularly into immune-compromised subjects where 
failure of immune surveillance mechanisms might furthe  favor the 
development of tumors in vivo. 
The aim of this study was to investigate the potential susceptibility of human 
BM-derived MSC to malignant transformation at different in vitro culture time 
points and to ascertain whether the biological prope ties of these cells after x 
vivo expansion remain appropriate for cell therapy approaches.  
 
Materials and methods 
Bone marrow donors 
BM cells were harvested, under local or general anesthesia, from 10 healthy 
hematopoietic stem cell donors (median age 18 years), fter obtaining written 
informed consent. Twenty-thirty ml of heparinized BM from each donor were 
employed for MSC generation and expansion. The Institutional Review Board 
of Pediatric Hematology-Oncology approved the design of this study.  
 
Isolation and long-term culture of BM-derived MSCs 
Mononuclear cells were isolated from BM aspirates by density gradient 
centrifugation (Ficoll 1.077 g/ml; Lymphoprep, Nycomed Pharma, Oslo, 
Norway) and plated in non-coated 75-175 cm2 polystyrene culture flasks 
(Corning Costar, Celbio, Milan, Italy) at a density of 160,000/cm² in complete 
culture medium: Mesencult (StemCell Technologies, Vancouver, Canada) 
supplemented with 10 % FCS (Mesenchymal Stem Cell Stimulatory 
Supplements, StemCell Technologies), 2 mM L-glutamine and 50 µg/ml 
gentamycin (Gibco-BRL, Life Technologies, Paisely, UK). Cultures were 
maintained at 37°C in a humidified atmosphere containing 5% CO2. After 48 
hour adhesion, non-adherent cells were removed and culture medium was 
replaced twice a week. MSCs were harvested after reaching ≥ 80% confluence, 






continuously until reaching a senescence phase or passage (P) 25. The 
senescence phase was defined as a decrease in MSC proliferative capacity, 
finally leading to cell cycle arrest. MSCs in the senescence phase were closely 
monitored for an additional 8-12 weeks before interrupting the cultures, in order 
to look for the appearance of a crisis phase defined as uncontrolled cell 
proliferation. Post-senescence clones were isolated by limiting dilution: to 
obtain single cell-derived clones, MSCs were seeded at 1 cell/well in a 96-well 
culture plate (Corning Costar) and cultured as described above. The cells were 
observed daily for 4-6 weeks to examine colony formation.  
 
Flow cytometry 
To phenotipically characterize MSCs and to define th ir purity, fluorescein 
isothiocyanate (FITC) or phycoerithrin (PE)-conjugated monoclonal antibodies 
specific for CD45, CD14, CD34, CD13, CD80, CD31, HLA A-B-C, HLA-DR, 
CD90 (BD PharMingen, San Diego, CA), CD73, CD105 (Serotec, Kidlington, 
Oxford, UK), CD133 (Miltenyi Biotec S.r.l., Bologna, Italy), VEGFR2 (Sigma-
Aldrich) were used. MSCs expanded from the 10 BM donors were analyzed 
every three passages, starting from P3 (P3, P6, P9, P12  etc.) Appropriate, 
isotype matched, non-reactive fluorocrome-conjugated antibodies were 
employed as controls. Analysis of cell populations was performed by means of 
direct immunofluorescence with a FACScalibur flow cytometer (BD BD 
PharMingen) and data calculated using CellQuest software (BD Pharmingen).  
 
Multilineage differentiation potential of MSCs 
To assess their differentiation capacity, MSCs cultured from all BM donors 
were induced into adipocytes and osteoblasts at P3, P6 and at later passages 
whenever possible, employing a method previously described.23,24 
To detect osteogenic differentiation, cells were stained for alkaline phosphatase 






Alzarin Red (Sigma-Aldrich). The adipogenic differentiation was evaluated 
through the morphological staining of fat droplets with Oil Red O (Sigma-
Aldrich). 
 
Telomerase activity detection assay 
Telomerase activity was measured by the polymerase chain reaction (PCR)-
based telomeric-repeat amplification protocol (TRAP).25 Samples containing 
0.1, 0.5 and 1 µg of protein were analyzed by the TRAPeze kit (Intergen 
Company, Oxford, UK) according to the manufacturer’s protocol. After 
extension of the substrate TS (5’-AATCCGTCGAGCAGAGTT-3’) 
oligonucleotide by telomerase, the telomerase products were amplified by PCR 
in the presence of a 5’[32P]-end-labeled TS primer for 28 cycles and resolved in 
10% polyacrylamide gels. Protein extract (0.5 µg) from the telomerase-positive 
tumor cell line (JR8) was used as a positive control sample in each TRAP assay. 
Each reaction product was amplified in the presence of a 36-bp internal TRAP 
assay standard (ITAS). A sample was scored as telomerase activity-positive 
when positive TRAP results were obtained from at least one protein 
concentration.  
 
RNA extraction and reverse transcriptase (RT)-PCR analysis of the human 
telomerase reverse transcriptase (hTERT) 
Total cellular RNA was extracted from frozen samples with RNeasy micro kit 
(QUIAGEN GmbH, Hilden, Germany) according to the manufacturer’s 
protocol. Total RNA (0.5 µg) from each sample was reverse-transcribed by 
using the RT-PCR Core kit (Applied Biosystems, Branchburg, NJ) with random 
hexamers, and the resultant cDNA was then amplified with the same kit. 
Amplification of full length and alternatively spliced hTERT cDNA was 







with initial heating at 95°C for 3 min, followed by 35 cycles at 95°C for 30 s, 
62°C for 50 s, 72°C for 50 s, and 72°C for 5 min. The amplification was 
performed in a mixture containing 0.3 µCi [α-32p]deoxycytidinetriphosphate 
(300 Ci/mmol; Amersham Pharmacia Biotech, Cologno Monzese, Milan, Italy). 
Primers for the internal β-actin control were added during cycle 15 at 72°C. 
Amplified products were electrophoresed on a 5% non-de aturing 
polyacrylamide gel in 1X Tris-borate EDTA buffer. The gel was dried and 
autoradiographed.  
 
Detection of alternative lengthening of telomere (ALT)-associated 
promyelocytic leukemia (PML) bodies (APBs) 
Cells were fixed in 1:1 methanol:acetone and processed to detect APBs by 
combined PML immunofluorescence and telomere FISH according to Henson 
et al.26 Images were captured on a Nikon Eclipse E600 fluorescence microscope 
using ACT-1 (Nikon, Tokyo, Japan) image analysis software and processed 
using Adobe Photoshop Image Reader 7.0 software. APB status was determined 
according to previously defined criteria. The presence of an APB was defined 
by the localization of a telomeric DNA focus within a nuclear PML body; 
samples were scored as APB-positive if they contained APBs in ≥0.5% of cells. 
To avoid false positives, an APB was considered to be present only when the 
telomeric DNA fluorescence within a PML body was more intense than that of 
telomeres, and a cell was not considered to contain APBs if >25% of the co-
localized foci occurred outside the nucleus. To avoid false negatives, at least 
2,000 nuclei were examined, and the assay was repeated in the presence of 
negative results. Samples from ALT-positive (IIICF/c-EJ-ras) or telomerase-
positive (JR8) tumor cell lines were used as positive and negative controls for 








Telomere length analysis 
Total DNA was isolated using QuicKpicK genomic DNA kit (BioNobile, 
Medi Diagnostici, Milan, Italy), digested with the HinfI restriction enzyme, 
electrophoresed using CHEF-DR II Pulsed Field system (BioRad, Hercules, 
CA), transferred to a nylon membrane, and hybridized with a 5’-end 
[γ-32P]dATP-labeled telomeric oligonucleotide probe (TTAGGG)4 as 
previously reported.27. Autoradiographs were scanned (ScanJet IIcx/T, 
Hewlett Packard, Milan, Italy) and digitalized by Image Quant (Molecular 
Dynamics, Sunnyvale, CA). Each gel was standardized by inclusion of DNA 
from GM847 (ALT-positive) and HeLa (telomerase-positive) cell lines. ALT 
status was determined by calculating whether the mean, variance and semi-
interquartile range of the terminal restriction fragment (TRF) length 
distribution was greater than 16 kb, 1,000 kb, and 4 kb, respectively. 
Samples were classified as ALT-positive when 2/3 or 3/3 of these criteria 
were met for unimodal or bimodal TRF length distribut ons, respectively.26 
Statistical analysis of TRF length distributions was performed using the 
Telometric software.28 
Molecular karyotyping 
Molecular karyotyping was performed through array comparative genomic 
hybridization (array-CGH) with the Agilent kit (Human Genome CGH 
Microarray, Agilent Technologies, Santa Clara, CA). The array-CGH platform 
is a 60-mer oligonucleotide-based microarray that allows a genome-wide survey 
and molecular profiling of genomic aberrations with a resolution of about 75 kb 
(kit 44B). The genetic situation of the 10 BM donors was tested before culture 
(defined as time 0 or T0), using either BM mononuclear cells (BMMNCs) or 
peripheral blood lymphocytes (PBLs), and after in vitro culture on MSCs at P3 






MSCs samples were also evaluated at later passages, between P11 and P15 (T2), 
after prolonged in vitro culture. The method for array-CGH analysis of MSCs 
has been reported in detail elsewhere.24 
 
Cytogenetic analysis (karyotyping and subtelomeric FISH)  
Prior to harvest, the cultures of all MSC BM donors at various passages (P2-
P11) were incubated at 37°C with colcemid (IrvineSci ntific, Santa Ana, CA) at 
1 µg/ml final concentration for 2 hours. The cells were fixed and spread 
according to standard procedures. Metaphases of cells w re Q-banded and 
karyotyped in accordance with the International System for Human Cytogenetic 
Nomenclature recommendations (ISCN, 1995). Fluorescent in situ hybridization 
(FISH) with chromosome subtelomeric-specific probes (ToTelVysion, Vysis, 
Downer’s Grove, IL) was performed on fixed metaphase chromosomes obtained 
from three of the ten karyotyped MSC donors, according to manufacturer’s 
instructions and protocol. In total, the kit makes it possible to analyze 36 short 




Characterization of human BM-derived MSCs during long term in vitro culture 
MSCs derived from BM of the 10 healthy donors were isolated and propagated 
in long term in vitro culture. MSCs from all donors were characterized by 
morphology, differentiation capacity and immune phenotype at different culture 
time points, namely P3, P6, P9, P12, P15 and later, whenever possible, every 2-











Figure 1. Characterization of human BM-derived MSCs during long term in vitro 
culture. A) Morphological appearance of BM-derived MSCs from DONOR #7 at P3 
(left) and P15 (right). MSCs at P15 are smaller in size as compared to the same cells at 
P3, although they maintained the typical spindle shape. Magnification x10. B) 
Osteogenic differentiation capacity of MSCs from DON R N. 5 at P3 (left) and P15 
(right). The differentiation into osteoblasts is demonstrated by the histological detection 
of AP activity (purple reaction) and calcium depositi n stained with Alzarin Red. 
Magnification x 20. C) Adipogenic differentiation capacity of MSCs from DONOR #5 
at P3 (left) and P15 (right). The differentiation into adipocytes is revealed by the 
formation of lipid droplets stained with Oil Red O. Magnification x 20. D) 
Immunophenotypic characterization of MSCs from DONOR #3 at P3 (superior row) 
and P15 (inferior row). E) Expression of CD133 and VEGFR2  molecules on the 






A wide variability between donors was noted in terms of proliferative capacity 
and in vitro life span of their cultured MSCs (see Figure 2). The first two donors 
(donor #1 and #2) showed an early arrest of MSC growth; these two samples 
entered the senescence phase after 44- and 56-days culture at P4 and P5, 
respectively. Thereafter, MSCs from both donors were monitored, during their 
senescence phase, daily for twelve weeks. A crisis phase did not occur in the 
two samples, even after repeated cryopreservation and thawing procedures. In 
fact, the MSCs progressively died during the senescence period (characterized 
by appearance of picnotic bodies within the cells) and detached spontaneously 
from the flasks. In the case of donor #1, after 8 weeks in the senescence phase, 
we observed the appearance of a few spindle-shaped cells growing in clones, at 
a very low rate (post-senescence phase). These cells w re analyzed by flow-
cytometry and showed the typical MSC markers (CD90, CD105, CD73, CD13: 
>95% positive cells; HLA-DR: <5% positive cells), whereas they were negative 
for hematopoietic markers (CD45, CD34) and for both CD133 and VEGFR2 
(data not shown). Post-senescence MSCs could not be further propagated; 
repeated attempts to obtain single cell-derived clones by plating 1 cell/well in a 
96-well plate failed. 
 
Figure 2. In vitro life span of MSC cultures, defined as number of passages before 
observation of senescence, derived from 10 different do ors (#1-10). A large variability 







Three BM donors (donors #9, #10 and #4) showed an intermediate arrest in 
MSC growth. These cells displayed a progressive decrease in their proliferative 
capacity until they reached a senescence phase at P10, 13 and P13, 
respectively. MSCs from these three donors maintained their typical spindle-
shaped morphology, differentiation capacity to form osteoblasts and adipocytes, 
and their surface markers throughout the culture peiod.  
Donors #8, #7 and #5 showed a late MSC growth arrest, pectively at P18, 
P22 and P24. Also in this group, MSCs were regularly characterized by 
morphology, differentiation potential and immune phenotypic analysis every 3 
passages and did not display any relevant abnormality (F gure 1B and 1C, 
pictures on the right; Figure 1D, lower panel). More ver, when exceeding P10, 
MSCs were routinely screened for the expression of CD133 and VEGFR2; 
these markers, which have been found to be expressed on a transformed MSC 
subpopulation derived from human BM35, resulted negative (Figure 1E). 
However, MSCs from donor #7 and #5, when cultured after P13, became 
smaller in size as compared to the same cells at P3 (Figure 1A, picture on the 
right), although maintaining the typical spindle shape and a constant growth 
rate. MSCs reached the senescence phase at 26 and 32 weeks respectively for 
donor #7 and #5, and required a rather uniform amount of time to reach 
confluence at 8 to 10 days at every passage. In the cas  of donor #7, MSCs 
spontaneously differentiated into adipocyte-like cells when approaching 
senescence at P22 and could not be further propagated.  
MSCs expanded from donor #3 and #6 were trypsinized and replated 25 times 
continuously with a total culture period of 33 and 44 weeks respectively; 
thereafter, their long term cultures were interrupted o allow data analysis. The 
behavior of MSCs expanded from the last two donors wa  very similar to that of 
MSCs from the previous couple of donors. With the exception of the acquisition 
of a smaller cell size, all other phenotypic and functional characterization 






agreement with the definition of in vitro expanded MSCs.1,29 In particular, we 
did not observe any acceleration in cell growth rates. 
  
Lack of expression of telomere maintenance mechamisms in human BM-
derived MSCs during long term in vitro culture 
MSC cultures obtained from all 10 donors were tested at different in vitro 
passages (from 2 to 6 passages for each culture) fo the expression of 
telomerase catalytic activity (Figure 3A) by TRAP ass y. Specifically, in all 
cultures, an early passage (P1-P3) and later passages (P6-P24) were studied. 
TRAP results failed to evidence the presence of enzyme catalytic activity in all 
tested samples, including a post-senescence culture obtained from donor #1.  
To gain insights into the molecular mechanisms respon ible for the repression 
of telomerase activity in MSCs, we assessed the expression of the hTERT gene, 
which codes for the catalytic component of human telom rase30, in the same 
cultures screened for telomerase activity. Since it has been demonstrated that 
alternative splicing of hTERT is involved in the regulation of telomerase 
activity31, we analyzed the expression of the different hTERT transcripts 
(including not only the hTERT full-length transcript, but also three additional 
splice variants, α-, β- and α-β-) through the use of a specific primer set for the 
reverse transcriptase domain of  hTERT. RT-PCR results failed to evidence the 
expression of any hTERT transcript in all cultures examined (Figure 3B), thus 
indicating that the absence of telomerase activity in cultured MSCs was 








Figure 3. A) Telomerase activity of MSC cultures deriv d from donors #1,2,5,6 at 
different passages (P). Telomerase activity was detect d by the TRAP assay using 
different protein concentrations. PS, post-senescence culture. The telomerase-positive 
cell line JR8 was used as a positive control. The location of the internal amplification 
standard (ITAS) is reported. B) Expression of h-TER mRNA transcripts, including the 
full length (FL) and alternative splicing variants α-, β-, and α-β- , as detected by RT-
PCR in MSC cultures derived from donors #1,2,5,6 at different passages (P). 
Telomerase subunits were coamplified with β-actin as the internal standard. The 
telomerase-positive cell line JR8 was used as a positive control. The blank represents a 
negative control to which no RNA was added. 
 
Consistent with the lack of telomerase activity, when we analyzed telomere 
length in cultures obtained from 4 donors (#3-5-6-7) at early (P1-P3) and late 






progressive reduction in the mean TRF length (from 12 Kb to 9.3 Kb in the 
cultures obtained from donor #6) or appearance of sh rter TRFs (<4 Kb in late 
cultures from donors #3-5-6-7) (Figure 4).  
To address the possibility that alternative mechanisms of telomere maintenance 
referred to as ALT32 are operating in telomerase-negative MSCs, we screened 
them for the expression of APBs, which are subnuclear structures containing 
telomeric DNA, telomere-specific binding proteins and proteins involved in 
DNA recombination and replication, and represent a peculiar characteristic of 
ALT cells33. However, the results we obtained through a combined 
immunostaining/FISH approach in the same cultures as ayed for telomere 
length failed to evidence the presence of APBs (data not shown). The absence 
of an ALT phenotype in these cultures was further confirmed by the pattern of 
TRF length distribution. In fact, ALT-type telomeres, which are extremely long 
and heterogeneous33, were not observed in MSCs (Figure 4). 
 
Figure 4. Telomere length distribution of MSC cultures derived from donors #3,5,6,7 at 
different passages (P). GM847 and HeLa cell lines wre used as ALT-positive and 









Karyotype and subtelomeric FISH analysis 
BMMNCs/PBLs (T0) and MSCs at P3 (T1) derived from all donors were tested 
for their genetic situation; MSCs at P11-21 (T2) from six of the ten donors were 
also studied. In all cases, molecular karyotyping was analyzed by means of 
array-CGH. The comparison of results from two or three experiments for each 
donor (T0, T1, and T2), allowed us to distinguish between large copy number 
variations (LCVs)34, constitutionally present in donor’s genome, and true 
chromosomal imbalances. Results of the array-CGH analysis demonstrated that, 
even after long term culture, BM-derived MSCs expanded in vitro did not show 
unbalanced chromosomal abnormalities, as well as submicroscopic 
rearrangements, considering that the resolution of our approach is about 75 kb 
(Figure 5). In fact, the array-CGH profiles of the repeated experiments from the 
same donor were perfectly overlapping and no deletions or duplications were 
present, besides the LCVs reported in the available databases1.  
 
Figure 5. Representative MSC array-CGH  profiles of chromosome 1 from donor #6 at: A) T0: 
PBLs); B) T1: MSCs at P3; C) T2: MSCs at P14. D) Three overlapping experiments: blue line 
applies to PBLs, red line to P3 and green line to P14. The array-CGH profiles of MSCs are linear 
and perfectly overlapped, even when there are duplications or deletions caused by LCVs. This 
demonstrates that in vitro expanded MSCs do not show unbalanced chromosomal rearrangements.  







Since array-CGH is not able to unravel balanced chromosomal rearrangements, 
classical cytogenetics with conventional QFQ banding a d FISH analysis with 
chromosome subtelomeric-specific probes were performed on chromosome 
metaphases obtained from MSCs at variable passages in culture (P2-11), in 
order to detect reciprocal translocations. Karyotyping was performed in all 
donors: only one out of the ten MSC samples was chara terized by a pericentric 
inversion of chromosome 9, which represents a well-known variant without any 
phenotypic effect. Therefore, all MSC donors were characterized by a normal 
karyotype (Figure 6A). FISH analysis with chromosome subtelomeric-specific 
probes was performed on chromosome methaphase of three donors (two at T1 
and one at T2, Figure 6B) and resulted normal in all cases.  
 
Figure 6.  A) Normal Q-banding karyotype (360-400 band) of MSCs from donor #2 at 
P2. B) FISH analysis with chromosome 16-subtelomeric-specific probes on a metaphase 
from donor #5 at P18. Green signals represent subtelomeric regions of the short arm of 
chromosome 16; red signals those of the long arm. The location of signals on 













In the present study, we have generated, propagated in long term in vitro culture 
and monitored human MSCs derived from 10 BM donors. Importantly, BM 
represents the source of MSCs most commonly used in cell-therapy approaches. 
MSCs from all donors were characterized, at several culture time points, on the 
basis of the typical parameters for MSC definition (such as morphology, 
immune phenotype and differentiation capacity), from a genetic point of view 
and by the expression of telomerase activity and alternative mechanisms of 
telomere maintenance. 
Considering the wide interest in MSCs, in particular for those derived from BM, 
for clinical approaches, the bio-safety features of these cells need to be carefully 
investigated, in order to exclude the occurrence of functional or genetic 
alterations before releasing these cells for clinical use. 
Our results demonstrate that human BM-derived MSCs can be cultured long 
term in vitro, without loosing their peculiar morphological, phenotypical and 
functional characteristics. Moreover, MSCs propagated in culture continuously 
for up to 44 weeks maintained a normal karyotype, without showing expression 
of telomere maintenance mechanisms. Consistent with these findings, a 
progressive reduction in the mean MSC TRF length, or appearance of shorter 
TRFs, was observed. 
In contrast to what has been recently described by Rubio et al.20 for human, 
adipose tissue-derived MSCs, none of our MSC samples bypassed the 
senescence period by developing a crisis phase characterized by a cell cycle rate 
accelerated compared to pre-senescence MSCs. On the contrary, all BM-derived 
MSCs demonstrated a progressive decline in their prolife ative/expansion 
capacity mainly resulting into the development of a senescence phase after 
variable in vitro culture times (6-44 weeks; Figure 2). These observations on the 
proliferative life-span of MSCs are in agreement wih previously published 






senescence phase, the appearance of a few spindle-shap d cells growing in 
clones at a very low rate was observed (post-senescce phase). However, these 
post-senescence MSCs could not be propagated further and never developed a 
crisis phase. Repeated attempts to obtain single cell-derived clones by plating 1 
cell/well in a 96-well plate failed; this cell behavior is very different from that 
described by Wang et al.35 on a subpopulation of human MSCs derived from 
one single BM sample (named ‘huBM020’) that showed v ry rapid population 
doubling and could be easily cloned in a single-cell assay. Post-senescence 
MSCs were analyzed by flow-cytometry and showed the typical MSC markers 
at high levels (including CD90 and CD105), whereas they were negative for 
hematopoietic markers (CD45, CD34) and for CD133 and VEGFR2. On the 
contrary, the transformed cells described by Wang and colleagues35 were shown 
to express the endothelial markers CD133 and VEGFR2, as well as low levels 
of CD90, and they were CD105 negative. The same down-regulation of the 
MSC membrane markers CD90 and CD105 was noted in the post-crisis cells 
described by Rubio et al20, which were derived from adipose tissue. 
Furthermore, the TRAP assay performed on post-senesc ce MSCs derived 
from donor N.1 failed to exhibit the expression of telomerase catalytic activity. 
All these findings demonstrate that our post-senescence cells are not different 
from normal MSCs, since they display the same particular MSC 
characterization parameters. 
Regarding morphology, we noticed that MSCs from four donors (#3-5-6-7) 
became smaller in size when cultured over P13-15, although they maintained 
the typical spindle shape and a constant, growth rate (Figure 1A, right). On the 
contrary, the cells described by both Wang and Rubio35,20 resulted in cells 
morphologically distinct from typical MSCs; they were round or cuboidal, and, 
in the paper published by Wang and colleagues35, also exhibited contact-
independent growth and formed foci with cells released into suspension. In our 






late passages (P9-25) did not show immune phenotypic abnormalities and 
maintained a high level of purity throughout the culture period (Figure 1D). 
Moreover, all cultures exceeding P10 were analyzed for the expression of 
CD133 and VEGFR2 and resulted negative. Also the ability to differentiate into 
osteoblasts and adipocytes was preserved throughout t e culture period in all 
MSC donors (Figure 1B and 1C). 
In agreement with previous reports36, all our MSC samples lack expression of 
telomerase activity both at early passages and after long term in vitro culture 
(up to P24). This finding was confirmed by the absence of hTERT transcript 
expression and reflected by a progressive telomere shortening in cultured 
MSCs. On the contrary, the transformed mesenchymal cells described by other 
authors20,35 exhibited telomerase activity. This phenomenon wasalso observed 
by Miura et al.21 in murine BM-derived MSCs that, after numerous passages in 
culture, gradually increased telomerase activity and proceeded to a malignant 
state, resulting in fibrosarcoma formation in vivo. Some human tumors, mainly 
those of mesenchymal origin including soft-tissue and osteogenic sarcomas and 
glioblastomas26, maintain their telomeres by the ALT mechanism. Telomere 
dynamics in ALT cells are consistent with a recombination-based mechanism, 
and characteristics of ALT cells include unusually long and heterogeneous 
telomeres, as well as the presence of peculiar subnuclear structures termed 
APBs. In all MSC samples tested, the presence of APBs failed to be evidenced. 
Moreover, the pattern of TRF distribution that we observed in the cultures was 
not consistent with the ALT phenotype. 
The bio-safety of BM-derived MSCs was further investigated by molecular 
karyotyping performed by array-CGH, classical cytogenetics and subtelomeric 
FISH analysis. Array-CGH is a rapid and high-resoluti n technique useful for 
the detection of both benign and disease-causing genomic copy-number 
variations in tumors and genetic disorders, and also for testing cultured 






difficulty in obtaining cultured MSC metaphases, array-CGH may be 
considered the method of choice for characterizing the genomic situation of 
MSCs expanded in vitro (Figure 5).24 However, this technique is unable to 
detect balanced chromosomal rearrangements, that have been excluded in our 
MSC samples by performing in parallel classical karyotype and subtelomeric 
FISH analysis. Altogether, the karyotype analysis experiments, performed 
before culture, as well as at early and late passages, demonstrated that 
extensively in vitro expanded human BM-derived MSCs are devoid of 
chromosomal abnormalities, as well as of unbalanced submicroscopic 
rearrangements. These findings are different from what is observed in 
embryonic stem cells maintained in vitro for a high number of passages.39 Of 
course, we cannot completely exclude that point mutations or other subtle 
molecular events, affecting oncogenes or tumor suppressor genes, might have 
occurred in cultured cells predisposing them to transformation. Likewise, 
mechanisms of oncogenesis facilitated by infusion into a immune compromised 
host are not explored by our approach. 
In conclusion, our data indicate that human BM-derived MSCs do not display 
an aptitude for spontaneous transformation and can be safely expanded in vitro 
without any sign of immortalization or development of chromosomal 
abnormalities. The susceptibility to malignant transformation described in 
murine BM-derived MSCs by Miura and colleagues21 might be related to the 
animal origin of the cells, which display a high degr e of chromosome 
instability, characterized by the development of both structural and numerical 
aberrations even at early culture passages. The same uthors could not 
demonstrate a similar behavior in human BM-derived MSCs which were 
propagated in vitro under similar culture conditions. Also in the case of human 
adipose tissue-derived MSCs20, the susceptibility to malignant transformation 
might be strictly connected with the origin of the tissue; indeed, in comparison 






differentiated cells, and it generates MSCs that are immune phenotypically 
slightly different from those derived from BM. Finally, in the study by Wang 
and colleagues36, it is very likely that the in vitro culture of BM-derived MSCs 
caused the transformation of a subpopulation of cells capable to express 
endothelial markers. This is further demonstrated by the fact that the same cells, 
thawed a few months later, propagated normally in culture and did not give rise 
to any transformed population. 
Our results provide support to the concept that the biological properties of 
human BM-derived MSCs after ex vivo expansion remain suitable for use in 
cell-therapy approaches; however, considering the rel vant interest in the 
utilization of MSCs in several fields of medicine and the potential risk of 
developing alterations during the expansion period, it is strongly recommended 
that phenotype, functional and genetic characteristics of MSCs after in vitro 
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Co-transplantation of ex-vivo expanded mesenchymal stem 
cells accelerates lymphocyte recovery and may reduce the 
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Haploidentical hematopoietic stem cell transplantation (HSCT) is associated 
with an increased risk of graft failure. Adult bone marrow-derived 
mesenchymal stromal cells (MSCs) have been shown to support in vivo normal 
hematopoiesis and to display potent immune suppressive effects. We co-
transplanted donor MSCs in 13 children undergoing transplantation of HLA-
disparate CD34+ cells from a relative.  While we observed a graft failure rate of 
20% in historical controls, all patients given MSCs showed sustained 
hematopoietic engraftment, without any adverse reaction. In particular, children 
given MSCs did not experience more infections as compared to controls. These 
data suggest that MSCs, possibly thanks to their potent immunosuppressive 
effect on alloreactive host T lymphocytes escaping the preparative regimen, 







T-cell–depleted hematopoietic stem-cell transplantation (HSCT) from an HLA-
haploidentical relative is a feasible option for children needing an allograft and 
lacking an HLA-compatible donor.1 However, both primary (defined as lack of 
hematologic recovery or absence of donor chimerism) and secondary (defined 
as loss of donor chimerism after initial engraftment)2 graft failure, mainly 
mediated by host alloreactiveT cells escaping the preparative regimen, have 
been reported in up to 15% to 18% of children given mismatched HSC 
transplants,3 despite the infusion of large numbers of hematopoietic stem cells.4 
Recipients of T-cell–depleted HSC transplants from an HLA-disparate relative 
are also exposed to an increased risk of life-threaening infections, especially of 
viral origin, due to the delay in reconstitution of adaptive immunity.1,3 
Bone marrow (BM) contains pluripotent mesenchymal stromal cells (MSCs), 
which form cartilage, fat, bone, and muscle.5 MSCs have been shown to 
modulate the function of T lymphocytes,6 including that of alloreactive T cells 
involved in graft-versus-host disease (GvHD) pathophysiology.7 In adult 
patients undergoing transplantation from an HLA-identical sibling,MSCinfusion 
was shown to be safe and possibly to accelerate hematopoietic recovery, as well 
as to reduce the incidence of both acute and chronic GvHD.8 However, it is still 
unknown whether co-transplantation of MSCs in haploidentical HSC transplant 
recipients can reduce graft failure. 
We carried out a phase 1/2 pilot study of co-transplantation of BM-derived, ex 
vivo–expanded MSCs of donor origin in children undergoing transplantation of 
granulocyte colony stimulating factor (G-CSF)–mobilized, CD34-selected 
progenitor cells from an HLAdisparate relative. The procedure was intended to 









Patients, materials, and methods 
Patients 
Children with hematologic malignancies or nonmalignant disorders, including 
primary immune deficiencies, lacking an HLA-matched donor were enrolled in 
the study by the 2 participating centers (Leiden University Medical Center and 
Fondazione IRCCS Policlinico San Matteo). Institutional Review Board 
approval was provided by the 2 participating centers. 
Parents or legal guardians of patients provided written informed consent for 
inclusion in the study. Written informed consent in accordance with the 
Declaration of Helsinki was also obtained from donors by an independent 
physician trained to explain risks associated with mesenchymal and 
hematopoietic stem cell donation. 
 
Preparation of MSCs 
Approximately 5 weeks before HSCT, mononuclear cells were isolated from 50 
to 70 mL donor BM by density gradient centrifugation n Ficoll. These were 
plated in noncoated 75- to 175-cm2 polystyrene culture flasks at a density of 
160 000/cm2 in complete culture medium (LG-DMEM [Invitrogen, Paisley, 
United Kingdom] supplemented with penicillin and streptomycin [Lonza, 
Logan, UT] and 10% fetal bovine serum [FBS; HyClone, V rviers, Belgium]). 
We used characterized and defined FBS batches preselected for their potential 
to support MSC expansion. All procedures were carried out under strict Good 
Manufacturing Practic (GMP) conditions. Flasks were incubated at 37°C in a 
CO2 incubator and culture medium was replaced twice e kly. After reaching 
at least 70% confluence, MSCs were replated at 4000 cells/cm2 using 
trypsine/EDTA (Lonza). MSCs were infused, fresh or after cryopreservation, at 
passage 3 or less to reduce the risk of genetic instability. MSCs release criteria 
for clinical use were as follows: spindle-shape morph logy, absence of 






expression of CD73, CD90, and CD105 surface molecules and the absence of 
CD34, CD45, and CD31. The target dose for infusion was 1 x 106/kg to 5 x 
106/kg body weight. MSCs were infused at a final concentration of 1 x 106 to 2 
x 106 cells/mL. 
Cotransplantation of MSCs and haploidentical peripheral blood stem cells at 
day 0, under monitoring of vital signs, patients were given MSCs intravenously 
via a central venous catheter and 4 hours later receiv d T-cell–depleted, G-
CSF+ mobilized CD34+ cells, positively selected using the CliniMacs 1-step 
procedure (Miltenyi Biotech, Bergisch Gladbach, Germany). The target number 
of CD34+ cells to be infused was 20 x 106 CD34+ cells/kg recipient weight. 
 
Statistics 
A Student t test, Fisher exact test, and chi-square test with Yates correction 
were used to assess differences between study and historic control groups. AP 







Table 1. Characteristics of patients and controls 
 Patients (n = 13) Controls (n = 52) p value 
Transplant years (range) Oct. 2004 – Feb. 2007  March. 1998- Oct. 2004  
Mean age (range) years 8 (1-16) 8 (1-17) NS 
Patient gender     
     Male 8 (61%) 31 (60%) NS 
     Female 5 (39%) 21 (40%) NS 
Original diseases    
Haematological malignancies 
ALL  
    CR1 
    CR 2 
    >CR2 
AML  
    CR1 
    CR 2 
    >CR2   
    Secondary  
    Refractory 
MDS   
     RC 
     RAEB 
     RAEBt 
     Aplastic MDS 










































    Immune deficiencies 2 (15%) 2 (4%)  
















Donor gender    
     Male: Female  7 :  6 29 : 23 0.9  
Conditioning regimen    
     TBI-based vs. Chemotherapy-based 8:5 (62 vs. 38%) 30:22 (58 vs. 42%) 0.8  
Graft characteristics    
 Number of CD34+ cells infused x 106/kg (median, range) 25.2 (11.6 – 38.6) 23.0 (12.1 – 47.5) NS 
 Number of CD3+ cells infused x 105/kg (mean, SD) 0.3 (0.3) 0.5 (0.7) NS 
Haematopoietic recovery    
 Number of days to PMN recovery (median, range) 12  ( 0-17) 14 (9-28)  0.1 
 Number of days to PLT recovery (median, range) 11 (10-18) 13 (9-100)  0.15 
 Number of days to reticulocyte recovery (median, rge) 11 (10-31) 23 (9-41) 0.02 
Number of days to leucocyte recovery (median, range) 11.6 (9-15) 16.5 (10-26) 0.005 
Post-HSCT complications    
Graft failure 
         Primary 









Acute GvHD  
        Grade I-II  










        Limited 









Table 1 Legend 
ALL = acute lymphoblastic leukaemia; AML = acute myeloid leukaemia; MDS = myelodysplastic syndrome; RC = refractory cytopenia; RAEB = refractory anemia with 
excess of blasts; RAEBt = refractory anemia with excess of blasts in transformation; CML = chronic myeloid leukaemia; HLH = hemophagocytic lymphochistiocyt sis; CR = 
complete remission; TBI = total body irradiation; PMN = polymorphonuclear neutrophils; PLT = platelets; HSCT = hematopoietic stem cell transplantation; GvHD = graft-






Results and discussion 
Table 1 shows the characteristics of the 14 study patients compared with 47 
historic controls that received transplants in either one of the 2 centers and were 
selected for an equivalent number of CD34+ cells infused and matched for 
transplant indication.  
There was no significant difference between patients and controls in terms of 
age, sex, malignant versus nonmalignant disease, method of CD34+ cell 
selection, and number of CD3+ cells infused. In all donors, both expansion of 
MSCs and mobilization of CD34+ cells were successful. Patients received a 
mean of 1.6 x 106 MSCs/kg (range, 1 x 106 MSCs/kg to 3.3 x 106 MSCs/kg). No 
MSC infusion–related toxicity was observed. 
Either primary or secondary graft failure occurred in 7 of the 47 children of the 
control group, whereas no rejection occurred in children who received 
cotransplants of haploidentical MSCs (P = .14). The number of CD34+ cells 
infused was superimposable in the study patients (mean, 21.5 x 106/kg; range, 
11.6 x106/kg to 38.6 x 106/kg), in controls with sustained engraftment (mean, 
21.2 x  106/kg; range, 12.1 x 106/kg to 47.5 x 106/kg), and in those who 
experienced either primary (mean, 21.7 x 106/kg; range, 14.7 x 106/kg to 39.4 x 
106/kg) or secondary (mean, 21.1 x 106/kg; range, 12.4 x 106/kg to 26.6 x 
106/kg) graft failure. 
Neutrophil and platelet recovery was comparable in study patients and controls 
(see Table 1 for definitions and details). 
However, patients given MSCs had faster recovery of a total leukocyte count 
above 1.0 x 109/L in comparison to historic controls (mean, 11.5 days [95% 
confidence interval [CI] 9.0-14.8] versus 14.9 days [95% CI 10.1-26.0], 
respectively, P = .009). 
Lymphocyte recovery accounted for this finding: the absolute numbers of 
natural killer (NK) cells 1 month after HSCT being 497/µL (95% CI 347-646) 






However, at 3 months, NK and T-cell recovery was quantitatively no different 
between study patients and controls. 
Chimerism analysis of ex vivo–expanded MSCs derived from recipient BM at 
3-month intervals up to 1 year after HSCT using polymerase chain reaction 
(PCR) for informative donor recipient polymorphisms9 did not show any 
evidence of donor cells in the majority of patients. In 3 patients, minimal (1%-
2%) transient engraftment of donor MSCs was found at 3 months. 





Table 2.  Patient follow up data 
UPN Sex Age at 
HSCT 




Time to last 
BM chimerism  































































95%  donor 
granulocyte 
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Alive and well CR 
 
Table 2 Legend 
UPN = unique patient number; BM = bone marrow; PB = peripheral blood; HSCT = hematopoietic stem cell transplantation; M = male; F = 
female; y = years; mo = months; ALL= acute lymphoblastic leukaemia; AML= acute myeloid leukaemia; X-LPD = X linked lymphoproliferative 








Four study patients died (Table 2), 2 due to relapse and 2 due to infection, 
compared with 11 controls (7 relapse, 2 infections, 2 GvHD). Episodes of viral 
reactivation were common in both patients and controls, occurring in 50% of 
patients belonging to the study group and in 35% of historic controls. However, 
only 1 study patient died, as a result of disseminated adenovirus infection 
complicated by grade 2 acute GvHD requiring steroid treatment, compared with 
2 historic controls. Since the follow-up of patients in the study group is shorter 
(range, 3-28 months) than that of historic controls (range, 32-110 months), both 
relapse rate and probability of overall survival in the study cohort (18% and 
72%, respectively) and in controls (26% and 63%, respectively) are not 
comparable. 
Our results indicate that in patients given a T-cell–depleted, HLA-disparate–
related allograft from a relative, expansion of donor MSCs is feasible and their 
clinical use is safe. Moreover, our data suggest tha MSC co-transplantation 
may modulate host alloreactivity and/or promote better engraftment of donor 
hematopoiesis, reducing the risk of early graft failure. 
A case-controlled study, with longer follow-up to exclude the risk of late 
rejections, can more precisely define the role played by co-transplantation of 
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Severe graft-versus-host disease (GVHD) is a life-thr atening complication 
after allogeneic transplantation with haemopoietic stem cells. Mesenchymal 
stem cells modulate immune responses in vitro and in vivo. We aimed to assess 
whether mesenchymal stem cells could ameliorate GVHD after haemopoietic-
stem-cell transplantation.  
Patients with steroid-resistant, severe, acute GVHD were treated with 
mesenchymal stem cells, derived with the European Group for Blood and 
Marrow Transplantation ex-vivo expansion procedure, in a multicentre, phase II 
experimental study. We recorded response, transplantatio -related deaths, and 
other adverse events for up to 60 months’ follow-up from infusion of the cells.   
Between October, 2001, and January, 2007, 55 patients were treated. The 
median dose of bone-marrow derived mesenchymal stem cells was 1.4×106 
(min–max range 0.4–9 ×106) cells per kg bodyweight. 27 patients received one 
dose, 22 received two doses, and six three to five doses of cells obtained from 
HLA-identical sibling donors (n=5), haploidentical donors (n=18), and third-
party HLA-mismatched donors (n=69). 30 patients had a complete response and 
nine showed improvement. No patients had side-effects during or immediately 
after infusions of mesenchymal stem cells. Response rate was not related to 
donor HLA-match. Three patients had recurrent malign nt disease and one 
developed de-novo acute myeloid leukaemia of recipint origin. Complete 
responders had lower transplantation-related mortality 1 year after infusion than 
did patients with partial or no response (11 [37%] of 30 vs 18 [72%] of 25; 
p=0.002) and higher overall survival 2 years after haemopoietic-stem-cell 
transplantation (16 [53%] of 30 vs four [16%] of 25; p=0.018). 
Infusion of mesenchymal stem cells expanded in vitro, r espective of the donor, 








Allogeneic haemopoietic-stem-cell transplantation is the treatment of choice for 
many malignant and non-malignant disorders.1,2 Severe graft-versus-host 
disease (GVHD) is a life-threatening complication after this treatment and 
donor lymphocyte infusion is used for treatment or prevention of relapse of 
leukaemia.3,4 Steroids are still the first-line treatment for established GVHD 
with a response rate of 30–50%; however, the outcome for patients with severe, 
steroid-resistant, acute GVHD is poor, and overall survival is low.1,3–5 
Mesenchymal stem cells are multipotent bone-marrow cells able to differentiate 
in vitro and in vivo into tissues of mesenchymal origin.6,7 Moreover, these cells 
provide support for the growth and differentiation f haemopoietic progenitor 
cells in bone-marrow microenvironments and, in animal models, promote 
engraftment of haemopoietic cells.8 In co-culture experiments with allogeneic 
lymphocytes, mesenchymal stem cells do not induce lymphocyte proliferation, 
interferon-gamma  production, or up-regulation of activation markers.9,10 
Mesenchymal stem cells suppress proliferation of activ ted lymphocytes in 
vitro in a dose-dependent, non-HLA-restricted, manner.9–11 In a baboon skin-
graft model, Bartholomew and co-workers11 showed that infusion of ex-vivo 
expanded donor-derived or third-party cells prolonged the time to rejection of 
histo-incompatible skin grafts. Furthermore, infused c lls improve the outcome 
of acute renal, neural, and lung injury, possibly by promoting a shift from 
production of pro-inflammatory cytokines to anti-inflammatory cytokines at the 
site of injury.12–14 
In phase I and II trials, HLA-identical mesenchymal stem cells expanded ex 
vivo have been infused to promote haemopoietic recov ry after autologous and 
allogeneic haemopoietic-stem-cell transplantation and to treat patients with 
osteogenesis imperfecta.15–20 So far, neither acute nor long-term adverse events 






the use of in-vitro expanded cells for the treatment of severe, acute GVHD have 
recently been published.21,22 
To facilitate large-scale, multicentre trials, the European Group for Blood and 
Marrow Transplantation Developmental Committee has adopted a common 
protocol for expansion of mesenchymal stem cells. We report the results of a 
multicentre, phase II study of the use of these cells in 55 patients with severe 




Between October, 2001, and January, 2007, patients of all ages with grade 2–4 
GVHD after haemopoietic-stem-cell transplantation, who did not respond to 
steroid treatment (≥2 mg per kg per day) for at least 7 days, or with progression 
of at least one grade within 72 h were eligible for the study. 55 patients were 
treated (Table 1); 48 had developed GVHD after transplantation of 
haemopoietic stem cells and seven after donor lymphocyte infusion. Most 
patients had grade 3 or 4 GVHD involving two or three organs, confirmed by 
biopsy in 36 patients (43 biopsies; table 2). 
23 patients were treated at Karolinska University Hospital, Huddinge, Sweden 
(of whom, eight were previously reported 21,22), 14 at Leiden University Medical 
Center, Leiden, the Netherlands, eight at Ospedale S n Martino or Gaslini 
Institute, Genova, Italy, seven at IRCCS Policlinico San Matteo, University of 
Pavia, Pavia, Italy, and three patients were from Royal Adelaide Hospital, 
Adelaide, Australia. 
This phase II study was a prospective registration study to include all patients 
consecutively treated with mesenchymal stem cells in the participating centres 
of the European Group for Blood and Bone Marrow Transplantation 






committees or institutional review boards of the participating institutions. 


























Multiple myeloma 2 
Myeloproliferative disorder 1 
Myelodysplastic syndrome 6 
Lymphoma 1 
Non malignant disorders 10 
Solid tumor 2 
Disease early , late* 21.24 
  
DONOR and CELLS  
Female donor to male recipient 10 
Male donor to female recipient 9 
HLA-identical sibling 19 
Unrelated A, B, DRβ1 identical 25 
Mismatched donor 6 
Unrelated CB (matched/mismatched) 3/2 
HLA-identical sibling 19 
 
 




 CsA 4 
 CsA + MTX 38 
 CsA + MMF 5 
 CsA + prednisolone 6 
 Other  2 
 ATG/ALG/Campath 30/1/5 
DOSE  
Nucleated cell dose x 108/kg 5.9 (0·17-20·6) 

















Abbreviations: ALG = Antilymphocyte globulin; ALL = Acute lymphoblastic leukaemia; AML = Acute 
myeloid leukaemia; ATG = Antithymocyte globulin; BM = Bone Marrow; CB = Cord blood; CML = Chronic 
myeloid leukaemia; CLL = chronic lymphocytic leukemia; JMML = Juvenile myelomonocytic leukaemia;  
CsA = Cyclosporine; HLA = Human leukocyte antigen; MTX = Methotrexate; MMF = Mycophenolate 
mofetil; PBSC = Peripheral blood stem cell.* Early: non-malignant disease, 1st complete remission, 1st 






Table 2.  GVHD grade and organ involvement 
 
  




GvHD II/III/IV 5/25/25  
   
ORGAN INVOLVEMENT   
 Only one organ S/G/L 3/6/1  
 Two: G+S/G+L/L+S 15/7/4  
 Three: G+ S+L 19  
   
GvHD CONFIRMED ON BIOPSY    
 S/G/L 10/31/2  
   
GvHD TREATMENT PRIOR TO MSC INFUSION   
 Cyclosporine or tacrolimus  55 (53)*  
 Prednisolone ≥ 2 mg/kg 55 (55)*  
 MMF 10 (10)*  
 Daclizumab + Infliximab 4 (-)  
 Daclizumab alone  1 (3)*  
 Etanercept and PUVA 1 (-)  
 Extra-corporeal photochemotherapy 10 (8)*  
 Cyclophosphamide 3  
 ATG† 2  
 Rituximab (1)*  
 
  
PREVIOUS FAILED THERAPY 
  
 First line 55  
 Second line 33  
 Third line 14  
 Fourth line 4  
 Fifth line 2  
   
 
Abbreviations:  
G = Gut; L = Liver; S = Skin.;  
ATG=antithymocyte globulin. MMF=mycophenolate mofetil. MSC=mesenchymal 
stem cell. PUVA=psoralen and ultraviolet-A irradiation.  
*Numbers in brackets hadimmunosuppressive therapy at time of MSC infusion. †One Thymoglobulin, 






Procedures and definitions 
Before treatment with haemopoietic stem cells, patients received either 
myeloablative or reduced-intensity conditioning (figure 1). Conditioning was 
myeloablative in 37 patients, who were given cycloph sphamide (120 mg per 
kg) combined mainly with busulfan (16 mg per kg), melphalan, or fractionated 
whole-body irradiation (≥ 12 Gy). 18 patients had low-intensity conditioning 
regimens with fludarabine phosphate combined with various cytotoxic drugs or 
2 Gy whole-body irradiation. 
As GVHD prophylaxis, most patients received ciclosporin combined with either 
four doses of intravenous methotrexate or mycophenolate mofetil. In patients 
receiving cord-blood transplantation, ciclosporin was combined with 
prednisolone. Recipients of haemopoietic stem cells from unrelated donors were 
treated with antithymocyte globulin, anti-lymphocyte globulin, or alemtuzumab. 
All patients had been treated with prednisolone 2 mg/kg per day or more as 
first-line immunosuppressive GVHD therapy and were resistant to this 
treatment. 
33 patients (60%) had failed two or more lines of immunosuppressive therapy 
before receiving mesenchymal stem cells (table 2). All patients continued 
treatment with steroids and a calcineurin inhibitor (n=53) or mycophenolate 
mofetil (n=2) at the time of infusion. 
20 patients also continued additional treatments while receiving stem cells 
(table 2). 
We defined resistance to treatment as no improvement in overall grade of 
GVHD or progression.  
Acute GVHD was graded according to internationally accepted criteria by 
physicians at individual centres.23 When possible, we confirmed diagnosis with 
biopsy of the involved organs. 
We used best response to define the response to treatment: complete response 






at least one grade; stable disease was no change in GVHD grade; and 
progressive disease was worsening of GVHD. 
Patients were judged to have responded if they had either complete or partial 
response. Transplantation-related mortality included all deaths associated with 





Figure 1: Scheme of mesenchymal stem-cell therapy 
 
Laboratory methods 
Table 3 shows the characteristics of the donors and grafts. Mesenchymal stem 
cells were derived from either HLA-identical stem-cell donors, haploidentical 
family donors, or unrelated HLA-mismatched donors. 
Clinical-grade mesenchymal stem cells were generated under good 
manufacturing practice conditions according to a comm n protocol devised by 
the European Group for Blood and Bone Marrow Transplantation 
developmental committee and approved by the medicinal-product agencies in 
the respective countries. Bone-marrow mononuclear clls were separated by 






Washed cells were re-suspended in Dulbecco’s modified Eagle’s medium–low 
glucose (Life Technologies, Gaithersburg, MD, USA, or Paisley, UK) 
supplemented with 10% fetal bovine serum (National Veterinary Institute, 
Uppsala, Sweden, or HyClone, Logan, UT, USA) and plated at a density of 160 
000 cells per cm2. Cultures were maintained at 37oC in a humidified 
atmosphere containing 5% CO₂ in 175 cm2 fl asks (Falcon, Franklin Lakes, 
New Jersey, USA, or Greiner Bio-One, Frickenhausen, Germany). When the 
cultures were near confluence (>80%), the cells were detached by treatment 
with trypsin and EDTA (Invitrogen, Grand Island, NY, USA, or Lonza 
Verviers, Verviers, Belgium) and re-plated at a density of 4000 cells per cm2. 
When 2×106 cells or more were obtained, they were harvested and either 
cryopreserved in 10% dimethyl sulphoxide (Research Industries, Salt Lake City, 
UT, USA, or Leiden University Medical Centre Pharmacy, Netherlands) or 
washed repeatedly and re-suspended to a final concentration of 2×106 cells per 
ml in saline solution according to local guidelines. 
Criteria for release of mesenchymal stem cells for clinical use included absence 
of visible clumps, spindle-shape morphology, absence of contamination by 
pathogens (as documented by aerobic and anaerobic cultures before release), 
viability greater than 95%, and immune phenotyping proving expression of 
CD73, CD90, and CD105 surface molecules (>90%) and bsence of CD34, 
CD45, CD14, and CD3.24  
Cells were given as intravenous infusions. Cells for 11 infusions were harvested 
fresh from culture and given to the patients. In all other cases, frozen cells were 







Table 3. Mesenchymal-stem-cell donor and graft characte istics 
 
  
 MEASURE  
DONORS   
No. of donors 45  
Donor sex (male/female) 25/20  
Donor age  36 (1-67)  
 
  
NUMBER OF INFUSIONS BY DONOR TYPE 
  
 HLA-identical sibling 5  
 HLA-haploidentical donor 18  
 Unrelated HLA-mismatched donor 69  
    
Volume of bone marrow harvested (ml) 
60 (32-220)  
Median MSC cell dose (x 106/kg, range) 1·4 (0·4-9)  
   
CULTURE PASSAGE AT MSC HARVEST 
  
 Passage 1 
14  
 Passage 2/2+3 42/7  
 Passage 3/3+4 23/2  
 Passage 4 
4  
   
NUMBER OF MSC INFUSIONS 
  
 One 27  
 Two 22  
 Three 4  
 Four 1  
 Five 1  
   
 








Data were analysed as of last data collection in March, 2007. We estimated the 
probability of survival with the Kaplan-Meier method and significance of 
differences with the log-rank test (Mantel-Cox). Transplantation-related 
mortality was estimated non-parametrically. Patients were censored at the time 
of death or last follow-up. Because relapse and non-relapse mortality are 
competing events, we estimated their incidence witha non-parametric estimator 
of cumulative incidence curves.25,26 All results were expressed as 2-year 
probability of survival or 1-year cumulative incidence (%) of transplantation-
related mortality and 95% CI. We used Fisher’s exact test to compare 
distribution of categorical variables. Analyses were done with the cmprsk 
package (developed by Gray, June, 2001), Splus 6.2 software, and Statistica 
software. 
 
Role of the funding source  
The sponsors of this study had no role in study design, data collection, data 
analysis, data interpretation, or writing of the report. The corresponding author 
had full access to all the data and had final responsibility for the decision t  
submit for publication. 
  
Results 
92 infusions of mesenchymal stem cells were given; 27 patients had one 
infusion, while 28 had two or more (figure 1, table 3). Of the 28 patients treated 
with multiple infusions, 15 received cells derived from two or more donors. No 
patients had acute side-effects either during or after infusion; and none have had 
late side-effects so far. Median time from transplantation of haemopoietic stem 







Just over half the patients had a complete response, and about a fifth had a 
partial response; most of the remainder had worsening d sease (table 4). A 
greater proportion of children responded than did aults (p=0.07). Median time 
from first infusion of mesenchymal stem cells to complete response was 18 
days (min–max range 3–63). 30 patients achieving complete response were 
available for assessment at 6 weeks after infusion. Of these, four had died, 19 
still had complete response, one had grade 1 and six had grade 2 acute GVHD. 
After one dose, 27 patients had complete response, two had partial response, 
and 26 did not respond. Of patients who responded to one dose, two were 
treated with HLA-identical mesenchymal stem cells, three with haploidentical 
cells, and 24 with third-party cells. The median dose given to patients who 
responded to the fi rst dose was 1.4×106 cells per kg (min–max range 0.8×106to 
9×106 cells per kg), which was similar to that given to non-responding patients 
(1.4×106 cells per kg; 0.6×106 to1.9×106 cells per kg). Six children and one 
adult who responded to the first infusion were given a second infusion to 
prevent GVHD recurrence when immunosuppressive drug treatment was 
reduced. 
17 of the patients who did not have sustained complete response after the first 
dose were treated with subsequent doses. Five patients had complete response 
but received several doses of mesenchymal stem cells b cause of GVHD 
recurrence. Five patients had partial responses and were given multiple doses. 
One patient did not respond to 0.6×106 cells per kg but responded to a second 
dose of 2×106 cells per kg. 12 patients did not respond despite sev ral infusions. 
22 of 30 patients with grade 2 or 3 acute GVHD responded, compared with 17 
of 25 with grade 4 disease (p=0.77). 28 (78%) of 36 patients with involvement 
of one or two organs had a response compared with 11 (58%) of 19 patients 
with involvement of three organs (p=0.21). 
The age or HLA-match of the mesenchymal-stem-cell donor had no effect on 






identical cells, two of five responded to first dose, compared with nine of 13 
patients given haploidentical cells and 27 of 37 receiving unrelated cells. 
Median time from acute GVHD onset to treatment with mesenchymal stem cells 
was 25 days (min–max range 3–114) in complete responders, compared with 29 
(3–116) days among all other patients (p=0.48). We noted variable responses 
when cells expanded from one donor were given to several recipients. There 
was no relation between the treatment given before infusion of mesenchymal 
stem cells and response. 
21 patients were alive at the time of analysis (March, 2007) with a median 
follow-up of 16 months (min–max range 1.5–64 months) after infusion of 
mesenchymal stem cells (table 4). 
 
Table 4. GvHD response and outcome  
  
 CHILDREN ADULTS ALL PATIENTS 
    
 
n = 25 n = 30 n = 55 
RESPONSE 
   
 Complete 17 (64%) 13 (47%) 30 (55%) 
 Partial 4 5 9 
 Stable disease 2 1 3 
 Progressive disease  2 11 13 
 Overall response 21 (80%) 18 (60%) 39 (69%) 








    
CHRONIC GvHD 








 Extensive 4 2 6 
    
 








The estimated probability of survival 2 years after haematopoietic-stem-cell 
transplantation for the entire cohort of patients was 35% (95% CI 22–38%); in 
adults, 2-year survival was 26% (10–42%) compared with 45% (23–67%) in 
children (p=0.06). The 2-year probability of survival in complete responders 
(52%, 34–70%) was significantly better than that in he patients with partial or 
no response (16%, 0–32%, p=0.018; figure 2).  
 
 
Figure 2:  Survival from time of haemopoietic-stem-cell transplantation in patients 
given mesenchymal stem cells  
Survival at the end of follow-up was 52% (95% CI 34–70%) for the 30 complete 
responders and 16% (0–32%) for the 25 partial responders or non-responders. 
 
The 100-day transplantation-related mortality from time of infusion of 
mesenchymal stem cells was 13% (0–26%) for patients with complete response 
compared with 60% (41–79%) in other patients (p=0.002). Transplantation-
related mortality 1 year after infusion was 37% (19–55%) in complete 
responders and 72% (55–89%) in patients with partial or no response (p=0.002; 
figure 3). Of the survivors, six with complete response developed chronic 
GVHD, which was limited (mild) in four and extensive (severe or involving 






developed extensive GVHD. At last follow-up (March 1, 2007), eight with 
complete response had discontinued all immunosuppressive drugs. Three 
patients had recurrence of the original disease one with multiple myeloma, one 
with acute lymphoblastic leukaemia, and one with acute myeloid leukaemia. 
One patient with Pearson’s disease developed acute myeloid leukaemia de novo 
originating in endogenous haemopoietic cells. All these patients died. Acute 
GVHD was the most common cause of death (18 patients), with or without 
concomitant infection. One patient died from chronic GVHD with obstructive 
bronchiolitis, and one patient died from multi-organ failure after severe 
haemorrhagic cystitis. Infections in patients who died to acute GVHD included 
aspergillosis (five), cytomegalovirus (four), and septicaemia caused by 
Enterococci (four), Klebsiella sp (one), Escherichia coli (one), and an 
unidentified pathogen (one). Three patients had infection with Epstein-Barr 
virus, one of whom developed post-transplantation lymphoproliferative disease 
related to the virus. Of the patients who responded to mesenchymal stem cells, 
nine died from infections. Pathogens included Klebsiella sp, E coli, 








Figure 3:  1-year cumulative incidence of transplantation related mortality from time of 
infusion of mesenchymal stem cells 
Transplantation related mortality was 37% (95% CI 19–55%) among the complete 
responders and 72% (55–89%) among the partial responders or non-responders. 
 
Discussion 
39 of 55 patients with steroid-resistant, severe, acute GVHD responded to 
treatment with mesenchymal stem cells. Survival in those with complete 
response was significantly higher and transplantation-related mortality after 
infusion was significantly lower than in people with partial or no response. The 
clinical course of the 13 patients with progressive disease despite treatment may 
represent the natural progression of severe GVHD resulting in death in most 
patients. No major toxicities were observed, and treatment with mesenchymal 
stem cells seemed to be safe. 
Although various immunosuppressive treatments have been used, there is no 
established therapy for steroid-resistant, severe, acute GVHD.1,3–5 The outcome 
for patients who do not respond to corticosteroids is therefore poor, and survival 






mesenchymal stem cells was higher (52%) than previously described for 
patients with a similar grade of acute GVHD. 
The response in patients with grade 2 and 3 acute GVHD was similar to that in 
patients with grade 4. More patients are needed to investigate responses to the 
treatment in various subgroups. For example, the diff rence in response rate 
between children and adults with acute GVHD of comparable severity was not 
significant. Because of the low number of patients, the statistical power was 
insufficient to detect significance for differences the size of that between 
response rates in adults and in children (estimated power 0.58). At least 80 
patients would be needed to detect such a differenc with p equal to or less than 
0.05. 
At present, little is known about mechanisms of suppression of GVHD by 
mesenchymal stem cells. In-vitro, these cells have various effects on immune 
cells, including T cells, antigen-presenting cells, natural-killer cells, and B 
cells.28–30 The biological relevance of these in-vitro findings is unknown. These 
cells might suppress donor-T-cell responses to recipient alloantigen. This 
suppression is probably induced by several mechanisms, including release of 
soluble factors, induction of regulatory T cells, and repair of damaged target 
organs.28–30 Immunological studies specifically addressing this issue are needed 
to improve our understanding the treatment of acute GVHD. 
Our study was designed to assess safety and efficacy of mesenchymal stem cells 
for refractory acute GVHD. It was not designed to identify the best dose of 
mesenchymal stem cells. At present we can note only that, on the one hand, 
clinically meaningful responses were obtained after infusing a dose as low as 
0.8×106 cells per kg, whereas on the other, doses as high as 1.9×106 cells per kg 
were not successful in all cases. Thus any conclusion as to relevant dose is 
premature. 
In more than half of patients, a single dose produce  a response, whereas in a 






were needed to induce a lasting response. The response was not restricted to 
single organs: skin, gastrointestinal tract, and liver GVHD showed similar 
responses. How long mesenchymal stem cells survive after injection and to 
what extent they are able to target tissues are unknown.22 Thus, whether GVHD 
multi-organ response to infusion occurs because the cells reach the lymph nodes 
and inhibit the immunological response that gives rise to GVHD is unclear; they 
might alternatively or additionally target various organs associated with a 
tissue-healing effect. Further tracking studies with labelled cells are needed to 
address these issues. Third-party mesenchymal stem cells were as effective as 
HLA-identical or haploidentical cells. This finding has practical implications 
and suggests that third-party cells can be prepared nd stored frozen to be used 
for GVHD therapy. Little is known about whether HLA disparity determines 
the response to treatment and survival of cells after systemic administration. 
Most data derived from animals indicate short survival of mesenchymal stem 
cells after injection in vivo. Clinical benefit t might not require sustained 
engraftment of many cells but could possibly result from production of growth 
factors or temporary immunosuppression. With the poor health of patients 
receiving mesenchymal stem cells, some deaths were exp cted, despite control 
of GVHD. Infections are common in severe GVHD because of the state of 
immunodeficiency that characterizes these patients. Whether treatment can 
further aggravate immune incompetence or not is unclear. To properly answer 
the question of whether treatment increases the risk of infections requires a 
controlled randomized study. 
The survival rate for patients with complete response was significantly better 
than that for those with partial or no response, suggesting that beneficial effects 
of mesenchymal stem cells are not overridden by a high number of severe 
infections. 
This study was a multicentre collaboration between c tres adopting a common 






significant differences in the response rate to treatm nt in patients in the 
different participating centres, we conclude that use of a common protocol 
affords reproducibility of results. Mesenchymal stem cells derived from bone 
marrow might be a safe and effective treatment for patients with severe, acute 
GVHD who do not respond to corticosteroids and other immunosuppressive 
therapies. The number of infusions needed, the bestdo e of cells in each 
infusion, and the possible interactions of cells with other drugs for acute GVHD 
require further investigation. Although the grim outl ok for patients who do not 
respond to treatment suggests that improved survival rate is probably related to 
infusions of mesenchymal stem cells, randomised clinical studies are needed to 
compare this treatment with more conventional approaches. 
In summary, this study shows that more than half of the patients with steroid-
refractory acute GVHD responded to treatment with mesenchymal stem cells. 
Whether the cell donor was HLA matched or unmatched did not affect the 
success of treatment. Just over half of patients wih a complete response were 
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Phenotypical/functional characterization of in vitro 
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Thanks to their capacity to modulate immune response and promote tissue 
repair, mesenchymal stromal cells (MSCs) represent a potential novel treatment 
for autoimmune/inflammatory diseases, including Crohn’s disease (CD). The 
aim of the study was the in vitro characterization of MSCs from active CD 
patients (CD-MSCs) for future clinical application.  
MSCs from bone marrow (BM) of 7 CD-patients (median age 32 years) were 
expanded ex vivo in the presence of 5% platelet lysate; cells were inv stigated 
for clonogenic efficiency, proliferative capacity, morphology, 
immunophenotype, differentiation potential, genetic stability and ability to 
suppress in vitro proliferation of both autologous and allogeneic lymphocytes to 
polyclonal mitogens. Results were compared with those f BM-MSCs of 4 
healthy donors (HD).  
MSCs were successfully expanded from all patients. Colony-forming unit-
fibroblast (CFU-F) frequency and proliferative capacity were comparable in 
CD- and HD-MSCs. CD-MSCs showed the typical spindle-shaped morphology 
and differentiated into osteoblasts, adipocytes and chondrocytes. Surface 
immunological markers did not differ between CD- and HD-MSCs, with the 
only exception of sizeable levels of HLA-DR at early culture passages (12%-
84% at P1) in the former. CD-MSCs ceased their growth at variable passages 
(from P8 to P25) and entered senescence, without any change in 
morphology/proliferation rate. Array-Comparative Genomic Hybridization 
demonstrated that CD-MSCs do not show imbalanced chromosomal 
rearrangements. CD- and HD-MSCs similarly inhibited in vitro proliferation of 
lymphocytes to mitogens.  
CD-MSCs show biological characteristics similar to HD-MSCs and can be 
considered for approaches of anti-inflammatory and reparative cell therapy in 







Within the bone marrow (BM) microenvironment, multipotent stromal cells, 
also referred to as mesenchymal stromal cells (MSCs), are known to be the 
precursor cells for stromal tissues that support hematopoiesis.1,2 For many years, 
MSCs have been considered mainly a component of marrow stroma, without 
any special function, and endowed only with structural support properties. It is 
now clear that MSCs give a substantial contribution t  the creation of the 
hematopoietic stem cell (HSC) niche, and play a crucial role in the development 
and differentiation of the lympho-hematopoietic system by secreting a number 
of growth factors and regulatory cytokines, and by promoting cell-to-cell 
interactions.3-5 
After the initial identification in post-natal BM,1 MSCs have been isolated from 
a variety of other human tissues, including muscle connective tissue, adipose 
tissue, foetal tissues, placenta and umbilical cord blood (UCB).6-10 The isolation 
and characterization of MSCs rely on their adherence to plastic, the ability to 
differentiate into the various mesenchymal differentiation lineages and on the 
expression or absence of a number of surface molecules on culture-expanded 
cells.11 MSCs possess unique immunological properties that are displayed on all 
cells involved in the immune response, including T- and B-lymphocytes, 
dendritic cells and Natural Killer (NK) cells, as demonstrated by several 
independent groups both in vitro and in vivo.12-16 Based on these biological and 
functional properties, MSCs have been already successfully employed in the 
clinical setting, either to enhance hematopoietic stem cell engraftment17,18 or to 
treat the most severe form of acute graft versus host disease (GvHD), refractory 
to conventional treatments.19,20 
Moreover, MSCs have been demonstrated to display chemotactic ability, to 
migrate to sites of inflammation and injury,21 as well as to secrete paracrine 
mediators able to reverse acute organ failure.22 Indeed, MSC infusions have 






hematopoietic stem cell transplantation (HSCT).23  
Based on these findings, MSCs can be considered as a sort of novel treatment 
for inflammatory diseases, where cell loss is accompanied by local and systemic 
inflammatory response.  
Crohn’s disease (CD) is a chronic inflammatory enteropathy, whose prevalence 
in Western countries has dramatically increased in the last decade, 24 and in 
which a dysregulation of the immune response towards intestinal bacteria in 
genetically susceptible individuals plays a pathogenetic role.25 Despite the large 
number of therapeutic options available, i.e. anti-inflammatory drugs, 
antibiotics, immunosuppressant drugs, biological agents and surgical 
strategies,26 there is a growing number of CD patients with refractory/recurrent 
disease. In view of this consideration and of the serious side effects of more 
aggressive therapies, alternative strategies are needed both to increase the 
proportion of patients achieving remission and to improve their quality of life. 
Very recently, the topical implantation of BM-derived MSCs has been 
demonstrated to be beneficial in the healing process of experimental colitis in 
rats, confirming the ability of MSCs to modulate immune-responses and to 
promote tissue repair through their trophic activity.27 Moreover, a phase I 
clinical trial for the treatment of perianal fistulas in 4 CD patients with 
autologous, adipose tissue derived-MSCs has been reported with promising 
results.28 
In this respect, we are currently investigating the potential role of autologous 
BM-derived MSCs as novel, anti-inflammatory cellular therapy to stimulate 
tissue repair in CD patients. However, no experimental data have been obtained, 
so far, on the biological and functional characterization of BM-derived MSCs 
from these patients. The aim of this study, therefore, was to evaluate the 
feasibility of isolating and expanding ex vivo MSCs from BM of CD patients 
with active disease, and to carry out a phenotypical and functional 






healthy subjects. In a perspective of future clinical use, in order to avoid any 
risk associated with the use of fetal calf serum (FCS), platelet lysate (PL, 5%) 
was employed as culture supplement to stimulate MSC growth.29 
 
Materials and methods 
CD Patients and Healthy Donors 
Peripheral blood (PB) and BM cells were harvested from 7 patients with active 
CD (5 males, 2 females, median age 32 years, range 18-59) and 4 healthy HSCT 
donors (2 males, 2 females, median age 33 years, range 16-47), after obtaining 
written informed consent. The Institutional Review Board of Fondazione 
IRCCS Policlinico San Matteo Foundation approved the design of this study.  
Peripheral blood mononuclear cells (PBMCs) were isolated from CD patients 
and healthy donors (HDs) by means of density gradient c ntrifugation (Ficoll 
1.077 g/ml; Lymphoprep, Nycomed Pharma, Oslo, Norway) and cryopreserved 
for future experiments. 
Patient characteristics at time of BM harvest are described in Table 1.
 
Pt.     Sex    Age    BMI  Disease duration  Behaviour      Location    CDAI                 Therapies                         Previous therapy 
(n.)           (years)                  (years)                        
1         F       45       31.0           8                   B3                   L2           323              MSZ, MTN, anti-TNFa     MSZ, PDN, AZT, AB,  
                                                                                                                                                                   anti-TNFa , surg.                        
 
2         M      29      19.6           13                        B3                   L1           197              MSZ, anti-TNFa                MSZ, PDN, AZT, AB,  
                                                                                                                                                                   anti-TNFa , surg.       
 
3         M      18       27.0           2                         B3                   L2           173              MSZ, MTN                        MSZ, PDN, AB, surg. 
 
4         F       59       28.0          1.2               B2/B3                L2           172             MSZ                                   MSZ, PDN, AB, surg. 
 
5         M      37       17.0          12                      B2/B3               L3            231            MSZ, AZT, MTN          MSZ,PDN,AZT,AB,surg. 
 
6         M      32       19.0          15                         B3                  L3            162             MSZ                                 MSZ, PDN, AB, surg. 
 
7         M      32       22.0            8                         B3                  L3            242             MSZ                                  MSZ, PDN, AB 
 
 
Table 1. Patients’ clinical features at time of bone marrow harvest  
Pt: patient; F: female; M: male; BMI: body mass index; CDAI: Crohn’s disease activity index; MSZ: mesalazine; MTN: Metronidazole; 
PDN: prednisone; AB: antibiotics; AZT: azathioprine; surg.: surgery. 
Disease behaviour and localization are classified according to the Vienna classification (*). Behaviour: B1 nonstricturing, nonpenetrating; 
B2 stricturing; B3 penetrating; location: L1 terminal ileum; L2 colon; L3 ileocolon; L4 upper gastrointestinal.  
A CDAI value ≥ 150 indicates active disease 
(*)Gauche C, Scholmerich J, BrynshowJ, et al. A simple classification of Crohn’s disease: report of the working party of the world 
congresses of gastroenterology, Wien 1998. Inflamm Bowel Dis 2000;6:8-15. 
Isolation and Culture of BM-derived MSCs 
Mononuclear cells were isolated from BM aspirates (20 ml) of CD patients 
and HDs by density gradient centrifugation (Ficoll 1.077 g/ml; Lymphoprep) 
and plated in non-coated 75-175 cm2 polystyrene culture flasks (Corning 
Costar, Celbio, Milan, Italy) at a density of 160,000/cm² in complete culture 
medium: LG-DMEM (Invitrogen, Paisley, PENN) supplemnted with 5% 
PL,29 and gentamycin 50 µg/ml (Gibco-BRL, Life Technologies, Paisely, 
UK). PL was prepared as previously described and use a  culture supplement 
for the generation and expansion of MSCs from all BM samples.29 Cultures 
were maintained at 37°C in a humidified atmosphere, containing 5% CO2. 
After 48-hour adhesion, non-adherent cells were removed and culture medium 
was replaced twice a week. MSCs were harvested after reaching ≥ 80% 
confluence, using Trypsin (Sigma-Aldrich, Milano, Italy), and propagated at 
4,000 cells/cm² until passage (P) 5. MSCs from 5 CD patients (CD-MSCs) 
were maintained continuously in culture until reaching senescence. Senescent 
MSCs were monitored for up to 8 weeks, in order to eveal any change in 
morphology and/or proliferation rate.30 
 
Characterization of ex vivo Expanded MSCs 
The colony-forming unit-fibroblast assay (CFU-F) was performed as 
described previously.29,31 CFU-F formation was examined after incubation for 
10 days; the clonogenic efficiency was calculated as the number of colonies 
per 106 BM mononuclear cells seeded.  
CD-MSCs from all 7 patients and MSCs from the 4 HDs (HD-MSCs) were 
phenotipically characterized by flow-cytometry; fluorescein isothiocyanate 
(FITC) or phycoerithrin (PE)-conjugated monoclonal antibodies specific for 
CD45, CD14, CD34, CD13, CD80, CD31, HLA A-B-C, HLA-DR, CD90 (BD 
PharMingen, San Diego, CA), CD73, CD105 (Serotec, Kidlington, Oxford, 






conjugated antibodies were employed as controls. Analysis of cell populations 
was performed by means of direct immunofluorescence with a FACSCanto 
flow cytometer (BD PharMingen) and data were calculted using FlowJo 
software (Tree Star, Inc. Ashland, OR).  
The osteogenic, adipogenic and chondrogenic differentiation capacity of 
MSCs was determined at P2 or P3 in 4 CD patients and 3 HDs, as previously 
described.29,32,33 To detect osteogenic differentiation, cells were stained for 
calcium deposition with Alzarin Red (Sigma-Aldrich). Adipogenic 
differentiation was evaluated through the morphological appearance of fat 
droplets stained with Oil Red O (Sigma-Aldrich). To detect chondrogenic 
differentiation, cells were stained for proteoglycans Toluidine Blue (Sigma-
Aldrich).  
 
In vitro PBMC Proliferation Assay with PHA and OKT3 
The proliferation of PBMCs from 6 CD patients and 4 HDs, in response to 
both phytohemagglutinin (PHA-L; Boehringer, Mannheim, Germany) and 
anti-CD3 (OKT3; Ortho, Raritan, NJ), in the absence or in the presence of 
BM-derived MSCs was performed in triplicate in flat-bottom microwells 
(Corning Costar, Celbio).  
In detail, irradiated (30 Gy) autologous or allogeneic MSCs were seeded at 
MSC:PBMC ratio 1:2, 1:10, 1:20 per well and allowed to attach overnight 
before adding 105 PBMCs per well. PBMCs, in RPMI 1640 medium (Gibco-
BRL, Life Technologies) supplemented with 10% FCS (Euroclone, Celbio), 
were then added with or without PHA (4 µg/ml) and OKT3 (5 ng/ml). After a 
3-day incubation at 37°C in a humidified 5% CO2 atmosphere, 
3H-thymidine 
(3HTdR 0.5 µCi/well; Amersham, Buckinghamshire, UK) incorporation was 
measured during the last 21 hours by standard procedure. The experiments 










Molecular karyotyping was performed by array-comparative genomic 
hybridization (array-CGH) with the Agilent kit (Human Genome CGH 
Microarray, Agilent Technologies, Santa Clara, CA). Since the minimum 
positive call was considered of three consecutive oligomeres with a log2 ratio 
different from zero, the theoretical resolution of the 105kb 60mer 
oligonucleotide platform was of about 40kb. The genetic profile of 4 CD 
patients was tested before culture (defined time 0 or T0) using PBMCs, and 
after in vitro culture on MSCs at P2 or P3 (T1). CD-MSCs of 2 patients (pt. n. 
3 and 4) were also evaluated at later passages (P10 and P13, respectively), 
after prolonged in vitro culture (T2). DNA extracted from saliva of the 4 CD 
patients was used as control DNA to test T0 cells. PBMC DNA of the analyzed 
patient was used as control DNA in every experiment on CD-MSCs. DNA 
was extracted using QIAamp DNA Blood Mini Kit (Qiagen, Milan, Italy) 
according to the manufacturer’s protocol. Array-CGH experiments were 
performed according to the manufacturer’s protocol version 5.0. and analyzed 
through the Agilent scanner and the Feature Extraction software (v9.1). 
Graphical overview was obtained using the CGH Analytics software 
(v3.4.27). Quality control parameters for every experiments were valuated 
using QC metric tool of CGH Analytics Agilent software.  
 
Statistical Analysis 
The non parametric Mann-Whitney test for independent samples was 






counts, inhibition of PBMC proliferation to mitogens. P values less than 
0.05 were considered significant.  
 
Results 
Characterization of BM-derived MSCs  
We have previously demonstrated that, as compared to MSCs cultured in 10% 
FCS, MSCs of HDs expanded in the presence of 5% PL display comparable 
morphology, phenotype and differentiation capacity, whereas are superior in 
terms of clonogenic efficiency and proliferative capacity.29 Based on these 
findings, we have chosen 5% PL as culture supplement for the ex vivo 
isolation and expansion of MSCs from BM of all CD patients and HDs 
evaluated in this study. 
As compared to HD-MSCs, BM-derived MSCs from CD patients showed a 
similar spindle-shape morphology in culture (see Figure 1A). In addition, 
when BM samples were assayed for CFU-F frequency after 10-day culture the 
results were as follows: HD-MSCs (obtained from 4 subjects) showed a 
median value of 24.5 (range 18-31) CFU-Fs per 106 mononuclear cells plated, 
whereas the median value for CD-MSCs (obtained from 7 patients) was 21.5 
(range 16-29; P=NS) CFU-Fs.  
Similar to HD-MSCs, CD-MSCs were able to differentiate into both 
osteoblasts, adipocytes and chondrocytes, as demonstrated by the histological 
detection of calcium depositions positive for Alzarin Red (Figure 1B), the 
morphological appearance of lipid droplets stained with Oil Red O (Figure 
1C) and the histological detection of proteoglycans po itive for Toluidine 
Blue, respectively (Figure 1D), respectively.  
No differences were observed in terms of proliferative capacity, calculated as 
cumulative cell counts from P0 to P5, between HD- and CD-MSCs (P=NS; 







Figure 1. Characterization of Crohn’s disease (CD)-MSCs, as compared to healthy 
donor (HD)- MSCs, expanded in the presence of platelet lysate (PL, 5%)-additioned 
medium. 
A) Morphology of CD-MSCs from patient . 2 at P3, as compared to HD-MSCs at P3. 
B) Osteogenic differentiation capacity of CD-MSCs from patient n. 4 at P3, as 
compared to HD-MSCs at P3. The differentiation into osteoblasts is demonstrated by 
calcium deposition stained with Alzarin Red. Magnification x 20. C) Adipogenic 
differentiation capacity of CD-MSCs from patient . 4 at P3, as compared to HD-
MSCs at P3. The differentiation into adipocytes is revealed by the formation of lipid 
droplets stained with Oil Red O. Magnification x 20. D) Chondrogenic differentiation 
capacity of CD-MSCs from patient . 4 at P3, as compared to HD-MSCs at P3. The 
differentiation into chondrocytes is demonstrated by deposition of extracellular matrix 
stained with Toluidine Blue (proteoglycans). E) Calculated cumulative cell counts 
from P0 to P5 of CD-MSCs and HD-MSCs cultured in the presence of 5% PL; results 
are expressed as the mean calculated from data obtained from 7 CD patients and 4 






Moreover, the median time to reach 80% confluence for all passages from 1 to 
5 was 6 days for both HD- and CD-MSCs.  
MSCs from 5 CD patients (pt. n. 1, 2, 3, 4 and 6) were propagated for long 
term in vitro culture. CD-MSCs from pt. n. 1, 2, 3, and 6 ceased their growth 
at P11, 9, 11 and 8, and entered a senescence phase after 18-, 19-, 20- and 16-
week culture, respectively. Patient . 4 showed a late MSC growth arrest 
(P25), when the cells entered senescence after 28-week culture. Senescent 
CD-MSCs were monitored in culture daily for up to 8 weeks, without showing 
any change in morphology, immunophenotype and/or prlife ation rate.  
CD-MSCs from all 7 patients expressed high levels (>95% positive cells) of 
CD90, CD73, CD105, CD13 and HLA A-B-C surface antigens, whereas were 
negative for CD34, CD45, CD14, CD80, CD31 molecules (see Figure 2), this 
pattern being similar to that observed in HD-MSCs. However, while in HD-
MSCs HLA-DR expression was always below 2% even at early passages (data 
not shown), CD-MSCs at P1-P3 expressed variably measurable levels of this 
marker (from 12 to 84% at P1; see Figure 2), which tended to decrease during 
in vitro culture and completely disappeared after P4.  
 
Figure 2. Immunophenotypic characterization of CD-MSCs from patient n. 1 at P1 by 
flow cytometry. CD-MSCs stain positive for CD90, CD105, and HLA A-B-C surface 






from patient n. 1 at P1 are positive for HLA-DR. B) Expression of HLA-DR on CD-
MSCs from patient n. 1 at P5. Only 2 % of CD-MSCs are positive for HLA-DR. 
 
The expression of HLA-DR was monitored throughout clture for all CD 
patients (see Table 2 for details). 
 
Pt (n.)                P1              P2              P3             P4              P5            P6 
  1                       60              45                22               9             2              0 
  2                       30              30                 4                2             ND            0 
  3                       20              10                 5                0               0              0
  4                       17              11                 0                0               0            ND 
  5                        84             44                 7                1              0              0 
  6                        12               0                 0                0               ND          ND 
  7                        13               0                 0                0               ND           0
 
Table 2. Percentages of HLA-DR expression on ex-vivo expanded Crohn’s 
disease (CD)-MSCs by flow cytometry. CD-MSCs at early passages (P1-P3) 
express variable levels of HLA-DR which tend to decrease during in vitro 
culture and disappear after P4. 
ND: not determined 
 
Effect of MSCs on PBMC proliferation 
The effect of CD- and HD-MSCs on the proliferation f PBMCs stimulated 
with PHA and OKT3 was evaluated in 6 CD patients and 4 HDs. Results are 
reported in Figure 3.  
As far as the autologous setting (i.e. CD-PBMCs/CD-MSCs) is concerned, 
PHA- and OKT3-stimulated proliferation of CD-PBMCs was reduced by up to 
61% ± 9.6% (MSC:PBMC ratio 1:10) and 59% ± 8.1% (MSC:PBMC ratio 
1:20), respectively, by the addition of CD-MSCs. However, a direct 
correlation between the number of CD-MSCs added andthe degree of 
inhibition of CD-PBMC proliferation was not found (see Figure 3A and 3B 






was observed when PHA- and OKT3-stimulated HD-PBMCs were tested in 
the presence of HD-MSCs: 44% ± 12.3% at MSC:PBMC ratio 1:10 for PHA 
(P=NS); 57% ± 11% at MSC:PBMC ratio 1:20 for OKT3 (P=NS, see also 
Figure 3C and 3D for the residual percentage of prolife ation). 
When the allogeneic setting was examined (i.e. CD-PBMCs/HD-MSCs), we 
found that HD-MSCs were comparable to CD-MSCs in the ability to reduce 
PHA- and OKT3-stimulated proliferation of CD-PBMCs (maximum 
inhibition for PHA at MSC:PBMC ratio 1:10 = 52.5% ± 21.2%, P=NS; 
maximum inhibition for OKT3 at MSC:PBMC ratio 1:20 = 45% ± 17%, 
P=NS). As already shown for the combination CD-PBMCs/CD-MSCs, also in 
this context a dose-dependent effect of MSC addition was not observed. 
Figure 3E and 3F report the residual percentage of r sponse. 
 
Figure 3. Residual proliferation of CD patient PBMCs (CD-PBMCs) and healthy 






patient MSCs (CD-MSCs) and healthy donor MSCs (HD-MSCs). Each bar represents 
the percentage of proliferation of 100.000 PBMCs in the presence of decreasing 
numbers of MSCs (MSC:PBMC ratio 1:2; 1:10; 1:20). The cpm values at each cell 
concentration were normalized to the cpm of PBMCs without MSCs in each 
experiment. Each bar represents the mean ± SD of multiple experiments (4 to 6 MSC 
samples, each point being in triplicate). A) CD-PBMCs/CD-MSCs, PHA stimulation; 
B) CD-PBMCs/CD-MSCs, OKT3 stimulation; C) HD-PBMCs/HD-MSCs, PHA 
stimulation; D) HD-PBMCs/HD-MSCs, OKT3 stimulation; E) CD-PBMCs/HD-
MSCs, PHA stimulation; F) CD-PBMCs/HD-MSCs, OKT3 stimulation. 
 
The condition HD-PBMCs/CD-MSCs was also tested: CD-MSCs induced a 
reduction of HD-PBMC proliferation comparable to that observed when HD-
MSCs were tested in the presence of HD-PBMCs (data not shown). 
Altogether, we did not find any significant difference between CD- and HD-
MSCs in the ability to reduce the proliferation of both autologous and 
allogeneic PHA- and OKT3-stimulated PBMCs in vitro. 
 
Molecular Karyotyping 
To test the genetic profile of CD-MSCs, array-CGH experiments were 
performed on cells from 4 CD patients before culture (T0), at early passages 
(T1) and after prolonged in vitro culture (T2; 2 patients). The comparison of 
results from two or three experiments for each patient (T0, T1 and T2), allowed 
us to evidence the possible presence of chromosomal micro-unbalances which 
could be present only in CD-PBMCs (T0) or both in CD-PBMCs and in ex 
vivo cultured CD-MSCs (T1 and T2). The use of DNA from saliva, as control 
DNA to test T0 cells, permitted to exclude copy number variations (CNVs)
34 
constitutionally present in the patients’ genome and, therefore, to evidence 
only acquired chromosomal imbalances. Moreover, the DNA from saliva 
allowed to detect chromosomal deletions typical of T lymphocytes and, thus, 
present only in PBMCs, but not in MSCs. Results of array-CGH experiments 
demonstrated that T0 cells were devoid of chromosomal imbalances, except for 






specifically in T cells. These anomalies were not present in CD-MSCs 
expanded in vitro, which did not show imbalanced chromosomal 
rearrangements even after long term culture (see Figure 4). In fact, the array-
CGH profiles of the repeated experiments from the same patient were 
perfectly overlapping and no deletions or duplications were present, 
considering the platform resolution of about 40kb.  
 
Figure 4. Representative array-CGH profiles of chromosome 14 from patients n. 4: A) T0: 
PBMCs versus saliva; B) T1: MSCs at P3 versus PBMCs; C) The two overlapping experiments; 
red line applies to PBMCs, blue line to MSCs at P3. D) T2: MSCs at P13 versus PBMCs; E) 
The three overlapping experiments; red line applies to PBMCs, blue line to MSCs at P3 and 
green line to MSCs at P13. The first experiment (A) shows the presence of a small deletions in 
PBMCs in 14q11.2 which involves the TCA (T-cell receptor alpha chain C region) locus. This 
gene is rearranged specifically in T cells and its organization is similar to an Ig gene, with V, D, 
J, and C regions. The deletion is present in cellular mosaic, because PBMCs contain all 
peripheral blood mononuclear cells, a portion of whom is represented by T cells. The somatic 
deletion of PBMCs is also revealed in experiments on MSCs, where it appears as a duplication, 
because PBMCs are hybridizated as control DNA. The array-CGH profile of CD-MSCs is 







Despite the large number of therapeutic options, diease control in CD 
remains hard to achieve in many patients.35 In such patients with refractory 
disease and in whom progression into an exacerbated form is associated with 
severe gut fibrosis and formation of strictures and/or fistulas, anti-
inflammatory and immunosuppressive therapies, as well as biological agents 
and surgery, have limited success.35 In this context, adult stem cells and, in 
particular, MSCs are under investigation as a novel c l  therapy-based 
approach that could ameliorate the management of CD patients.36,37 
In the present study, we have isolated and propagated in culture MSCs derived 
from the BM of 7 patients affected by active CD, with the aim of 
characterizing their in vitro biological and functional properties in view of 
their possible clinical use in patients refractory to conventional therapies. For 
this purpose, CD-MSCs have been cultured in the presence of a PL-additioned 
medium and compared to PL-cultured, BM-derived, MSCs obtained from 
HDs. 
Our data demonstrate that both the isolation and the ex vivo expansion of BM-
derived MSCs from CD patients are feasible and thatis cell population 
exhibits similar morphology and differentiation poten ial into osteoblasts, 
adipocytes and chondrocytes, as compared to HD-MSCs (Figure 1A-D).  
Moreover, CD-MSCs display similar CFU-F ability and proliferative capacity 
(Figure 1E), as compared to HD-MSCs, guaranteeing the possibility of 
expanding in vitro sufficient numbers of cells for clinical application.  
As regards the immunophenotype, CD-MSCs displayed th  panel of surface 
markers characteristic of MSC, with the only exception of HLA-DR (Figure 
2). The consistent expression of this latter antige in CD-MSCs at early 
passages (Table 2) might be related to the conditio of active disease found in 
all patients when their BM was harvested, as demonstrated by the activity 






shortly after in vitro culture, namely when cells are grown in a medium devoid 
of inflammatory signals/cytokines, which, by contras , are potentially released 
by the cells involved in the immune/inflammatory response and present in the 
extracellular milieu of CD-BM. Support to this interpretation is provided by 
the observation that BM-derived MSCs from healthy volunteers, expanded in 
the presence of PL, did not show any expression of HLA-DR,29 this 
suggesting that the increased expression of HLA-DR is likely to be 
attributable to the disease status of the patients. It has been previously shown 
that in vitro exposure of MSCs to IFN-gamma, a cytokine known to be 
involved in inflammatory processes including those f CD,38 can induce the 
expression of HLA-DR on MSC cell surface.39,40 Moreover, Le Blanc et al.39 
have already demonstrated that HLA-DR positive MSCs display comparable 
immunomodulatory properties as their counterpart not expressing HLA-DR, 
thus suggesting that this peculiarity of CD-MSCs should not affect their 
function and does not preclude their possible use in the clinical setting. 
We also demonstrated that CD-MSCs are equally effective, as HD-MSCs, in 
inhibiting in vitro polyclonally-induced proliferation of both autologous (i.e. 
derived from the patients themselves) and allogeneic (i. . derived from healthy 
subjects) PBMCs (Figure 3). In particular, it is noteworthy that CD-MSCs are 
able to display the same magnitude of inhibition on CD-PBMCs proliferation, 
as compared to the effect exerted by HD-MSCs on CD-PBMCs. This finding 
supports the use of patient-derived MSCs, instead of utilizing third party cells. 
The use of autologous MSCs offers significant advantages in light of the 
observations that MSCs can be lysed by both allogeneic T cells41 and NK 
cells.15 In the allogeneic setting, it is conceivable that an HLA-disparity 
possibly resulting in NK alloreactivity42 could be a condition where NK cells 
are particularly prone to kill mesenchymal progenitors. Finding an inhibitory 






that a meaningful favorable clinical effect could be obtained even after the 
infusion of a low number of autologous mesenchymal progenitors.  
BM-derived MSCs from CD patients could be cultured long term in vitro, 
without loosing their peculiar morphological and phenotypical characteristics 
and maintaining a normal genetic asset, as demonstrated by array-CGH 
experiments (Figure 4). In this study, we used for the first time array-CGH 
with a higher resolution30 (about 40kb) to test MSCs, in order to have a deeper 
and more sophisticated evaluation of the genomic situation of ex vivo 
expanded cells, even if this approach is not able to unravel balanced 
chromosomal rearrangements (detectable only by conventional karyotype) and 
cell mosaicisms lower than 20%.43 When studying the genetic stability of ex 
vivo, extensively cultured BM-derived MSCs from HDs, we found that a 
normal array-CGH profile was associated with the absence of any abnormality 
in the conventional cytogenetic analysis.30 Our present results obtained 
through array-CGH indicate that CD-MSCs do not apper to be susceptible to 
malignant transformation even after long-term culture, thus rendering these 
cells suitable for cell-therapy approaches. 
Both in animal models and in patients, it has been shown that BM-derived 
cells play a role in the healing process following testinal injury and in the 
regeneration of various cellular components of the mucosa.44-46 MSCs, through 
the secretion of soluble factors (such as indoleamine 2,3-dioxygenase, 
prostaglandin E2, hepatocyte growth factor, etc.) as well as through a direct 
cell-to-cell contact, have been demonstrated to be a le to inhibit T-
lymphocyte proliferation to mitogens and allo-antigens, to inhibit cytotoxic T-
lymphocytes generation, to influence the secretion of cytokines favouring the 
anti-inflammatory ones and to promote the differentiation of regulatory T 
cells.40,47 Thus, in view of their immunosuppressive properties, as well as of 
their role in tissue repair and trophism, BM-derived MSCs represent a 






therapy.48 Indeed, the potentiality of MSCs in the clinical setting has been 
already shown both in prevention and in treatment of GvHD occurring after 
allogeneic HSCT.17,19,20 In particular, a dramatic effect, in terms of complete 
resolution of the disease, has been observed in many p tients suffering from 
acute GvHD of the gut refractory to conventional therapy.19,20 The therapeutic 
efficacy of BM-derived MSCs on this severe complication of HSCT, as well 
as the demonstration that MSCs colonize the site of histological injury in 
patients with gastrointestinal acute GVHD,19 have suggested their potential 
use in the treatment of other inflammatory and immune-mediated diseases, 
including CD. In this regard, recently, the results of a phase-I clinical trial, in 
which autologous, adipose tissue (AT)-derived MSCs have been used for the 
treatment of fistulizing CD in 4 patients, have been published. Eight weeks 
after MSC local infusion, 75% of the fistulas were considered healed and no 
adverse effect was observed.28 Based on these encouraging results, a phase-II 
trial on autologous AT-derived MSCs49 and a phase-III trial on third-party, 
BM-derived MSCs (Osiris Therapeutics, Inc. Columbia, MA)50,51 in CD 
patients refractory to conventional therapies, are underway.  
In this respect, it is worthy to note that ex vivo cultured human AT-derived 
MSCs have been reported to be prone to undergo spontaneous transformation 
characterized by significant chromosomal instability,52 while, as mentioned 
above, BM-derived MSCs do not.30 The biological and functional 
characterization of BM-derived CD-MSCs, which we have demonstrated to be 
comparable to HD-MSCs, confirm the plasticity of these cells, together with 
their immunomodulatory and differentiation propertis, and provide the 
experimental background to consider their use as innovative therapeutic 
strategy in the management of CD patients with refractory disease. Moreover, 
the bio-safety profile of these cells is sustained not only by the genetic 
stability of their chromosome asset, but also by the fact that they were 






of this reagent for the x vivo expansion of MSCs allows to avoid the potential 
risks associated with FCS, such as the possible transmission of zoonoses and 
the rejection of the transplanted cells due to immune reactions against animal 
serum proteins,53 while providing rapid and efficient expansion. 
In summary, this study provides, to our knowledge for the first time, a 
comprehensive characterization of BM-derived MSCs from CD patients; our 
results support the potential use of autologous BM-derived MSCs as novel, 
anti-inflammatory and reparative approach for treating patients with CD 
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Mesenchymal stromal cells (MSCs) are employed in diverse clinical settings 
in order to modulate immune response. However, relativ y little is known 
about the mechanisms responsible for their immunomodulatory effects, which 
could be influenced by both cell source and culture conditions.  
We tested the ability of a 5% platelet lysate (PL)-supplemented medium to 
support isolation and ex-vivo expansion of MSCs from full-term umbilical-
cord blood (UCB). We also investigated the biological/functional properties of 
UCB-MSCs, in comparison with PL-expanded bone marrow (BM)-MSCs. 
Success rate of MSC isolation from UCB was in the order of 20%. UCB-
MSCs exhibited the typical morphology, immunophenotype and 
differentiation capacity. Although they have a low clonogenic efficiency, 
UCB-MSCs may possess high proliferative potential. The genetic stability of 
UCB-MSCs was demonstrated by a normal molecular karyotype; in addition, 
these cells do not express hTERT and telomerase activity, express p16ink4a 
protein and do not show anchorage-independent cell growth. Concerning 
alloantigen-specific immune response, UCB-MSCs were abl  to: i) suppress 
T- and NK-lymphocyte proliferation, ii) decrease cytotoxic activity and iii) 
only slightly increase IL-10, while decreasing IFNγ secretion, in mixed 
lymphocyte culture (MLC) supernatants. While an IDO-specific inhibitor did 
not reverse MSC-induced suppressive effects, a PGE2-specific inhibitor 
hindered the suppressive effect of both UCB- and BM-MSCs on alloantigen-
induced cytotoxic activity. Both UCB- and BM-MSCs expressed HLA-G.  
UCB- and BM-MSCs may differ in terms of clonogenic efficiency, 
proliferative capacity and immunomodulatory properties; these differences 








In addition to hematopoietic stem cells (HSCs), the bone marrow (BM) also 
contains mesenchymal stromal cells (MSCs).1,2 These latter cells exhibit 
multilineage differentiation potential and are endowed with 
immunomodulatory properties that have been demonstrated both in vitro and 
in vivo.3,4 In the setting of hematopoietic stem cell transplantation (HSCT), ex 
vivo expanded MSCs have been employed in view of both their 
immunomodulatory activity and their ability to support hematopoiesis. In 
particular, in a phase I/II multicenter study, MSCs proved safe and effective 
when administered to 55 patients with severe, steroid-refractory acute graft-
versus-host disease (GvHD).5 Moreover, in another phase I/II study, co-
transplantation of MSCs, together with T-cell depleted peripheral blood stem 
cells (PBSCs), overcame the problem of graft failure in 14 children given 
HSCT from an HLA-haploidentical family donor.6 Similarly, co-
transplantation of MSCs and umbilical cord blood (UCB) stem cells is under 
investigation.7,8 Recently, in view of their immunosuppressive propeties, as 
well as their role in tissue repair and trophism, MSC infusion has also been 
proposed as a novel approach for reparative/regenerativ  medicine in the 
treatment of autoimmune disorders and chronic inflammatory diseases.9-11  
Although BM represents the most commonly employed source of MSCs for 
both experimental and clinical use,3,12-16 MSCs have been isolated from other 
sources, including adipose tissue, placenta, amniotic fluid, fetal tissues and 
UCB.17-22  
Notably, it has not always been possible to grow MSCs from UCB and in 
many cases the yield was low. In particular, the prsence of mesenchymal 
progenitors in full-term UCB has been questioned in recent years by many 
groups, whose attempts to obtain MSC have either failed23,24 or yielded low 
numbers.21,25 In fact, the frequency of MSCs in UCB is very low and, in fetal 






mononuclear cells in first trimester fetal blood to 0.3/106 mononuclear cells in 
term cord blood.20 Despite this limitation, Bieback et al. have demonstrated 
that, when critical parameters for the selection of ‘g od quality’ term UCB 
units are employed, MSCs can be successfully isolated in more than 60% of 
the processed cord blood units.22  
MSCs have been mainly expanded in vitro in the presence of fetal calf serum 
(FCS). Cells thus obtained, when infused into patients, may potentially carry 
the risks for both transmitting zoonoses and causing immune reactions 
directed against residual animal proteins. For these reasons, culture 
supplements devoid of animal components, such as platelet lysate (PL), have 
been tested in recent years for the isolation and expansion of MSCs.26-28 In 
particular, our group previously demonstrated that a 5% PL-supplemented 
medium can support large-scale, x-vivo expansion of BM-derived MSCs 
(BM-MSCs) and that this medium is superior to 10% FCS in terms of both 
clonogenic efficiency and proliferative capacity.27 Conversely, BM-MSCs 
expanded in PL seem to be endowed with relatively low immunosuppressive 
activity, as compared with BM-MSCs grown using FCS as culture 
supplement.27 
The aim of this study was to test the ability of a PL-supplemented medium to 
support the generation and ex vivo expansion of MSCs from full-term UCB 
(UCB-MSCs), as well as to characterize these latter cells for their biological 
and functional properties, in comparison with PL-expanded BM-MSCs. In 
particular, we focused on the investigation of both the genetic stability and the 
immunoregulatory function, exerted on alloantigen-specific immune response, 
by UCB-MSCs. Moreover, we have evaluated the possible mechanisms at the 









Design and methods 
UCB unit collection and selection   
UCB units were collected after full-term delivery and stored at the Cord Blood 
Bank of our Hospital after obtaining signed written informed consent. The 
Institutional Review Board of the Fondazione IRCCS Policlinico San Matteo 
approved the study. Citrate Phosphate Dextrose-A, 20 ml, was employed as 
anticoagulant in the collection bags. Whole UCB units were employed for 
MSC generation. Ten fresh UCB units (median volume 45 ml, range 40-60) 
were selected according to the following criteria: 1) total nucleated cell (TNC) 
count ranging from 500 to 750 x106; 2) manipulation performed within 24 
hours from delivery; 3) overall cell viability greater than 75%, investigated by 
7-amino-actinomycin D (7-AAD) and Aldefluor (ALDH). Samples obtained 
from UCB units before and after mononuclear cell (MNC) separation were 
analyzed by a Becton Dickinson FACSCanto instrument (BD BioSciences, 
San Jose, CA, USA), FACSDiva software 5.0, according to the EWGCCA 
guidelines (European Working Group on Clinical Cell Analysis).29,30 Cell 
viability was determined using the 7-AAD dye test (Molecular Probes, 
Eugene, OR, USA) within the context of expression of surface markers 
identified by fluorochrome-labeled antibodies. The following monoclonal 
antibodies were used: anti-CD34 phycoerythrine (PE), anti-CD45 peridinin 
chlorophyll protein (PerCP), anti-CD133 allophycocyanin (APC) (all from BD 
BioSciences) and ALDH (StemCell Technologies, Vancouver, Canada). 
ALDH was detected using the green fluorescence channel following 
manufacturer’s instructions.  
  
PL preparation  
PL was prepared as previously described.27 In brief, aliquots of 50 ml 
platelet-rich plasma, collected by apheresis, were obtained from ten healthy 






products contained a minimum of 5x1011 platelets (PLTs). Written 
informed consent from donors was always obtained anll apheresis 
products were screened for infectious agents according to National 
regulations. Immediately after collection, PLT apheresis products were 
frozen at -80°C and subsequently thawed at 37°C to ob ain the release of 
PLT-derived growth factors. Heparin (5000 UI) was added to PLT bags to 
avoid gel formation. Apheresis products were centrifuged three times at 
900 g for 30 minutes to eliminate PLT bodies. Finally, PL preparations 
obtained through this procedure were pooled in a single culture supplement 
to be used for the generation and expansion of UCB-MSCs.  
 
Isolation and culture of UCB- MSCs  
MNCs were isolated from the 10 UCB units by density gradient 
centrifugation (Ficoll 1.077 g/ml; Lymphoprep, Nycomed Pharma, Zurich, 
Switzerland) after 1:1 dilution with Dulbecco’s phosphate buffered saline 
(D-PBS; Euroclone, Celbio, Milan, Italy) and plated in non-coated 75-175 
cm2 polystyrene culture flasks (Corning Costar, Celbio) at a density of 
160,000/cm² in complete culture medium: Mesencult (StemCell 
Technologies) supplemented with 2 mM L-glutamine, 50 µg/ml 
gentamycin (Gibco-BRL, Life Technologies, Paisely, UK) and 5% PL. 
This concentration of PL was chosen on the basis of results previously 
obtained with BM-MSCs.27 Cultures were maintained at 37°C, in a 5% 
CO2 humidified atmosphere. After 48 hours, non-adherent cells were 
discarded; culture medium was replaced twice a week. Upon the 
appearance of MSC-like clones, cells were harvested using Trypsin 
(Sigma-Aldrich, Milan, Italy), re-plated for expansion at a density of 4,000 
cells/cm² and propagated in culture until reaching a senescence phase. 
Senescent cells were monitored for up to eight weeks, in order to reveal 






analyzed by direct cell counts and cumulative population doublings (PD) 
were determined. Number of PD were calculated using the formula 
log10(N)/log10(2) where N=cells harvested/cells seeded and results were 
expressed as cumulative PD.31 
 
UCB-MSC multilineage differentiation potential  
The adipogenic and osteogenic differentiation capacity of UCB-MSCs was 
determined at passage (P) 2, as previously described.27 To detect 
osteogenic differentiation, cells were stained for alkaline phosphatase (AP) 
activity using Fast Blue (Sigma-Aldrich) and for calcium deposition with 
Alzarin Red (Sigma-Aldrich). Adipogenic differentiation was evaluated 
through the morphological appearance of lipid droplets stained with Oil 
Red O (Sigma-Aldrich). 
 
Immunophenotypic characterization of UCB-MSCs  
FITC, PE, PerCP-Cy5.5 monoclonal antibodies specific for the following 
antigens were employed: 1) CD45 (clone HI30), CD14 (clone MΦP9), 
CD34 (clone 581), CD13 (clone L138), CD80 (clone L307.4), CD31 (clone 
L133.1), HLA A-B-C (clone G46-2.6), HLA-DR (clone G46-6[L243]), 
CD90 (clone 5E10), CD73(clone AD2) (all from BD Biosciences), CD105 
(clone SN6; Serotec, Kidlington, Oxford, UK), HLA-G (clone MEM-G/9; 
Exbio, Praha, CZ) for the assessment of MSC surface phenotype; 2) CD3 
(clone SK7), CD4 (clone SK3), CD8 (clone SK1), CD56 (clone 
NCAM16.2), CD25 (clone 2A3), CD152 (CTLA4; clone BNI3), Foxp3 
(clone PCH101; eBioscience, San Diego, CA, USA) for evaluation of 
lymphocyte subsets. Appropriate isotype-matched controls (BD 
Bioscience, eBioscience) were included. Intracellular staining for CD152 
(CTLA4), Foxp3 and HLA-G was performed as previously described.27,32 






performed with FACScalibur flow cytometer (BD Biosciences) and data 
calculated using CellQuest software (BD Biosciences).  
 
Telomerase activity detection assay and reverse transc iption (RT)-PCR 
analysis of the human telomerase reverse transcriptase (hTERT)  
Telomerase activity was measured by the polymerase chain reaction 
(PCR)-based telomeric-repeat amplification protocol (TRAP) using the 
TRAPeze kit (Intergen Company, FLA, USA) on samples containing 0.6 
and 6.0 µg of protein. Protein extract from a telomerase-positive human 
cell line (JR8) was used as a positive control.33 A sample was scored as 
telomerase activity-positive when positive TRAP results were obtained 
from at least one protein concentration. 
For hTERT assessment, total cellular RNA was extracted from frozen 
samples with the RNeasy micro kit (Qiagen GmbH). A 0.5 µg aliquot from 
each sample was reverse-transcribed by using the RT-PCR Core kit 
(Applied Biosystems, Foster City, CA, USA) with random hexamers, and 
the resultant cDNA was then amplified with the same kit. Amplification of 
hTERT cDNA was obtained as previously described.34 
 
Western immunoblotting 
MSCs were lysed on ice in lysis buffer. Total cellular lysates were 
separated on 15% SDS-polyacrylamide gel and were transferred onto 
Hybond ECL nitrocellulose membranes (GE Healthcare Europe GmbH, 
Cologno Monzese, Italy). Nitrocellulose membranes wre blocked in PBS-
Tween 20 with 5% skim milk, first incubated overnight with the primary 
antibody specific for p16ink4a (Abcam Inc., Cambridge, MA, USA) and then 
with the secondary peroxidase-linked whole antibody (GE Healthcare 
Europe). Bound antibody was detected using the enhanced chemi-






DU145 human prostate cancer and U2OS human osteogenic sarcoma cell 




Single-cell suspensions of 100,000-1,000 cells/ml in complete medium and 
0.3%(w/v) agarose were plated in triplicate in 35 mm culture dishes, over 
chilled 0.6% agarose feeder layers. Cultures were incubated at 37°C in 5% 
CO2 humidified atmosphere and examined at 14 days after plating under an 
inverted microscope. 
 
Molecular karyotyping  
Molecular karyotyping of UCB-MSCs at early (P3) and late (P8-9) 
passages was performed through array-comparative genomic hybridization 
(array-CGH) with the Agilent kit 44B (Human Genome CGH Microarray, 
Agilent Technologies, Santa Clara, CA, USA), as previously described.27,34 
A pool of characterized genomic DNA (Human Genomic DNA Male, 
Promega, Madison, WI, USA) was used as control DNA for all 
experiments. Quality control parameters for every experiment were 
evaluated using the CGH Analytics Agilent software-QC tool. 
 
Mixed lymphocyte cultures (MLCs) and cytotoxicity ass y   
Peripheral blood mononuclear cells (PBMCs) were obtained by Ficoll-
Hypaque density gradient from heparinized PB samples from healthy 
volunteers. Primary MLCs were set up according to previously described 
methods.27,32,35 Briefly, non-irradiated, “third-party” UCB-MSCs, 
allogeneic to both responder (R) and irradiated stimulator (S) PBMCs, 






up in the absence of UCB-MSCs. UCB-MSCs employed in MLC 
experiments had been harvested and cryopreserved at P3. The total number 
of PBMCs recovered after 10-day MLC was counted in vitality with 
Trypan Blue (Sigma-Aldrich). Then, recovered cells were analyzed by flow 
cytometry and percentage of lymphocyte subsets (CD3+ 4+ and 
CD3+CD8+ T-cells, as well as CD3negCD56+ NK-cells) was determined. 
Number of lymphocyte subsets per ml culture was, therefore, calculated 
and compared with the initial number of cells (day 0). Differentiation of 
regulatory T cells (Treg) was evaluated by measuring the percentage of 
CD4+CD25+ and CD4+CD25bright T lymphocytes, together with the 
expression of Foxp3 and CTLA4 on CD4+CD25+ lymphocytes. 
Alloantigen-induced cell-mediated cytotoxic activity was tested in a 5-hour 
51Cr-release assay, as previously described.27,32,35 Results are expressed as 
percent specific lysis of target cells. 51Cr-labeled target cells included 
PHA-activated S-PBMCs (S-PHA) and the same lots of UCB-MSCs that 
had been added to MLCs.  
To evaluate the possible involvement of indoleamine 2,3-dioxygenase 
(IDO) and/or prostaglandin E2 (PGE2) in the immunosuppressive effect of 
PL-expanded UCB-MSCs, we set up MLCs in which, in some wells, 
specific inhibitors of IDO activity (1-Methyl-Tryptophan, 1-M-Trp, Sigma-
Aldrich), or of PGE2 (NS-398, Cayman Chemicals, Irvine, CA) were 
added to MSCs/MLC co-culture at a concentration of 1 mM and 5 µM, 
respectively.36 In this set of experiments, BM-MSCs, expanded in 5% PL-
supplemented medium,27 were employed as a control for UCB-MSCs. Cell 
counts per ml of culture recovered after 10-day MLC as compared to day 0, 
and alloantigen-induced cell-mediated cytotoxic activity (using 51Cr-
labeled S-PHA as target cells) were evaluated for each culture condition. 
After 72-hour culture, supernatants were collected for the evaluation of 






Detection of IDO activity 
IDO activity was evaluated by quantifying tryptophan (tryp) and 
kynurenine (kyn) concentrations in 72-hour culture supernatants with high-
performance liquid chromatography (HPLC), by using the HPLC pump, 
model SCL-10 VP (Shimadzu, Kyoto, Japan). For separation, pre-columns 
(cartridge holder and guard cartridge) from Phenomenex (Torrance, CA, 
USA) and reverse-phase C18 (octyl) columns (250 mm length, 460 mm 
internal diameter, 5 micron grain size) from Beckman-Coulter (Milan, 
Italy), were used. The incorporated UV/VIS detector model UV-SPD-M10 
VP (Shimadzu) was employed for detection of both kyn and nitrotyrosine 
at a wavelength of 360 nm. Tryp was detected by a fluorescence detector 
(Shimadzu, Model RF-535) at 285-nm excitation wavelength and an 
emission wavelength of 365-nm. Samples were prepared s previously 
reported.37 L-tryp, L-kyn, 3-nitro-L-tyrosine, trichloroacetic acid, 
potassium phosphate and acetonitrile for the HPLC elution buffer were 
obtained from Sigma-Aldrich. All chemicals used were of analytical grade. 
Peak area counts were used to calculate concentratio s (EZStart software, 
version 7.3). Tryp and kyn were referred to nitrotysine. The 
reproducibility of the system was controlled by nitrotyrosine counts and 
variations less than 5% were tolerated.  
 
Measurement of cytokines and HLA-G by ELISA  
The concentrations of interferon-gamma (IFN-γ), interleukins (IL)10, IL6, 
IL12, IL7, IL2, IL15 and transforming growth factor beta (TGFβ) in MLC 
supernatants after 12, 24, and 48 hours, were quantified by ELISA using 
monoclonal antibody pairs (Pierce Endogen, Rockford, IL), as previously 
described.27 PGE2 levels were evaluated using a commercially available 






instructions. The concentration of soluble HLA-G (sHLA-G) in culture 
supernatants was quantified by ELISA (sHLA-G ELISA, Exbio); clone 
MEM-G/9 was employed as anti-HLA-G capture antibody.  
 
Statistical analysis 
The non-parametric Kolmogorov-Smirnov test for independent samples 
was performed for the comparison of cumulative cellounts at P0 and P5 
of UCB- and BM-MSCs. Due to the small size of the groups, the maximum 
significance value obtained was P = 0.1. 
 
Results 
Characterization of UCB-MSCs 
Ten UCB units obtained at full-term delivery were selected according to 
the ‘quality’ criteria described in the Design and Methods section. MNCs 
were separated, plated as P0 and cultured in medium supplemented with 
5% PL. The cultures at P0 were monitored for up to four weeks to allow 
identification of MSC clones in the flasks. Two out of the ten UCB units 
(20%; UCB3 and UCB6) gave rise to three and four MSC-like clones after 
15- and 14-day culture, respectively. In the remaining 8 UCB units, we did 
not obtain MSCs, despite the long observation time in culture. MSC clones 
from UCB3 (UCB3-MSCs) and UCB6 (UCB6-MSCs) were expanded ex 
vivo and characterized for their morphology, differentiation potential, 
immunophenotype, proliferative capacity, biosafety profile and 
immunoregulatory properties. 
UCB-MSCs displayed the typical spindle-shaped morphlogy, similar to 
that of BM-MSCs expanded in the same culture medium (see 
Supplementary data, Figure 1s A).27 As already observed for BM-MSCs 
expanded in the presence of PL,27 UCB-MSCs required only 2-3 minutes 






detachment of cells from the flasks, whereas 5–8 min at 37°C are usually 
necessary to harvest MSCs grown in the presence of 10% FCS. 
UCB-MSCs were induced to differentiate into osteoblasts and adipocytes 
and examined for this capacity by histological staining. The cells were able 
to differentiate into osteoblasts, as demonstrated by the histological 
detection of AP activity (purple reaction) and calcium deposition stained 
with Alzarin Red (Figure 1A), and into adipocytes, as revealed by the 
formation of lipid droplets, stained with  Oil Red O (Figure 1B).  
The surface phenotype of UCB-MSCs was analyzed by flow cytometry 
every two passages (at P1, P3, P5 and so on) and showed the typical panel 
of MSC markers, in agreement with previous reports.2,3,20-24,27 In particular, 
by the second passage, contamination with hematopoietic cells was no 
longer detectable and more than 98% UCB-MSCs were positive for CD90, 
CD73, CD105 and CD13 surface antigens and negative for CD34, CD45, 
CD14, CD80, CD31 molecules. The expression of HLA-DR was always 
less than 2%, whereas HLA-class I was uniformly present on UCB-MSCs 
(more than 98% of positive cells). See Supplementary d ta, Figure 1s B. 
Calculated cumulative cell counts from P0 to P5 for UCB3- and UCB6-
MSCs, together with counts for BM-MSCs cultured in the presence of 5% 
PL,27 for comparison are shown in Figure 1C. UCB-MSCs yielded similar 
numbers at P5 (1.62 x 109 MSCs for UCB3 and 2.02 x 109 MSCs for 
UCB6), as compared with BM-MSCs (3.2 ± 1.02  x 109 MSCs as mean ±
SD of 8 BM donors; P>0.1),27 even when starting with low cell numbers. In 
fact, the number of UCB-MSCs collected after trypsinization at P0 was 0.2 
x 106 for both units, whereas the mean of MSCs from eight BM donors at 
the same passage was 2.6 ± 0.58 x 106 cells (P<0.1). UCB-MSC growth 
was also evaluated in terms of PD; cumulative PD from P1 to P5 were as 
follows: 12.9 for UCB3-MSCs, 13.3 for UCB6-MSCs, 10.9 for BM-MSCs 






frequency of clones in case of UCB-MSCs, a comparison of the colony-
forming unit-fibroblast (CFU-F) assay with BM-MSCs could not be 
performed. The median time to reach 80% confluence for all passages from 
P1 to P5 was 6.5 days for both UCB3- and UCB6-MSCs, as compared with 
5.5 days in case of BM-MSCs expanded in the presence of 5% PL.27 Taken 
together, these results suggest that UCB-MSCs, althoug  displaying a 
rather low clonogenic efficiency, possess high proliferative potential.  
UCB-MSCs were cultured continuously in vitro until reaching senescence 
and monitored daily for up to eight weeks, in order to investigate their 
propensity to undergo spontaneous transformation in vitro. UCB3-MSCs 
and UCB6-MSCs displayed a progressive decrease in their proliferative 
capacity until they reached a senescence phase after 73- and 81-days 
culture at P9 and P10, respectively. The cells maintained their typical 
spindle-shaped morphology, differentiation capacity and surface markers 







Figure 1. A) Osteogenic differention capacity of UCB-MSCs, as compared with 
BM-MSCs (right panel). Shown are representative photographs from UCB3-MSCs 
at P3 and BM-MSCs from donor 2.27 Magnification x 20. B) Adipogenic 
differentiaton capacity of UCB-MSCs, as compared with BM-MSCs (right panel). 
Shown are representative photos from UCB3-MSCs at P3 and BM-MSCs from 
donor 2.27 Magnification x 20. C) Calculated cumulative cell counts from P0 to P5 
of UCB3- and UCB6-MSCs, as compared with BM-MSCs cultured in the presence 
of 5% PL-additioned medium (mean of 8 BM-donors) and lready reported.27 
 
Biosafety profile of UCB-MSCs - Lack of telomerase expression in UCB-
MSCs during long-term in vitro culture 
MSC cultures from both UCB3 and UCB6 were tested at two different in 
vitro passages (P4 and P8) for the expression of telomerase catalytic 






of enzyme catalytic activity in all tested samples (Figure 2A). To gain 
insights into the molecular mechanisms responsible for the repression of 
telomerase activity in UCB-MSCs, we assessed the expression of the 
hTERT gene, which codes for the catalytic component of human 
telomerase,38 in the same cultures screened for telomerase activity. RT-
PCR failed to evidence the expression of hTERT mRNA (see 
Supplementary data, Figure 2s), thus indicating that t e absence of 
telomerase activity in cultured UCB-MSCs was ascribable to lack of 
hTERT gene transcription. 
MSC cultures from both UCB3 and UCB6 were found to express p16ink4a 
protein, as detected by Western immunoblotting, at all tested in vitro 
passages (Figure 2B). In addition, UCB3-MSCs (P3 and P6) and UCB6-
MSCs (P4 and P11) did not show anchorage-independent cell growth, since 
they failed to generate colonies when plated in double-layer agarose (data 
not shown).  
UCB-MSCs were also tested for their genomic assets; in particular 
UCB3- and UCB6-MSCs were investigated at early passage  (P3) 
and at later passages in culture (P8 and P9, respectively) by means of 
array-CGH (see Figure 2C for UCB6-MSCs at P3 and P9). The 
results of array-CGH experiments revealed that UCB-MSCs 
expanded in vitro do not show unbalanced chromosomal 
rearrangements; in fact, deletions or duplications of genomic 
material, excluding Copy Number Variations (CNVs) 









Figure 2. (A) Telomerase activity of UCB3- and UCB6-MSC cultures at P4 and P8. 
Telomerase activity was detected by the TRAP assay uing two protein concentrations. 
The telomerase-positive cell line JR8 was used as a positive control. The blank 
represents a negative control to which no protein extract was added. The lane labelled 
+RNAse represents an additional negative control containi g 0.6 µg cell extract of JR8 
pretreated with RNAse. The location of the internal amplification standard (ITAS) is 
reported. (B) P16ink4a expression in UCB3- and UCB6-MSC cultures at different in 
vitro passages as evaluated by Western immunoblotting. The p16ink4a-positive DU145 
cell line and the p16ink4a-negative U2OS cell line were used as positive and negative 
controls, respectively. (C) Representative array-CGH profiles of chromosomes 1 of 
UCB6-MSCs at P3 (left, red profile) and P9 (middle, blue profile). The array-CGH 
profiles are linear and perfectly overlappeing (right), thus demonstrating that in vitro 








Immune regulatory properties of UCB-MSCs  
In a first set of experiments, the immune regulatory capacity of UCB-
MSCs was evaluated by assessing UCB-MSC interaction w th alloantigen-
specific immune response, elicited in vitro in primary MLC. In agreement 
with previously reported studies,4 we observed that UCB-MSCs were able 
to strongly inhibit alloantigen-induced lymphocyte proliferation (Figure 
3A). A strong inhibitory effect was evident on whole T lymphocytes and 
their subsets (CD3+, Figure 3B; CD3+CD4+, Figure 3C; CD3+CD8+, Figure 
3D), as well as on NK lymphocytes (CD3negCD56+, Figure 3E). The 
percentage of CD4+CD25+ T cells considerably increased, as compared 
with day 0, after 10-day primary MLC, both in the presence and absence of 
UCB-MSCs, even though the percentage of this subset was higher in UCB-
MSC/MLC as compared with ctrl-MLC (Figure 3F). In an attempt to 
discriminate CD4+CD25+ Tregs from conventional, recently activated 
CD4+CD25+ T lymphocytes, the degree of expression of CD25 
(CD4+CD25bright T cells, Figure 3G), as well as of CTLA4 and FoxP3 
molecules was evaluated within the CD4+CD25+T cell subset (Figure 3H). 
We found a higher percentage of CD4+CD25bright and CTLA4+ cells in 
UCB-MSC/MLCs as compared with ctrl-MLCs, while the p rcentage of 








Figure 3. Immune modulatory effect of UCB-MSCs on theexpansion of T and NK-
lymphocyte subsets, induced by allogeneic stimulus. Recovery of total number of 
lymphocytes (A), CD3+ (B), CD3+CD4+ (C), CD3+CD8+ (D), CD3negCD56+ NK cells (E), 
CD4+CD25+ (F), CD4+CD25bright (G) T-lymphocytes subsets and with respect to the initial 
number (white columns), was assessed after 10-days primary culture (gray columns). 
Percentages of CTLA4+ and Foxp3+ cells were calculated on gated CD4+CD25+ T cells (H). 
MLC was performed in the absence (Ctrl-MLC) or presence of third-party MSCs derived 
from UCB3 (MLC+UCB3-MSCs) or UCB6 (MLC+UCB6-MSCs). Results are expr ssed as 






 The cytokine production kinetics induced in vitro by allogeneic stimulus 
documented that addition of UCB-MSCs: (i) inhibits IFNγ secretion; (ii ) 
strongly increases IL-6 secretion in MLC supernatants (see Supplementary 
data, Table 1s). Differently from what shown in a previous study where the 
addition of BM-MSCs grown in 5%PL to the MLC substanti lly increased 
IL-10 secretion,27 UCB-MSCs only slightly enhanced IL-10 secretion in 
24-hour MLC supernatants; (iii ) IL-2, IL-7, IL-12, IL-15 were undetectable 
in all experimental conditions. 
In order to assess the effect of UCB-MSCs on alloantige -induced 
cytotoxic activity, effector cells recovered after 10-day MLC were tested in 
a cytotoxicity assay, employing as targets either MLC-stimulator PHA–
blasts (Figure 4A) or third-party UCB-MSCs from the same lots added to 
the MLC at day 0 (Figure 4B, Figure 4C). Results obtained in all 
experiments showed a striking inhibitory effect mediated by both lots of 








Figure 4. Immune modulatory effect of third-party UCB-MSCs on cell-mediated 
cytotoxic activity induced by an allogeneic stimulus (MLC). 51Cr-labeled target 
cells included PHA-activated S-PBMCs (S-PHA) (A) and the same UCB3-MSCs 
(B) and UCB6-MSCs (C) added to MLCs. Effector to target (E:T) ratios ranged 
between 20:1 and 0.6:1. Results are expressed as percent specific lysis of target 
cells. 
  
With the aim of better understanding the biological mechanisms 
responsible for the immunosuppressive effect exerted by UCB-MSCs on 
alloantigen-induced immune response, in a second set of experiments, 
MLCs were carried out in the presence of IDO- or PGE2-specific 
inhibitors. As control, the same experimental conditions were also tested 






supplemented medium.27 Moreover, the constitutive expression of 
intracellular, membrane and soluble HLA-G (iHLA-G, mHLA-G, sHLA-
G, respectively) was evaluated in UCB-MSCs, as well as in BM-MSCs 
harvested at P3.  
In terms of alloantigen-induced lymphocyte proliferation, neither IDO-
specific inhibitor, nor PGE2-specific inhibitor were able to reverse the 
MSC-induced suppressive effect (data not shown). By contrast, when 
alloantigen-induced cytotoxic activity was evaluated, a clear-cut effect of 
the PGE2-specific inhibitor was observed; indeed, adition of PGE2-
specific inhibitor to MLC was able to reverse the suppressive effect exerted 
by both UCB-MSCs and BM-MSCs on alloantigen-specific cytotoxic 
activity, even though this reagent was apparently more effective when BM-
MSCs were employed (see Figure 5). On the contrary, IDO-specific 
inhibitor was not able to reverse the suppressive eff ct exerted by both 
UCB-MSCs and BM-MSCs on alloantigen-specific cytotoxic activity 
(Figure 5).  
 
Figure 5. Involvement of IDO and PGE2 in UCB- and BM-MSC mediated 
suppression of cell-mediated cytotoxic activity induced by an allogeneic stimulus 
(MLC). 51Cr-labeled target cells were PHA-activated S-PBMCs (S-PHA). Effector 






specific lysis of target cells. BM-derived MSCs (BM1-MSCs and BM2-MSCs) 
expanded in PL-supplemented medium were employed as a control.27 IDO or PGE 
inhibitors (inhib) were added to the MLC as described in the “Design and 
Methods” section. Results obtained at the E:T of 1:1 for Exp. 1 (broken bar) and 
10:1 for Exp. 2 (full bar) are shown, UCB3-MSCs and BM1-MSCs were employed 
in Exp. 1 whereas UCB6-MSCs and BM2-MSCs were tested in Exp 2. 
 
As shown in Table 1, PGE2 concentrations were considerably higher in 
supernatants of MLCs carried out in the presence of BM-MSCs than in the 
presence of UCB-MSCs. These data might explain the s riking effect of a 
PGE2-specific inhibitor observed in MLCs performed using BM-MSCs 
(Figure 5). The presence of PGE2-specific inhibitor c nsiderably decreased 
PGE2 secretion in MLC experiments carried out with eit er BM-MSCs or 
UCB-MSCs (Table 1). Interestingly, a striking increas  in PGE2 secretion 
was observed in the presence of the IDO-specific inhib tor (Table 1). 
 This observation may explain why IDO-specific inhibitor was unable to 
reverse the suppressive effect exerted in vitro by MSCs on alloantigen-
specific cytotoxic activity (see Figure 5). In fact, the striking increase in 
PGE2 secretion, induced by the presence of IDO-specific inhibitor, could 
exert an effective suppressor function on alloantigen-specific cytotoxic 
activity, thus masking the effect of the IDO-specific inhibitor on IDO-
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60 *NA <0.01 20 *NA <0.01 
 
 
Table 1. Concentration of PGE2, Tryptophan (tryp) and Kynurenine (kyn) in MLC-
supernatants Concentrations of PGE2, tryptophan and ky urenine were quantified in 
MLC-supernatants collected after 72-hours culture in the absence (ctrl-MLC) or 
presence of BM-MSCs (MLC+BM-MSCs) or UCB-MSCs (MLC+UCB-MSCs) and 
in the absence or presence of IDO inhibitor (MLC+MSCs+IDO inhib) or PGE2 
inhibitor (MLC+MSCs+PGE2 inhib). PGE2 levels are reported as pg/ml. Tryptophan 
and kynurenine levels are reported in µM as mean ±SD of three repeated runs for the 
same samples. Two independent experiments are presented, in which UCB3-MSCs 
and BM1-MSCs from donor 227 (Exp 1) and UCB6 MSCs and BM2-MSCs from 
donor 527 (Exp 2) were tested.*NA = not assessable. The tryptophan value could not 
be evaluated in the experimental condition as its fluorescence signal was 










IDO activity was evaluated in MLCs supernatants, as indirect evidence of 
IDO-mediated tryp degradation. Results reported in Table 1 demonstrate 
the presence of detectable levels of kyn only in culture supernatants 
recovered from MLCs carried-out in the presence of ither UCB- or BM-
MSCs. This finding indicates that IDO-activity is dependent on the 
interaction between MSCs and cells active in MLC. Kyn was more 
abundant in the presence of UCB-MSCs, as compared with BM-MSCs. As 
expected, kyn was undetectable in culture supernatants collected from 
MSC/MLCs carried out in the presence of IDO-specific inhibitor; however, 
kyn was also undetectable in culture supernatants collected from 
MSC/MLCs carried-out in the presence of PGE2-inibitor. The latter 
observation is in accordance with recently published data demonstrating 
that PGE2 is able to up-regulate IDO activity in den ritic cells.39,40 The 
inter-relationship among PGE2 secretion and IDO activ tion could also 
hypothetically explain why, even though PGE2 levels detected in 
MLC+BM-MSC+PGE2 inhibitor culture condition of Experiment 1 is 
comparable to that detected in Ctrl-MLC (see Table 1), alloantigen–
induced cytotoxic activity is strikingly higher in the former than in the 
latter culture condition (see Figure 5).  
Evaluation of constitutive HLA-G-expression in MSCs showed that UCB-
MSCs displayed a higher percentage of mHLA-G+ cells as compared with 
BM-MSCs, while more than 95% of both UCB-MSCs and BM-MSCs were 
iHLA-G+. UCB-MSCs and BM-MSCs secreted similar amount of sHLA-G 
in culture supernatants (see Supplementary data, Table 2s).   
 
Discussion  
In this study, we have demonstrated that MSCs generated from full-term 
UCB in a culture medium containing 5% PL are similar to BM-MSCs in 






proliferative ability. On the contrary, they differ for clonogenic efficiency. 
In spite of their high proliferative potential, UCB-MSCs do not show any 
signs of in vitro transformation. Moreover, in view of our findings, 
although obtained in a limited number of UCB-MSC samples, UCB-MSCs 
are apparently as effficient as BM-MSCs when tested in terms of capacity 
of suppressing an alloantigen-specific immune respon e (see Figure 3s and 
Figure 4s). 
Bieback et al. have demonstrated that MSCs can be isolated from full-term 
UCB with a success rate greater than 60%, when critical parameters for the 
selection of ‘good quality’ units are employed.22 These critical parameters 
included: a storage time shorter than 15 hours, a net UCB volume greater 
than 33 ml; a MNC count greater than 1 x 108 and absence of clots or signs 
of hemolysis. The quality criteria adopted in our study were less stringent 
in terms of storage time and UCB cellularity, but included a viability test 
on the manipulated cells. Despite this, the 5% PL-supplemented culture 
medium, which we had documented to be superior to 10% FCS in terms of 
clonogenic efficiency and proliferative capacity when employed for BM-
MSCs,27 did not provide higher efficiency of isolation of UCB-MSCs, as 
compared to a FCS-based medium.22 In fact, only 20% of UCB units we 
tested gave rise to MSCs, whereas in the remaining UCB units MSCs could 
not be obtained, despite the extended culture time. We cannot exclude that 
either the relatively long storage time of the UCB units employed or their 
inferior cellularity might have influenced our inferior isolation rate, despite 
the use of a PL-supplemented medium. 
Once obtained, UCB-MSCs expanded in the presence of 5% PL display the 
typical MSC morphology, immune phenotype and differentiation capacity 
(see Figure 1s and Figure 1A and 1B). UCB-MSCs possess high 






with the same medium27 at P5, although starting from lower cell counts at 
P0 (Figure 1C).  
Given the high proliferative capacity and the published reports on in vitro 
transformation of MSCs,41,42 we monitored UCB-MSCs during their whole 
culture period and, particularly, during their senescence phase, which 
occurred after 9 and 10 passages for UCB3- and UCB6-MSCs, 
respectively. Neither phenotypical, nor functional alterations of the cells 
were observed; the favorable bio-safety profile of UCB-MSCs was further 
demonstrated by the absence of telomerase activity and hTERT expression, 
the expression of p16ink4a protein, the absence of anchorage-independent 
cell growth and by a normal molecular karyotype as proved by array-CGH 
analysis (Figure 2).  
These data suggest that UCB-MSCs, expanded in our cult re system in the 
presence of 5% PL, do not display a tendency for spontaneous 
transformation, in accordance with data published evaluating BM-MSCs 
cultured with both PL- and FCS-supplemented media.27,33 This is, to our 
knowledge, the first report to include a thorough investigation of the 
genetic stability of MSCs derived from UCB. This type of evaluation, also 
in view of the high proliferative potential of UCB-MSCs, is mandatory, in 
our opinion, for any clinical application of these c lls.  
When tested for their capacity to influence the alloantigen-specific immune 
response, in comparison to BM-MSCs grown in 5% PL (see also Figure 3s 
and 4s for details on BM-MSCs),27 UCB-MSCs have similar suppressive 
effect on T- and NK-lymphocyte subset proliferation a d on alloantigen-
induced cytotoxic activity, while only slightly increase IL-10 in MLC 
supernatants. The results obtained in our study suggest that UCB-MSCs are 
able to exert an immunosuppressive effect on alloantige -specific immune 
response by means of several mechanisms, including IDO activation and 






these biological mechanisms have been previously decribed to be active in 
MSCs derived from other sources, such as BM-MSCs.4,11,35,43-49 In 
particular, it is noteworthy that our data confirm and extend previously 
reported results, underlying the inter-relationship among PGE2 secretion 
and IDO activation, two well-known mechanisms involved in anti-
inflammatory immune response.39,40 Indeed, the presence of PGE2-specific 
inhibitor, besides reducing PGE2 levels in culture supernatants, was also 
able to inhibit IDO activity. Moreover, in the presence of IDO-specific 
inhibitor, we observed a striking increase in PGE2 secretion.  
A distinctive feature of UCB-MSCs seems to be the constitutive surface 
expression of HLA-G on the majority of cells, while t has been reported 
that BM-MSCs mainly express only the soluble isoform of HLA-G.45 
However, it is worth considering that MEM-G/9 monoclonal antibody, 
which is specific for both membrane-bound (HLA-G1) and soluble (HLA-
G5) HLA-G isoforms was employed to evaluate HLA-G expression in flow 
cytometry. Therefore, we were unable to formally prove that soluble HLA-
G5 isoform is the only one expressed by UCB-MSCs, as documented by 
Selmani et al.45 for BM-MSCs. Further experiments are warranted to 
clarify this point.  
Membrane HLA-G expression, as well as sHLA-G isoforms have been 
demonstrated to exert a strong suppressive effect on pr liferation and 
activation of effector functions of both T and NK lymphocytes. For 
instance, it is well known that HLA-G expression at the feto-maternal 
interface is one of the most potent mechanisms protecting the fetus from 
maternal immune attack.48 Moreover, surface HLA-G expression is one of 
the systems employed by tumor cells to evade the cytotoxic activity of both 
tumor-specific T lymphocytes and NK cells, and it has been recently 
suggested that transfer of membrane patches containing HLA-G molecules 






might be a mechanism of immune suppression protecting HLA-Gneg tumor 
cells.49 It may, thus, be speculated that UCB-MSCs expressing mHLA-G 
may be more protected than BM-MSCs from attack mediat  by the host 
immune system. However, it has been recently demonstrated in a murine 
model that while local implantation of MSCs results in ectopic bone 
formation in syngeneic recipients, it leads to transplant rejection in 
allogeneic mice.50 This is in line with previously published data that MSCs 
can be lysed by cytotoxic T-lymphocytes, when infused into MHC-
mismatched mice, resulting in their rejection.51 These observations 
supports the use of MSCs, in hard tissue repair strategies, preferably in an 
autologous or tolerant host.50 Further studies specifically addressing this 
issue are underway. 
In conclusion, while the ability of BM-MNCs to generate MSCs reaches 
100% under appropriate culture conditions, the success rate of isolating 
MSCs from UCB ranges, according to different reports, from 20 to 63%.21-
24,52-54 In particular, Reinisch et al. have recently shown that MSCs can be 
obtained from full-term UCB in the presence of human PL, yielding cell 
numbers suitable for clinical application. The same authors report an 
isolation efficiency of 46%, considering both FCS-expanded and PL-
expanded MSCs. However, their PL preparation procedure, percentage of 
PL employed in the culture medium (10%), as well as MSC plating 
density, differ from our approach. These differences might explain the 
different results obtained, in particular in terms of isolation efficiency, as 
compared with our data.  Despite this, also in our experience, UCB-MSCs 
display a high proliferative capacity, which allow the expansion of 
sufficient cell numbers for clinical application, i a reasonable time-frame.  
Given their high proliferative capacity, immunosuppressive properties and 
potential for avoiding attack by immune cells, UCB-MSCs, also in view of 






prevention and treatment of alloreactive-related immune complications, 
namely severe GvHD and graft rejection, following HSCT. However, as 
note of caution, recent data, obtained in a xenogenic model of NOD/SCID 
mice, showed that human UCB-MSCs, when administered in multiple 
doses, are effective in the prevention, but not in the treatment of GvHD.55 
This discrepancy with the clinical efficacy displayed by MSCs on acute 
GvHD5 in human HSCT might be explained by the animal model 
employed and also by the unfavorable ratio between th  number of UCB-
MSCs and the huge number of effector cells mediating the tissue damage at 
time of acute GVHD onset.  
UCB-MSCs could also serve as a tool in strategies of 
reparative/regenerative medicine, where the combinatio  of the 
immunosuppressive and tissue repair properties could ameliorate the 
management of autoimmune and chronic inflammatory diseases.9-11  
Our results, although obtained in a limited number of MSC samples tested, 
suggest that the differences between BM- and UCB-derived MSCs and 
between cells expanded in the presence of PL and FCS may be relevant for the 
clinical application of MSCs. 
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9.1 Introduction  
To completely exploit the potential of MSCs as new treatment modality, more 
in vitro and in  vivo work is required. These studies will aim to increas  our 
knowledge on how MSCs mediate their suppressive effct and reduce 
inflammatory responses.  
Once more precisely defined, the in vivo biological activities of MSCs could 
be applied in novel therapeutic strategies to stimulate tissue repair, and to 
modulate immune response against allo- and autoantigens. 
 
9.2 Characterization of MSCs 
9.2.1 The lack of markers and functional assays 
In most laboratories, MSC isolation still relies ontheir adherence to plastic, 
resulting in a heterogeneous population of cells, refer ed to as MSCs. 
Immunephenotyping by flow cytometry is applied to characterize ex vivo 
expanded MSCs and to define their purity. However, at present, no specific 
marker or combination of markers has been identified that specifically defines 
true MSCs and ex vivo expanded cells are currently stained with a number of 
positive markers (CD105, CD73, CD90, CD166, CD44, CD29) in 
combination with negative markers (CD14, CD31, CD34, CD45). Although 
recently many research groups have reported the identification of new MSC 
markers,1-4 none of the available has demonstrated to be singularly capable to 
identify the true mesenchymal progenitors. Different cell subsets might be 
responsible for specific functions and might be characterized by different cell 
surface markers. Therefore, research should include the identification of MSC-
specific markers. This will allow to dissect the developmental hierarchy of 
MSCs and will facilitate the generation of homogenous cell populations.  
 
Novel techniques, such as proteomic approaches, might be useful to define 






collaboration with Fondazione Istiuto Nazionale di Genetica Molecolare 
INGM, Milano and PRIMM s.r.l. Milano, we have designed an approach to 
identify cell subsets based on the use of a library of polyclonal antisera 
specific for human membrane proteins with unknown fu ction. We have 
selected, cloned and expressed in bacteria the open reading frames coding for 
all proteins that are predicted to be either transmembrane or secreted. With the 
recombinant proteins we have generated a library of 1,700 mouse antisera 
that, in principle, can be used to discover new subset defining proteins on 
every cell population of interest. We are currently screening the antisera 
library by flow cytometry on ex-vivo expanded BM-MSCs, with the aim of 
possibly identifying and functionally characterize n w proteins expressed by 
subsets of MSCs. 
 
Microarray analysis is another useful instrument to characterize MSCs. 
Microarray analyses have being employed to compare gene expression 
profiles of MSCs and fibroblasts5,6 or MSCs and differentiated cells,7,8 but no 
definitive conclusions have been drawn. MSCs derived from different donors 
using the same culture conditions might yield consistent and reproducible 
gene expression profiles, whereas several genes might be differentially 
expressed in MSCs derived from different sources or culture conditions.9 In 
order to develop novel markers able to identify MSC subsets with specific 
functions, microarray analysis should focus on: i) comparison of gene 
expression profiles in different MSC populations (i.e. MSCs from different 
tissue sources, cultured in different conditions, at different in vitro passages; 
ii) changes induced in the course of in vitro differentiation.  
 
9.2.2 The effect of tissue source  
Altough similar MSCs can be cultured from various fetal and adult tissues,10-14 






cells; only few studies have employed different sources, such as adipose 
tissue.15 The frequency of mesenchymal progenitors, the prolife ative 
capacities and differentiation potential, as well as phenotypical and 
immunomodulatory properties have been shown to vary in different 
sources.11,12,16 Whether one source might be more useful in a defined clinical 
setting needs to be investigated.  
Recently, Sacchetti et al. have shown that stromal progenitors expressing 
MCAM/CD146 in human BM are capable of transferring, the hematopoietic 
microenvironment to heterotopic sites, giving rise to identical bone and 
stroma.17 These authors believe that the functional properties of ‘MSC-like’ 
cells isolated from tissues other than BM and expressing CD146+CD34-
CD45- phenotype, are different and not linked with the ability to establish the 
hematopoietic microenvironment in vivo (Bianco P., personal 
communication). 
To gain more insights into tissue-dependent functioal differences, we have 
compared the chondrogenic differentiation potential of culture-expanded 
MSCs derived from fetal and adult tissues (chapter 2). We demonstrated that 
fetal BM- and adult BM-derived MSCs exhibit a superior capacity to 
differentiate into chondrocytes, than fetal lung and placenta-derived MSCs. 
We speculate that the cell source, rather than their fetal origin, could account 
for this higher differentiation capacity, since no differences could be found in 
chondrogenic potential between fetal and adult BM-MSCs. Intrinsic 
diversities of MSCs residing in the tissue, as well as their physiological role in 
a specific tissue, might explain the properties of a specific tissue source, as 
compared to other sources. Alternatively, the frequency of cells with lineage-
specific differentiation capacity may differ between tissue sources and 
therefore chondrogenic MSCs might be present in higher frequency in BM 






the expansion of the cells might influence their differentiation ability, leading 
to the committment of the cells towards a specific lineage.  
In chapter 8 we focused on UCB as a potential novel source of MSCs for 
clinical application. To this aim, the biological and functional properties of ex 
vivo expanded UCB-derived MSCs were investigated, in comparison with 
BM-MSCs. We found that differences exist n vitro in terms of clonogenic 
efficiency, proliferative capacity and immunomodulatory properties between 
UCB- and BM-MSCs. These differences should be taken into account when 
considering the clinical application of MSCs in the various clinical settings. 
For example, given their high proliferative capacity, immunosuppressive 
properties and potential for avoiding attack of immune cells, UCB-MSCs 
might be employed in the clinics for the prevention a d treatment of 
alloreactive-related immune responses after HSCT, namely severe GvHD and 
graft rejection. UCB-MSCs might also be useful in regenerative medicine, 
where the combination of immunosuppressive and tissue repair properties 
could ameliorate symptoms of autoimmune and chronic i flammatory 
diseases. These in vitro findings need to be confirmed in the clinical setting; 
altough UCB-MSCs might be as suppressive as BM-MSCs upon interaction 
with alloantigen-specific immune response in vitro, this might not happen in 
vivo. Moreover, while it is possible to isolate MSCs from BM with a success 
rate of 100%, the isolation efficiency of MSCs from UCB varies from 20 (in 
our hands) to 63%.10,18-21 This could represent a limitation for the clinical 
application of UCB-MSCs, despite the fact that this source offers the 
advantage of easy collection.  
 
9.3 In vivo use of MSCs in experimental animal models 
9.3.1 MSC homing and survival 
Data on the fate of transplanted MSCs in vivo are scarce. Whether they home 






responsible for their effect is still largely unclear. It might be possible that 
therapeutic benefit is obtained by local paracrine growth factors produced by 
the cells and/or by the local microenvironment and that survival it is not 
necessary for their clinical effect. In rats, radiolabeling experiments showed 
localization of MSCs after intraarterial and intravenous infusion mostly in the 
lungs and secondarily in the liver and other organs.22 Studies in baboons using 
a green fluorescent retroviral construct suggest engraftment in the gastro-
intestinal tract and in various tissues in the range of 0.1-2.7 %, with 
comparable results for autologous and allogeneic cells.23 Other authors have 
shown that active homing of MSCs to BM depends on stromal-derived factor-
1 (SDF-1) which interacts with CXCR4 on the MSC surface.24 Similar 
mechanisms have been shown for migration to pancreati  islets25 and ischemic 
tissues.26 MSC mobilization and homing might depend on cytokines, 
chemokines and growth factors released during systemic and/or local 
inflammatory conditions and might be mediated by the interaction with 
integrins and selectins expressed on the surface of MSCs. Homing of MSCs to 
inflamed and ischemic tissues would increase the feasibility of cellular therapy 
in the setting of autoimmune diseases (AID) and tissue repair.  
A possible strategy to facilitate homing of MSCs, involves the modification of 
surface structures that play a role in migration to specific tissues, as suggested 
by Sackstein at al.27 These authors converted the native CD44 glycoform 
expressed on MSCs into E-selectin/L-selectin ligand (HCELL) (expressed on 
hematopoietic cells) using fucosyltransferase. Intravi al microscopy in 
NOD/SCID mice showed BM infiltration by HCELL(+) MSCs within several 
hours after intravenous infusion. 
In vivo labelling of MSCs will allow to investigate in vivo ‘trafficking’ and 
biodistribution of MSCs  both in animal models and in humans. 
Supermagnetic iron-oxide nanoparticles can be employed to label MSCs and 






interfering with MSC biological functions and without inducing toxic effects 
in the recipients.28,29 
One potential limitation of this technique is ingestion of iron particles by 
macrophages that prevents specific labelling of MSCs. Further efforts should 
focus on the development of new tracers; the acquisition of information on 
survival of MSCs in vivo, on their ability to engraft in host tissues and o the 
mechanisms that regulate their interaction with damaged tissues. 
 
9.3.2 Disease models in experimental animals  
The implementation of experimental disease models is essential for a better 
understanding of MSC biology and for producing pre-clinical data that could 
be useful for therapeutic in humans. Several animal odels of tissue 
protection and autoimmunity have been recently developed and tested. Similar 
results have been obtained by the infusion of MSCs in two different murine 
models of acute lung injury and hepatic fibrosis.30,31 In both models a 
protective effect of MSCs was noted despite limited engraftment in the target 
organs. In a rat model, MSC-derived conditioned medium proved effective in 
reversing fulminant hepatic failure.32 In addition, MSCs displayed tissue-
protective effects in animal models of kidney, retinal and central nervous 
system injury.33-36 These effects do not seem to be mediated by MSC 
transdifferentiation; bystander mechanisms including inhibition of pro-
inflammatory cytokines and anti-apoptotic effects on target cells seem to be 
involved.  
 
9.4 In vivo use of MSCs in patients 
The role of MSCs in the clinical setting has been exploited mainly in 
allogeneic stem cell transplantation, where MSCs have been infused either to 
facilitate engraftment (chapter 5) or to treat steroid- esistant acute GvHD 






particular those relating to the repair of damaged tissues and/or requiring an 
anti-inflammatory effect. An international registry of patients treated with 
MSCs has been recently launched under the auspices of the EBMT 
Developmental Committee.37 This allows to collect data on patients treated 
with MSCs for any disorder, as well as to analyze their clinical characteristics 
and outcome. Besides retrospective data analyses, th  registry represents the 
basis for future multicenter clinical trials. 
 
9.4.1 Hematopoietic stem cell transplantation 
In chapter 5 the role of MSCs in sustaining hematopoietic engraftment and 
reducing the risk of graft failure after haploidentical T-cell depleted HSCT 
from a HLA-partially matched family donor was explored in a phase I/II 
study. Feasibility of expansion of comparable BM-MSC products in 2 
different sites (Pavia and Leiden) was demonstrated, as well as safety of MSC 
clinical use. The data obtained also suggest that co-infusion of ex vivo 
expanded BM-MSCs might help to overcome graft rejection, since none of the 
25 study patients experienced graft failure as compared to 20% (11 out of 52 
children) graft failure rate in the historical controls. One possible explanation 
for this finding is that MSCs might display an immunosuppressive/anti-
proliferative effect on alloreactive host T lymphocytes escaping the 
preparative regimen, resulting in an engraftment promoting effect. 
Alternatively, MSCs might favor the engraftment of d nor HSCs through non-
immunological mechanisms; for instance, by contribuing to the hematopoietic 
stem cell niche or by stimulating the functional recovery of the BM-
microenvironment through the secretion of paracrine mediators. Chimerism 
analysis of ex vivo expanded MSCs derived from recipient BM after HSCT 
did not show evidence of donor cells in the majority of patients. This finding 
suggests that sustained engraftment of MSCs might not be necessary to induce 






The use of MSCs for the treatment of steroid-resistant, severe acute GvHD 
was evaluated in a phase II multicenter clinical trial conducted within the 
EBMT Developmental Committee (chapter 6). The 5 participating centers 
adopted a common MSC expansion protocol that allowed th  generation of 
similar products at the different sites.  
The safety of the infusion of HLA-identical or disparate, in vitro expanded, 
BM-MSCs was demonstrated. A complete response rate w s observed in 55% 
of the patients and the overall response rate was 69%. The 2-year probability 
of survival of complete responders was significantly better that that of patients 
with partial or no response; whereas transplantation-related mortality (TRM) 
was significantly lower in complete responders. There was a non-statistically 
significant trend for a better response rate in children, as compared with adult 
patients. We concluded that the infusion of BM-MSCs might be a safe and 
effective treatment for patients with severe, acute GvHD who do not respond 
to steroids and/or other immunosuppressive therapies.  
 
Based on the experience of the co-transplantation of MSCs and CD34+ 
peripheral blood stem cells (chapter 5), we have design d and conducted a 
similar phase I/II study on the co-transplantation of MSCs and UCB-derived 
HSCs in 3 centers (Pavia, Leiden and Stockholm). Thirteen pediatric patients 
with haematological malignancies received co-infusion of UCB cells and 
parental-derived BM-MSCs, and were compared with 39 historical controls. 
The feasibility and safety of the approach was confirmed also in this setting, 
since no MSC-related toxicities were registered. In co trast with pre-clinical 
results38 and our own experience in the haploidentical transplants (chapter 5), 
there was no difference in haematological recovery between the 2 groups, 
although less G-CSF was administered in the study patients as compared to 
the controls (p<0.05). This difference may reflect that graft disfunction in 






of HSCs infused. Moreover, the relatively variable number of CD34+ cells 
administered and the use of G-CSF in historical controls might have masked 
any effect of MSCs in this setting. The overall rate of acute GvHD did not 
significantly differ between MSC patients and contrls, but severe grade III-
IV acute GvHD did (0% vs 26%). Although overall survival was not 
significantly improved by the addition of MSCs, early TRM showed a 
reduction, related to the decrease in death due to s vere GvHD. This suggests 
that co-infusion of MSCs at the time of transplantation might allow to 
sufficiently reduce donor T cell alloreactivity to abrogate the most severe 
manifestations of acute GvHD, thus reducing TRM in UCB transplantation 
(manuscript in preparation). 
 
9.4.2 Crohn’s Disease 
MSCs are currently investigated as a novel cellular the apy for patients with 
refractory CD.39,40 In chapter 7, we investigated the potential role of 
autologous BM-derived MSCs as immunomodulatory/anti-inflammatory 
treatment to stimulate tissue repair in CD and demonstrated that both isolation 
and ex vivo expansion of BM-MSCs from these patients are feasible. 
Moreover, CD-MSCs proved effective in inhibiting in vitro polyclonally-
induced proliferation of both autologous and allogeneic peripheral blood 
lymphocytes.These findings, although limited to an in vitro observation, might 
suggest that patient-derived MSCs, rather than third party cells, could be 
employed for the treatment of refractory CD patients. The use of autologous 
MSCs might offer significant advantages over allogeneic cells, in light of the 
observations that MSCs can be lysed by both allogeneic T cells41 and NK 
cells.42 In non-profoundly immunodepressed subjects, such as most CD 
patients, allogeneic MSCs might be rejected after infusion without having the 







9.4.3 The concept for treating autoimmune diseases  
On the basis of their immunomodulatory properties, anti-inflammatory and 
tissue-protective effects, MSCs may be used in the treatment of refractory 
AID. Several reports on experimental models of autoimmunity have shown a 
beneficial effect of MSCs on various AID43-46 Despite this, few clinical data 
on the use of MSCs in human AID are available. The few published reports 
include a feasibility study of 10 patients47,48 with multiple sclerosis (MS) and 
phase I/II trials in CD patients refractory to conventional treatment.15,49,50  
Discussion is underway also concerning other AID such as type 1 diabetes 
mellitus, systemic sclerosis (SS) and Systemic lupus erythematosus (SLE).  
Contradictory results have been published on the properties of ex vivo 
expanded MSCs from AID patients.51,52 Whether these “diseased” cells are 
functionally impaired or whether they display similar characteristics as those 
of healthy donors needs further investigation. Although most studies, 
including our own experience (chapter 7), support the use of autologous cells 
for transplantation purposes. Whereas in many acute linical situations the 
time necessary for MSC expansion (3-4 weeks) preclud s the use of 
autologous cells, in AID it is feasible to isolate and culture the cells from 
patient tissues. Moreover, the immune privilege observed in heavily immune 
suppressed patients, such as patients with steroid-refractory acute GvHD, 
might not be guaranteed in immunocompetent hosts and, therefore, allogeneic 
MSCs might be rejected. On the other hand, this might not be important if 
MSCs are capable to home to target organs and to survive long enough to 
exert a therapeutic effect.  
 
9.4.4 Efficacy of MSC treatment and future clinical prospects 
Thus far, MSCs have been employed in phase I/II clinical trials, addressing 
the issues of feasibility and safety of infusion. To date no adverse effects have 






necessary to draw definitive conclusions on potential late adverse events. No 
demonstration of efficacy of MSC therapy has been obtained; this requires the 
execution of large multicenter randomized clinical trials specifically 
addressing response to MSC therapy, in comparison with more conventional 
treatment modalities.  
 
In the setting of haploidentical T-cell depleted HSCT in children, preliminary 
data of the phase I/II study suggest that MSCs might help to overcome graft 
rejection. This finding should be confirmed in adults undergoing 
transplantation from disparate donors; in this group f patients, where a lower 
number of CD34+ cells is infused per kilogram of recipient body wieght, co-
infusion of MSCs might provide useful data on the engraftment promoting 
effect of these cells. The execution of a randomized clinical trial in this 
context is difficult to implement. Calculations revealed that at least 100 
patients per arm should be enrolled in the trial to statistically prove efficacy of 
this approach. The use of haploidentical transplantation is relatively limited by 
the number of patients undergoing this procedure and by the center experience 
in this type of transplant. 
 
Regarding GVHD treatment, recently the first phase III double blind, placebo 
controlled, randomized clinical trial has been launched within the EBMT 
Developmental Committee. The primary objective of this study is to establish 
efficacy of infusions of allogeneic MSCs on steroid-resistant grade II–IV 
acute GvHD, as compared to second line treatment of GVHD. Patients are 
randomized to receive either MSCs (2 intravenous infus ons at a dosage of 2 x 
106/kg recipient weight) or equal volume of saline infusions, in combination 
with second line treatment. Besides efficacy, a follow-up of 2 years will also 
document any long-term side effect of MSC infusion, such as increased TRM, 






In the setting of refractory AID and tissue repair, phase I/II studies of MSC 
therapy are underway.15,49,50 Although promising, preliminary results need to 
be confirmed in larger cohorts of patients and in cl ical studies aimed at 
evaluating efficacy. Open issues also include patient s lection, disease stage 
and activity, MSC source and expansion conditions. The possibility of 
obtaining functional MSCs and in sufficient number fo  clinical applications 
from patient’s material needs to be confirmed in the different diseases.  
We are currently conducting, in collaboration with the Department of Internal 
Medicine and Gastroenterology of Fondazione IRCCS Policlinico San Matteo, 
a phase I/II study aimed at assessing the feasibility and safety of local 
intrafistolous infusion of autologous BM-MSCs in patients with refractory CD 
and perianal fistulas. Preliminary results in 8 patients demonstrate the 
feasibility/safety of this approach and suggest a potent reparative effect of 
MSCs on the damaged intestinal mucosa, characterized by complete healing 
of the fistulas in the majority of the patients and a critical decrease in their 
disease activity indices (manuscript in preparation). 
 
9.5 Safety issues  
The utilization of ex vivo expanded MSCs for clinical application is associated 
with potential risks i.e. the immunogenicity of the c lls or the medium 
components, in vitro transformation of the cells during expansion, and ectopic 
tissue formation.  
 
9.5.1 Culture conditions 
At present, MSCs are extensively expanded ex vivo before used in the clinical 
setting. The adoption of different isolation methods and culture conditions 
may lead to multiple MSC populations with slightly different biological and 
functional characteristics. For instance, differences in culture medium or 






of confluency at cell detachment may influence their proliferative capacity, 
expression of surface markers or differentiation capa ity, leading to the 
committment towards a specific phenotype or tissue lineage. This supports the 
need for the definition and validation of common isolation and expansion 
protocols for the preparation of MSCs both for experim ntal and clinical 
purposes. The use of a uniform expansion method facilitates the comparisons 
between cell-products generated at different sites and allows to perform large 
multicenter collaborative studies. 
To avoid the potential risks associated with the us of FCS as culture 
supplement for MSCs (transmission of infections, formation of antibodies 
against bovine proteins), alternative expansion methods have been 
investigated. The possibility of using autologous or allogeneic human serum 
for in vitro expansion of MSCs has been tested;53 the reduction of bovine 
antigens by a final 48-hour incubation with medium supplemented with 20% 
human serum has also been proposed.54 Platelet-rich plasma (PRP) or PL, 
containing high levels of PLT-derived GFs, have been tested in the clinical 
setting.55-58,21 In chapter 3 we have employed PL as alternative culture 
supplement for in vitro expansion of human BM-MSCs and compared PL-
expanded MSCs with those cultured in the presence of FCS. We were able to 
demonstrate the superiority of a culture medium supplemented with 5% PL, as 
compared with 10% FCS, in terms of clonogenic efficien y and proliferative 
capacity. Moreover, we showed that PL-expanded MSCs maintain their 
immunoregulatory properties in vitro. Despite the fact that expansion 
procedures using PL have demonstrated their interest and have been 
implemented in different laboratories, definitive standards to produce clinical-
grade PL-MSCs are lacking. It remains to be studied whether the clinical 








9.5.2 Genetic stability and risk of malignant transformation 
Given the reports of potential transformation of adult human MSCs after ex 
vivo culture,59-62 genetic stability of MSCs should be routinely asses ed prior 
to infusion In chapter 4 we investigated the potential susceptibility of human 
BM-MSCs, expanded in the presence of FCS, to undergo transformation after 
in vitro culture. We found that these cells can be cultured for long term 
without loosing their phenotypical and functional characteristics. Using 
genetic studies, performed through conventional and molecular karyotyping, 
the absence of chromosomal abnormalities was observed. Similar findings 
have been obtained in 18 BM-MSC cultures for clinical application prepared 
in the last 2 years in our Center, that showed no signs of cell transformation. 
These latter cells were prepared following the commn expansion protocol 
developed within the EBMT Developmental Committee and their expansions 
were interrupted at passage 3 in order to minimize the risk of transformation. 
The genetic profile of MSCs expanded in the presence of PL and isolated both 
from BM (chapter 3) and UCB (chapter 8) was also tested and these cultures 
revealed no signs of transformation. In particular, both MSC sources displayed 
a normal molecular karyotpype by array-Comparative Genomic Hybridization 
(array-CGH); moreover, in case of UCB-MSCs, p16ink4a was normally 
expressed and anchorage growth independence in soft agar was never 
observed.  
Recently, French researchers have reported the presnc  of aneuploidy in a 
number of MSC preparations for clinical application, after cultivation both in 
the presence of FCS+ Fibroblast Growth factor-2 (FGF-2) and PL.63 To 
further characterize the genetic abnormalities, quantitative analysis of genes 
related to transformation and senescence was performed. Normal and stable 
expression of c-myc, p53 and p21 was demonstrated, whereas human 
telomerase reverse transcriptase (hTERT) was never xp essed. Moreover, 






agar was never obtained. These data suggest that, although aneuploidy can 
occur during MSC expansion, it does not reflect cell transformation, but rather 
senescence of the cells. Based on these results, the French MSC clinical trials 
which were temporary interrupted due to the potential risk of transformation 
of the cells, have been recently re-opened. 
In light of these observations, phenotypic, functional and genetic assays, 
although of limited sensitivity, should be routinely performed on MSCs before 
in vivo use to demonstrate whether their biological properties, after ex vivo 
expansion, remain suitable for clinical application.  
 
9.6.1 Risks associated with MSC-mediated immunemodulation and 
ectopic tissue formation 
Whether MSC treatment can further aggravate immune incompetence and 
increase the risk of developing infections in patients with severe acute GvHD, 
as well as favor relapse in patients with malignant disorders, needs to be 
further investigated. Karlsson et al. performed specific analysis of subsequent 
Epstein-Barr virus and Cytomegalovirus reactivity in 2 patients included in the 
phase II GvHD study and demonstrated that effector functions of virus-
specific T-cells were retained after MSC infusion.64 Recent data in 10 patients 
suggest that co-transplantation of MSCs and HSCs may result in increased 
risk of relapse in patients with hematologic malignancies, as compared to 
patients receiving standard HSCT.65 Data obtained so far in the phase I/II trials 
performed within the Developmental Committee do notshow an incerased 
risk of developing both infection and relapse, as compared with historical 
controls. Large collaborative randomized studies, encountering long-term 
follow-up, are necessary to define whether MSCs might induce suppression of 
the host antitumor immune response, abrogate or weaken graft-versus-
leukemia (GvL) activity and reduce the ability to respond to infectious agents 






Recently, calcifications were observed in the infarcted hearts of mice that 
received local infusion of MSCs.66   This study reveals the potential risk of 
ectopic tissue formation in patients treated with MSCs for myocardial 
infarction and other diseases.  So far clinical data have shown the safety of 
MSC infusion without any occurrence of ectopic tissue or tumor formation in 
vivo; however, factors governing post-infusion fate of MSCs and the influence 
of the local environment on MSC behaviour are largely unknown and need 
further investigation. Given the paucity of available clinical data and the rather 
short follow-up, it is reasonable to advise strict and long-term follow-up for 
patients treated with MSCs.  
 
9.6 Open clinical and experimental issues 
9.6.1 Clinical issues 
- Autologous versus allogeneic MSCs – 
Whether autologous or allogeneic MSCs should be preferred will depend on 
the clinical setting in which the cells are employed and on the desidered 
therapeutic effect. In clinical situations of ‘urgent’ MSC treatment, such as in 
patients suffering from severe acute GvHD, allogeneic third-party, ‘ready off 
the shelf’ MSCs should be preferred. In disorders in which sufficient time for 
MSC harvest and ex vivo expansion is available, such as in refarctory AID 
patients, autologous cells can be employed, provided that they are functionally 
active. The potential rejection of infused MSCs should be carefully considered 
in the different clinical contexts. This might be eith r unfavourable or 
profitable, when only a temporary effect of MSCs is needed. In some cases a 
‘hit and run’ effect of MSCs might be sufficient toinduce a clinical response 
and might be useful to protect the patient from the risks of MSC-mediated 
immunosuppression. The rejection of MSCs would also av id the risk of 
ectopic tissue formation and of the potential engraftment of a transformed 






sensitization in the patient, characterized by the formation of alloantibodies 
directed against MSCs and responsible for their rejection. Alternatively, the 
manipulation in vitro of MSCs might be sufficient to alter their biological 
properties and to cause the development of antibodies against components of 
the culture medium incorporated in the cells during expansion, finally leading 
to cell rejection. In contrast to this hypotesis, we have recently reported the 
outcome of 2 children undergoing unrelated UCBT with parental BM-MSCs 
co-transplantation who initially rejected the graft. They were later succesfully 
re-transplanted using the father as the donor of both haploidentical PBSCs and 
MSCs. Despite previous exposure to paternal MSCs, they did not 
subsequently reject the paternal stem cell graft. This observation suggests that, 
in heavily immunodepressed patients, such as those und rgoing myeloablative 
HSCT, multiple infusions of allogeneic MSCs might not be immunogenic and 
might not induce rejection (manuscript submitted).  
 
- Dose and schedule - 
Optimal timimg of MSC administration, cell dose and additional 
immunosuppressive therapy need also to be defined. Dose and schedule of 
administration will probably depend on the clinical context. For facilitating 
engraftment one MSC infusion might be sufficient to prevent graft failure, in 
case of severe acute GvHD several MSC administration might be necessary to 
control the disease. In chronic inflammatory and autoimmune diseases, MSCs 
might not be a ‘once-in-a-life treatment’, but could represent a helpful tool 
during the active and severe phases of the disease. Wh ther the simultaneous 
administration of other immunosuppressive treatments could potentiate or 
abolish MSC therapeutic benefit needs also to be addressed in future 








9.6.2 Experimental issues 
Most of the available data on MSC immunomodulatory properties have been 
obtained in vitro on ex vivo expanded cells. The mechanisms by which MSCs 
display their effects in vivo are still largely unknown and need to be further 
investigated.  Several mechanisms of action, including cell-cell contact as well 
as the release of soluble mediators by MSCs or upon interaction with immune 
cells,41,67,68 have been proposed, but no definitive conclusions can be drawn. 
The high variability of the reported results might be partly explained by 
employing different culture conditions, different MSC and lymphocyte 
populations, as well as different MSC:lymphocyte ratios. Defined animal 
models, in vitro and in vivo studies are necessary to more precisely unravel the 
mechanisms underlying the anti-proliferative/anti-iflamatory effect of MSCs. 
In light of the observations made in chapter 8 on UCB- and BM-MSCs, we 
plan to more precisely investigate the role of the different biological 
mechanisms employed by MSCs. For instance, PGE2 secretion and IDO 
activation, two well known mechanisms involved in ati-inflammatory 
responses in vitro,69,70 might be crucial in attenuating the inflammatory state in 
AID. We therefore aim to investigate the relevance of these 2 mechanisms in 
the context of refractory CD to test whether they are functionally active in 
patient-derived cells. Expression of HLA-G, is known to be one of the most 
potent mechanisms protecting from immune attack at the feto-maternal 
interface.71 This will be investigated in UCB-derived MSCs where it is likely 
to be functionally relevant, as well as in the setting of HSCT and organ 
transplantion where MSCs are infused with the aim to prevent rejection. The 
ability of MSCs to favor in vitro the differentiation of 
CD4+CD25+FoxP3+Tregs,72 will be tested in vivo by analyzing the percentage 
of this lymphocyte population in peripheral blood after MSC treatment in both 
severe acute GvHD and AID patients. We also plan to investigate the 






the recent experimental observation that MSCs may promote proliferation and 
differentiation of transitional and naive B cells isolated from healthy donors 
and patients with SLE.73 If confirmed in vivo, MSC therapy in the context of 
AID might be detrimental and could lead to worsening of signs and 
symphtoms of autoimmunity.  
 
9.7 Conclusions  
Over the past years MSCs have been broadly applied in a variety of clinical 
settings. Areas of clinical application include modulation of alloimmune 
responses in the setting of allogeneic stem cell and organ transplantation and 
AID, as well as direct promotion of tissue repair (bone, cartilage and heart 
repair). MSC therapy appears to be relatively safe and encouraging therapeutic 
results have been obtained in several pilot studies. However, MSC therapy is 
still experimental and no standard treatment has emerged. In the coming years 
randomized studies will be completed to establish therapeutic efficacy. At the 
same time in vitro and in vivo studies will help to understand mechanisms 
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LIST OF ABBREVIATIONS 
 
 
AID  autoimmune diseases  
Array-CGH array-Comparative Genomic Hybridization  
AT  adipose tissue  
BM  bone marrow  
CD  Crohn’s Disease  
CIA  collagen-induced arthritis   
DC  dendritic cell   
DLI  donor lymphocytes  
EAE  experimental autoimmune encephalomyelitis  
EBMT  European Group for Blood and Marrow Transplantation 
FCS  fetal calf serum  
G-CSF  granulocyte colony stimulating factor  
GFs  growth factors  
GvHD  graft-versus-host disease  
GvL  graft-versus-leukemia  
HGF  hepatocyte growth factor  
HSCs  hematopoietic stem cells  
HSCT  hematopoietic stem cell transplantation  
IDO  indoleamine 2,3-dioxygenase  
MAPCs multipotent adult progenitor cells  
MLD  metachromatic leukodystrophy  
MR  magnetic resonance   
MS  multiple sclerosis   
MSCs  mesenchymal stem cells  
NK  Natural Killer  
O.I.  Osteogenesis Imperfecta  
PBSCT peripheral blood stem cell transplantation   
PGE2  prostaglandin E2  
PL  platelet-lysate  
PRP  Platelet-rich plasma  
SDF-1  stromal-derived factor-1  
SLE  Systemic lupus erythematosus  
SS  systemic sclerosis  
SSEA-1 stage-specific embryonic antigen-1  
TGF-β3 Transforming growth Factor-β3  
Treg  regulatory T cells  
TRM  transplantation-related mortality  
UCB  umbical cord blood  

























































Dit proefschrift richt zich op de karakterisering van de biologische en 
functionele eigenschappen van humane Mesenchymale Stromale Cellen 
(MSC’s). Hierbij is een vergelijking gemaakt tussen MSC’s afkomstig uit 
foetale weefsels, waaronder placenta en navelstrengbloed welke zijn 
vergeleken met MSC’s afkomstig uit het beenmerg van volwassen individuen. 
Navelstrengbloed (Umbilical Cord Blood, UCB) is onderzocht als een 
potentieel nieuwe bron van MSC’s voor klinische toepassing. Om deze reden 
zijn de immunomodulatoire eigenschappen van MSC’s afkomstig van 
navelstrengbloed vergeleken met die van MSC’s afkomstig uit beenmerg. 
Daarnaast zijn de experimentele condities waaronder MSC’s in het 
laboratorium kunnen worden geëxpandeerd onderzocht en verder 
geoptimaliseerd. Hierbij zijn ook alternatieve kweekm thoden onderzocht, 
waarbij geen gebruik gemaakt wordt van dierlijke eiwitten die aanwezig zijn 
in “fetal calf serum”. Als alternatief hiervoor werd een expansiemethode 
onderzocht gebaseerd op het gebruik van trombocyten l saat waarin zich 
groeistimulerende factoren bevinden.  
 
Eén van de belangrijkste potentiële risico’s van MSC expansie is de 
mogelijkheid van maligne transformatie. Dit risico treedt met name op bij het 
langdurig ex-vivo kweken van MSC’s. Daarnaast zou het risico verder kunnen 
worden vergroot door de toepassing van deze cellen bij immuun 
gecompromitteerde patiënten. Er werden geen structurele of numerieke 
chromosomale afwijkingen gevonden bij MSC’s die gekw ekt werden onder 
serumbevattende dan wel onder serumvrije kweekcondities. Andere potentiële 
risico’s van MSC therapie omvatte immunogeniciteit bij het toedienen van 
allogene cellen en het risico van ectopische weefselformatie na systemische of 






Eén van de problemen bij het karakteriseren van MSC’s is het ontbreken van 
specifieke oppervlaktemarkers waarmee MSC’s uit weefsels kunnen worden 
geisoleerd. Als gevolgd hiervan zijn de klinische MSC producten heterogeen 
wat betreft hun immuun fenotype en ook wat betreft hun functionele 
eigenschappen. Nieuwe technieken waaronder gen-expressieprofielen en 
eiwitprofielen worden voorgesteld om MSC’s nauwkeurige  te karakteriseren.  
 
De in-vivo biodistributie en “trafficking” van ex-vi o geëxpandeerde MSC’s 
is nog weinig onderzocht. Het belang van de ontwikkel ng van geschikte 
labelings technieken om MSC’s in-vivo te kunnen volgen na inspuiting wordt 
besproken.  
 
De belangrijkste toepassing van MSC therapie ligt in de context van 
hematopoietische stamceltransplantatie. Dit betreft ondermeer de co-
transplantatie van MSC’s en Hematopoietische Stamcellen (HSC’s) om het 
aanslaan van het transplantaat (“engraftment”) te bevorderen. Daarnaast zijn 
MSC’s vooral toegepast ter behandeling van steroïd resistente ernstige acute 
graft-versus-host ziekte. Een relatief nieuwe indicatie voor MSC therapie 
omvat de behandeling van “Inflammatory Bowel Disorders”, waaronder de 
ziekte van Crohn. Bij een kleine groep patiënten werd de rol van autologe 
MSC’s afkomstig uit beenmerg onderzocht met betrekking tot hun 
immunomodulatoire en ontstekingsremmende eigenschappen. Behandeling 
met MSC’s vindt nu reeds plaats bij een groot aantal aandoeningen die 
gekenmerkt worden door inflammatie en weefselschade. Het is te verwachten 
dat in de nabije toekomst MSC therapie als een nieuwe therapeutische 
modaliteit kan worden toegepast bij een groot aantal verschillende 
immunologische-, en ontstekingsgemedieerde ziekten, met het doel om 







Summary in English 
 
This thesis focuses on the characterization of the biological and functional 
properties of human mesenchymal stromal cells (MSCs), isolated from 
different tissue sources. The differentiation capacity of MSCs from fetal and 
adult tissues has been tested and compared. Umbilical cord blood (UCB) has 
been investigated as a potential novel source of MSCs for clinical application 
and the immunomodulatory properties of UCB-derived MSCs have been 
characterized in comparison with those of MSCs of bone marrow (BM) origin. 
Moreover, it has been attempted to optimize the experimental conditions for 
MSC ex vivo expansion. Alternative culture methods, devoid of animal 
proteins, have been applied by introducing expansion procedures based on 
platelet-derived growth factors. The potential susceptibility of MSCs to 
undergo malignant transformation after long-term in vitro culture has been 
investigated and discussed in view of their clinical application, especially in 
immunocompromised hosts. The immunogenicity of the cells and/or their 
medium components, the risk of ectopic tissue formation and that of MSC-
mediated immunosuppression have been also discussed as potential risks 
associated with the clinical use of ex vivo expanded MSCs. 
The lack of surface markers and functional assays to pecifically identify 
MSCs and to facilitate the generation of homogenous cell products has been 
analyzed and efforts for future MSC development have been discussed. Novel 
techniques, such as proteomic approaches and microarray nalysis, have been 
proposed with the aim to improve the knowledge on MSC biological and 
functional properties; imaging studies, based on the use of suitable labeling 
techniques and able to investigate in vivo MSC ‘trafficking’ and 
biodistribution, have been discussed. 
The role of MSC therapy in the context of hematopoietic stem cell 






transplantation of MSCs to promote engraftment of hematopoietic progenitors, 
and on the administration of MSCs for the treatment of steroid-resistant, 
severe acute graft-versus-host disease (GvHD). The role of MSCs in the 
treatment of inflammatory bowel diseases refractory  conventional therapies, 
as well as the concept for treating refractory autoimmune diseases has been 
discussed. In particular, the potential role of autologous BM-derived MSCs as 
immunomodulatory/anti-inflammatory treatment to stimulate tissue repair in 
Crohn’s Disease (CD) patients has been investigated. Based on these 
experimental and clinical findings and by broadening the knowledge on MSC 
biological activities, these cells could be employed in the near future as a 
novel therapeutic strategy to stimulate tissue repai  and modulate immune 





















Riassunto in Italiano 
 
Questa tesi verte sulla caratterizzazione delle proprietà biologiche e funzionali 
delle cellule stromali mesenchimali (MSC) umane isolate da differenti tessuti. 
In questo lavoro sono state testate e confrontate le capacità differenziative 
delle MSC umane derivate da tessuti fetali e di tipo adulto. Quale potenziale 
sorgente di MSC per l’applicazione clinica è stato studiato il sangue 
placentare; le proprietà immunomodulatorie delle MSC da sangue placentare 
sono state confrontate con quelle delle MSC di derivazione midollare. Sono 
state, poi, ottimizzate le condizioni di coltura per l’ spansione ex vivo delle 
MSC. Un terreno basato sull’impiego di fattori di crescita derivati dalle 
piastrine è stato preparato ed impiegato quale sistma di coltura alternativo in 
quanto privo di proteine di origine animale. É stata, inoltre, valutata la 
potenziale suscettibilità delle MSC alla trasformazione in senso neoplastico 
dopo coltura in vitro a lungo termine; ciò risulta particolarmente interessante 
in funzione del loro impiego clinico, in particolare in soggetti 
immunocompromessi. Sono stati valutati quali potenziali rischi associati 
all’uso clinico delle MSC i seguenti fattori: l’immunogenicità delle cellule e/o 
dei componenti del terreno di coltura, il rischio di formazione in vivo di 
tessuto ectopico e l’eventuale immunosoppressione favorita dalle MSC stesse 
in vivo. 
 
In questo lavoro sono stati altresì discussi ed approfonditi eventuali sviluppi 
futuri riguardanti l’identificazione di marcatori di superficie e di test 
funzionali atti tanto all’identificazione specifica delle MSC, quanto alla 
generazione di prodotti per terapia cellulare omogenei. Inoltre, al fine di 
migliorare la conoscenza delle proprietà biologiche e funzionali delle MSC, 
sono state esplorate tecnologie innovative, quali tecniche di proteomica e 






sull’impiego di appropriati sistemi di marcatura e capaci di studiare il 
trafficking e la biodistribuzione delle MSC in vivo. 
 
E’ stato, inoltre, testato il ruolo delle terapie cllulari con MSC nel contesto 
del trapianto allogenico di cellule staminali emopoietiche. In particolare, sono 
stati condotti studi clinici di fase I/II basati sia sul co-trapianto di MSC allo 
scopo di facilitare l’attecchimento dei progenitori emopoietici sia sulla 
somministrazione di MSC per il trattamento della malattia del trapianto contro 
l’ospite steroido-resistente di grado severo. Sono stati discussi tanto il ruolo 
della terapia con MSC nel trattamento delle malattie infiammatorie croniche 
intestinali non responsive alle terapie convenzional , quanto il potenziale 
utilizzo delle stesse nel trattamento delle malattie autoimmuni refrattarie. In 
particolare, è stato quindi valutato l’impiego di MSC autologhe di origine 
midollare quale approccio immunomodulante/anti-infiammatorio con lo scopo 
di stimolare la riparazione tessutale in pazienti con malattia di Crohn 
refrattaria. 
 
Sulla base di quanto emerso da questo studio e attraverso l’ampliamento della 
conoscenza biologica delle MSC, queste cellule potranno, in un prossimo 
futuro, essere impiegate, quali strumenti innovativi, per facilitare la 
rigenerazione dei tessuti e modulare la risposta immune in numerose affezioni 













Maria Ester Bernardo was born in Voghera (Pavia), It ly on September 14, 
1975. In 1994 she took her high-school diploma at Liceo Classico “U. 
Foscolo” in Pavia. In July 2000 she took her Medical Degree in Medicine and 
Surgery, University of Pavia with a thesis entitled “Immunological 
Reconstitution after placental stem cell transplantation” (cum laude). In April 
2001 she was licensed to practice medicine and surgery.  
From June 2004 to June 2005 she served an internship at the Department of 
Haematology, Leiden University Medical Centre (head Prof. Dr. R.Willemze), 
under the supervision of Prof. Dr. W.E. Fibbe, focusing on research projects in 
hematopoietic stem cell transplantation utilizing mesenchymal stromal cells as 
therapeutic support.   
In October 2005 she specialized in Pediatrics, University of Pavia, with a 
thesis entitle “Study of the chondrogenic potential of mesenchymal stem cells 
isolated from different tissue sources”(cum laude). From November 2005 to 
March 2007 she served as a fellow at the Department of Paediatric 
Oncohematology, Foundation IRCCS Policlinico San Matteo, Pavia. From 
April 2007 to present she is a Staff Paediatrician, specialized in Paediatric 
Oncohaematology, Department of Paediatric Oncohematology, Foundation 
IRCCS Policlinico San Matteo, Pavia. 
Maria Ester Bernardo is a member of the Italian Association of Paediatric 
Haematology and Oncology (AIEOP) and of the American Society of 
Haematology (ASH). She is a member of the Editorial Review Board of the 







List of publications 
 
Bernardo ME, Locatelli F, Fibbe WE. Mesenchymal stromal cells: a novel 
treatment modality for tissue repair. Ann N Y Acad Sci. 2009;1176:101-117. 
Review. 
 
Bernardo ME, Emons JAM, Nauta AJ, Roelofs H, Romeo S, Marchini A, 
Rappold GA,  Vukicevic S, Karperien M, Locatelli F, Willemze R, Fibbe WE. 
Human mesenchymal stem cells derived from bone marrow display a better 
chondrogenic differentiation compared with other sources. Connect Tissue 
Res. 2007;48:132-140. 
 
Bernardo ME, Avanzini MA, Perotti C, Cometa AM, Moretta A, Lenta E, 
Del Fante C, Novara F, de Silvestri A, Zuffardi O, Maccario R, Locatelli F. 
Optimization of in vitro expansion of human multipotent mesenchymal 
stromal cells for cell-therapy approaches: further insights in the search for a 
fetal calf serum substitute. J Cell Physiol. 2007; 211:121-130.  
       
 
Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta 
A, Montagna D, Maccario R, Villa R, Daidone MG, Zuffardi O, Locatelli F. 
Human bone marrow-derived mesenchymal stem cells do not undergo 
transformation after long-term in vitro culture and do not exhibit telomere 
maintenance mechanisms. Cancer Res. 2007;67:9142-9149.   
          
Ball LM *, Bernardo ME *, Roelofs H, Lankester A, Cometa A, Egeler RM, 
Locatelli F, Fibbe WE. Co-transplantation of ex-vivo expanded mesenchymal 
stem cells accelerates lymphocyte recovery and may reduce the risk of graft 
failure in haploidentical hematopoietic stem cell transplantation. Blood. 
2007;110:2764-2767. 
 
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, 
Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo 
A, Fibbe WE, Ringdén O. Mesenchymal stem cells for treatment of steroid-
resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 
2008;371:1579-1586.  
 
Bernardo ME *, Avanzini MA *, Ciccocioppo R, Perotti C, Cometa AM, 
Moretta A, Marconi M, Valli M, Novara F, Zuffardi O, Maccario R, Corazza 
GR, Locatelli F. Phenotypical/functional characterization of in vitro expanded 








Avanzini MA *, Bernardo ME *, Cometa AM, Perotti C, Zaffaroni N, Novara 
F, Visai L, Moretta A, Del Fante C, Ball LM, Fibbe WE, Maccario R, 
Locatelli F. Generation of mesenchymal stromal cells in the presence of 
platelet lysate: a phenotypical and functional comparison between umbilical 
cord blood- and bone marrow-derived progenitors. Haematologica. 
2009;94:1649-1660. Epub 2009 Sep. 22. 
 




Pozzi S, Lisini D, Podestà M, Bernardo ME, Sessarego N, Piaggio G, 
Cometa A, Giorgiani G, Mina T, Buldini B, Maccario R, Frassoni F, Locatelli 
F. Donor multipotent mesenchymal stromal cells may engraft in pediatric 
patients given either cord blood or bone marrow transplantation. Exp Hematol. 
2006;34:934-942. 
 
Ball LM, Bernardo ME, Locatelli F, Egeler RM. Potential role of 
mesenchymal stromal cells in pediatric hematopoietic SCT. Bone Marrow 
Transplant. 2008;42:S60-S66. 
 
Bernardo ME *, Ball LM *, Cometa AM, Roelofs H, Zecca M, Avanzini MA, 
Bertaina A, Vinti L, Lankester A, Maccario R, Ringden O, Le Blanc K, Egeler 
RM, Fibbe W, Locatelli F. Co-infusion of ex vivo expanded, parental, 
mesenchymal stem cells prevents life-threatnening acute GvHD, but does not 
reduce the risk of graft failure in pediatric patien s given allogeneic umbilical 
cord blood transplantation. Bone Marrow Transplant., in press.  
 
Ball LM, Bernardo ME, Roelofs H, Zwaginga JJ, Locatelli F, Egeler RM, 
Fibbe WE. In children undergoing transplantation for n n malignant disease, 
previous exposure to parental mesenchymal stromal cell infusions does not 
induce rejection of subsequent haploidentical hematopoietic stem cells. 
Submitted. 
 
 
 
  
 
 
 
260 
 
